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Het leven staat in een delicate relatie tot zijn omgeving. Maar dit betekent niet dat het leven in 
balans is met de omgeving. Integendeel, de staat waarin cellen verkeren die in perfecte balans 
zijn met hun omgeving wordt in wetenschappelijke terminologie dan ook “dood” genoemd. 
Om te kunnen overleven moeten cellen hun inwendige omgeving stabiel houden, ondanks de 
veranderlijke buitenwereld. Alleen in een stabiele inwendige omgeving kunnen de complexe 
chemische reacties plaatsvinden die het voedsel wat we eten omzetten tot de cellen van ons 
lichaam. Het proces van het behouden van een stabiele inwendige omgeving heet homeostase 
en de som van alle chemische reacties die plaatsvinden in een organisme noemt men het 
metabolisme.
Het behouden van homeostase kan alleen door continu energie aan te voeren via een 
ononderbroken metabolisme van voedingsstoffen. Maar omdat ononderbroken aanvoer 
van voedingsstoffen niet altijd gegarandeerd kan worden in de natuur is een buffer van 
opgeslagen energie van cruciaal belang, bijvoorbeeld in de vorm van vet. Het goed reguleren 
van de opbouw en afbraak van deze energievoorraden zou een groot evolutionair voordeel 
opleveren als periodes van overvloed en schaarste elkaar afwisselen. Er wordt zelfs gedacht 
dat een goede regulatie van energievoorraden aan de basis heeft gestaan van de evolutionaire 
ontwikkeling van het relatief grote menselijke brein: menselijke baby’s worden als één van de 
vetste landdieren geboren, wat het mogelijk maakt om onze energieverslindende hersenen te 
kunnen voeden en te laten ontwikkelen [1,2]. Het is dus duidelijk dat energievoorraden in 
de vorm van vet essentieel zijn voor de mens.
1 Leonard, W. R., Robertson et al. 2003; Metabolic 
correlates of hominid brain evolution. 
Comparative Biochemistry and Physiology Part 
A: Molecular & Integrative Physiology 136:5
2 Cunnane, S. C., and Crawford, M. A. 2003; 
Survival of the fattest: fat babies were the 
key to evolution of the large human brain. 
Comparative Biochemistry and Physiology Part 










In today’s world, more people die from complications of overweight than from underweight. 
Overweight and obesity significantly increase the risk for type 2 diabetes and cardiovascular 
disease (CVD). Globally, CVD is the number one cause of death (World Health Organization, 
March 2013). Preventing obesity-related diseases is estimated to save a substantial amount of 
medical care costs, but also diminish environmental, labor productivity and human capital 
loss [1]. Therefore, obesity is a growing societal and political point of concern. Understanding 
how susceptibility to obesity-related diseases arises and how to tip the balance back in favor of 
a more healthy energetic state is crucial.
Energy metabolism
Energy is taken up by the body by digesting energy-rich nutrients in the diet. These digestion 
products can be further metabolized according to the requirement at that time. Nutrients 
can be used either as building blocks for biomass, or oxidized for generating heat and/or 
the cellular chemical energy currency: Adenosine triphosphate (ATP). Nutrients can also be 
stored. The metabolic fates (oxidation, biomass and storage) of dietary protein, carbohydrates 
and fats are depicted in figure 1.
In the post-prandial state, dietary fats and carbohydrates are broken down in the 
gastrointestinal tract to fatty acids and monosaccharides, respectively. Monosaccharides such 
as glucose enters the blood stream directly, but fatty acids are first converted to triglycerides 
in the small intestine and loaded into chylomicron lipoprotein particles (built around 
apolipoprotein (apo) B48), used to transport water-insoluble lipids. The lipoprotein particles 
are then transported via lymph and the water soluble nutrients via the blood to all organs, 
which will take up nutrients according to their need. Chylomicrons adhere to the vascular 
endothelial wall to release fatty acids near the cell membrane. Adipocytes can store excess 
fatty acid as triglycerides. The liver can store excess glucose as glycogen. 
In the fasting state, the body relies on the release of stored glycogen and triglycerides to 
fulfill the energy requirements of each cell. Adipocytes can hydrolyze the stored triglycerides, 
releasing non-esterified fatty acids (NEFA). As NEFAs are toxic, they are quickly shielded 
from the environment. For example, NEFAs in the blood complex with albumin. The liver can 
rapidly take up NEFAs from albumin complexes. The NEFAs are then esterified to glycerol 
to reform triglycerides. These TGs are loaded by the liver onto very low density lipoprotein 
particles (VLDL, built around apoB100) and secreted into the blood. Similarly, glycogen can 
be broken down, thus secreting glucose. 
The energy-rich lipids and carbohydrates are important building materials. The cells of 
the body grow, divide and develop by metabolizing dietary nutrients. Lipids are important 
components of the cell membrane, creating a closed compartment wherein homeostasis is 




for the synthesis of enzymes and other proteins.
Fatty acids and glucose are mostly used as fuel. They can both be metabolized to acetyl-
CoA, which is the main input metabolite of the mitochondrial tricarboxylic acid (TCA) cycle. 
In the TCA cycle acetyl-CoA is oxidized in a step-wise controlled fashion generating carbon 
dioxide, water, but also reducing equivalents (NADH). The reducing equivalents are fed into 
in the mitochondrial electron transfer chain to generate a proton gradient which drives the 
conversion of ADP to ATP or the generation of heat. ATP is the central energy currency of the 
cell, needed to maintain homeostasis. 
The energy buffer capacity of available intracellular ATP is generally very small. Therefore 
an energy buffer of triglycerides and glycogen is stored mostly in adipose tissue and liver, 
respectively. Since the energy density of triglycerides is about six times higher than glycogen, 
triglycerides are the preferred energy storage form. Glucose can be converted to fatty acids 
as storage, but it is impossible to convert fatty acids back to glucose. As the brain is mostly 
















Figure 1: Macronutrient composition of the human diet, which is absorbed and processed in the body and 
subsequently allocated to fuel oxidation for energy, energy storage or to growth of biomass. The macronutrient 
composition is given as a stacked bar graph: Carbohydrates (C, White), Protein (P, Grey) and Fat (F, Black). Western 
Diet (Standard American Diet) composition in C/P/F = 50/15/35 kcal% [2]. Average muscle biomass composition in 
C/P/F = 0/75/25 kcal% [3] and average human storage composition in C/P/F = 1/0/99 kcal% [4]. Average human 
oxidative respiratory quotient in C/P/F = 40/0/60 kcal% [5, 6].
Figure 1 describes the schematic roadmap that dietary nutrients follow, from nutrient intake 
to nutrient usage and storage. It does not describe how the decision is made to allocate certain 
nutrients to certain processes under certain conditions. In order to gain more insight in this 
allocation process, it is useful to determine the energy balance. If the balance has shifted from 
the homeostatic set point, nutrient allocation should be adjusted to regain balance. The energy 
balance describes how the energy intake from the diet compares to the energy expended in 
order to fuel the nutrient usage: 
∆Energy storage(kJ/h) = Energy intake(kJ/h) - Energy expenditure(kJ/h)
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If the energy intake of an organism over a period of time is in balance with the energy 
expenditure, the amount of energy storage will stay the same. In the case of a positive energy 
balance the energy storage will increase over time. 
Balancing energy metabolism
Regulating the energy storage and release is crucial to keep up with the ATP demand of every 
cell in the organism. To regulate most processes in biology, negative feedback loops have 
evolved. The concentration of a certain metabolite is sensed by a sensor. If the concentration 
(input) increases beyond a threshold, the sensor will elicit a response (feedback) leading to 
increased consumption and/or decreased production of the metabolite, thereby bringing the 
input concentration back to the set-point homeostatic level. Due to its robustness, negative 
feedback loops are the most abundant regulatory mechanism to balance consumption and 
production at a homeostatic level [7].
The first step in the regulation of energy metabolism is therefore to sense the energy balance. 
Sensing the energy balance is done at multiple levels: The intracellular energy availability, the 
energy available circulating in the blood and the energy available in storage. It is important to 
sense the energy balance at these different levels, so that energy allocation can be adjusted to 
fit the local and global requirements of the organism, but also to fit the acute and long-term 
requirements of the organism. 
In the post-prandial state, more energy intake has occurred than required for energy 
expenditure at that moment. When the digestion products enter the bloodstream, the 
concentration of glucose, amino acids and lipids will rise. Pancreatic β-cells taking up 
increasing levels of glucose will sense an increase in their intracellular ATP/AMP energy 
balance [8]. This leads to the secretion of insulin, which will bind to the insulin receptor 
present on the cell membranes. Insulin will signal the switch from a catabolic state (burning 
nutrients for fuel) to an anabolic state (use nutrients to build up storage and biomass), required 
during the switch from fasting to feeding. This results in an increased nutrient uptake and a 
decrease of the blood nutrient concentrations back to homeostatic set-point levels, at which 
insulin secretion is not stimulated any longer. 
In contrast, in the fasting state, more energy is expended than is taken up via the intestine. 
This might cause cells to use up their ATP supply faster than they rebuild ATP. Each cell can 
sense the drop in ATP/AMP energy balance via amongst others the enzyme AMPK. Activated 
AMPK will locally stimulate the cell’s insulin sensitivity, thereby increasing insulin-induced 
glucose import from the circulation into the cell [9]. AMPK signaling can also activate the 
production of extracellular energy demanding hormones, namely glucagon (by pancreatic 
α-cells), adrenaline and cortisol (by the adrenal glands). These hormones will travel via the 
blood to the storage cells, signaling the release of fatty acids and glucose into the blood, from 




The energy balance is also sensed at the storage level. Storage cells must also be able to 
signal the total amount of stored nutrients present, otherwise the buffer capacity might not 
be sufficient for unforeseen fasting conditions. The glycogen buffer in the liver is small, but 
crucial. Therefore, when the glycogen content is low, hepatocytes stimulate adipocyte lipolysis 
forcing a switch from oxidizing low-abundant glucose to oxidizing fatty acids [10]. Reversely, 
when the glycogen content is high, hepatocytes stimulate adipocyte lipogenesis to convert 
high-abundant glucose to triglycerides [11]. The mechanism for sensing and signaling 
according to glycogen content are not yet completely known. Adipocytes release leptin, an 
adipokine, according to their lipid content. Therefore, sensing the adipocyte lipid content is 
possible by sensing the blood leptin concentration. When stored energy is in abundance, it 
can be used for growth, development and reproduction processes. These global and long-term 
responses are indeed stimulated by leptin [12]. 
The response to sensing the energy balance is mostly mediated via blood hormones, 
which can manipulate the cellular energy metabolism. However the response can also be 
mediated via neuronal signaling, which could manipulate not only energy metabolism, but 
also behavior [13]. Leptin for example acts as an extracellular hormone, inducing a neuronal 
satiety signal in the brain. Low leptin levels will not signal satiety, thereby steering behavior 
to finding food. High leptin levels induce satiety behavior [12]. Many different hormones 
have been found to manipulate neuronal satiety signaling. Even in anticipation of nutrients 
entering the blood, different gastro-intestinal sensory cells secrete ghrelin, cholecystokinin 
and peptide YY in response to nutrients, which are all stimulatory signals of satiety [13]. In 
response to high levels of blood nutrients insulin also acts as a stimulus of satiety. The default 
signal in food intake regulation is appetite signaling, which can be suppressed by for example 
the satiety mechanisms described above.
Negative feedback is present in many different energy balance sensing processes, ranging 
from neuronal and hormonal to intracellular processes. Although it is a very robust regulatory 
mechanism, resistance to negative feedback can occur. Resistance can be useful physiologically 
to adapt to a short-term overwhelming response. However, resistance can also occur if certain 
environmental triggers become chronic triggers. For example, in the event of a chronic 
overconsumption of energy-rich nutrients. Resistance to some of the regulatory hormonal, 
neuronal and intracellular feedback responses described above can have adverse metabolic 
effects, such as insulin resistance, leptin resistance and neuronal satiety resistance [14]. With 
negative feedback, an altered level of the input (for example a high glucose concentration) is 
sensed and accordingly feedback is given (for example a higher insulin concentration). With 
resistance to feedback, a chronically elevated level of the feedback (for example a high insulin 
concentration) is sensed and accordingly feedback resistance arises (for example a lower 
insulin receptor concentration). Therefore, resistance to negative feedback is paradoxically 
governed by negative feedback itself. It is an adaptation to chronically altered (environmental) 
feedback triggers. And it is precisely this altered ‘obesogenic environment’ that has led to a 
sudden rise in the prevalence of obesity and the metabolic syndrome since the late 1970’s.
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 Unbalanced energy metabolism
Metabolic syndrome
Starting from the 1920’s, the recognition of a particular clustering of metabolic abnormalities 
in patients led to a new diagnosis: Metabolic syndrome (MetS) [15]. There are multiple clinical 
definitions for MetS used worldwide, but MetS is predominantly characterized by increased 
risk for cardiometabolic diseases such as type 2 diabetes, atherosclerosis and subsequent 
CVD and infarction. The risk factors used in the various MetS definitions include obesity, 
high levels of blood glucose (hyperglycemia), abnormal levels of blood lipids (dyslipidemia), 
increased inflammation and high blood pressure. The utility of the diagnosis MetS is debated, 
as the MetS definition does not predict cardiovascular disease development any different from 
the sum of the individual risk factors [16]. Nonetheless, the co-occurrence of the metabolic 
risk factors indicates a common underlying cause or causes, most likely a combination of 
genetically determined susceptibility and a change in environmental factors affecting energy 
metabolism at large. The different risk factors and their known genetic and environmental 
interactions will be reviewed.
Obesity
In obesity, the adipose tissue mass expansion can be due to increased triglyceride storage 
in the lipid droplet of the adipocyte (hypertrophy), and/or increased formation of new 
adipocytes (hyperplasia). The relative importance of hypertrophy and hyperplasia in obesity 
has been estimated and although total adipose tissue mass predictions were highly correlated 
to adipocyte size, the correlation failed for morbidly obese individuals. When adipocyte 
number was also taken into account [17] the majority of the variability in adipose tissue 
mass could be explained. Therefore both hypertrophy and hyperplasia contribute to (morbid) 
obesity. In obesity, the absolute adipocyte number is often higher than normal weight 
controls, as determined by an increased hyperplasia rate before adulthood [17]. Regulation 
of both hypertrophy and hyperplasia occurs, most likely via negative feedback. A homeostatic 
set-point of adipocyte size was found in studies conducting short term food restriction or 
overfeeding studies and a set point of adipocyte number was found in studies towards the 
effects of liposuction [18, 19]. 
The expansion of the adipose tissue mass can occur at different adipose tissue depots. 
Adipose tissue surrounding the internal organs (visceral white adipose tissue, vWAT) has been 
shown to produce relatively more fatty acids and inflammatory compounds [20] compared 
to fat stored under the skin (subcutaneous, sWAT). Therefore, expanded vWAT has been 
associated with an increased risk of the obesity-related complications of the MetS compared 
to expanded sWAT [21]. Although vWAT is an important risk factor, the abdominal fat in 




sWAT located around the hips remains largely unsolved [22].
The evolutionary mechanisms that have shaped our energy balance seem to favor 
mechanisms which create a positive energy balance in preparation of periods of shortage. 
It drives our behavior to eat energy rich foods used for energy storage in order to overcome 
these periods. Intriguingly, a large part of the known genetic contributors to obesity are 
polymorphisms in genes involved in eating behavior, regulating the neuronal satiety balance 
between orexic and anorexic appetite signals [23, 24]. It was estimated that between 40-
80% of the variation in body mass index (BMI) can be explained by heritable factors such as 
genetic variants involved in appetite regulation and pre-adipocyte differentiation regulation 
[24, 25]. The non-heritable variation is also strongly affected by variation in socio-economic 
status (SES), as a lower SES is generally associated with a higher body mass [26] or in the 
variation of individual economic insecurity and related uncertainty stress [27]. These non-
heritable factors could prompt less healthy eating habits. 
The prevalence of obesity is rising in a timeframe too short to be explained by changes in 
heritable factors. Therefore, the increased prevalence must be due to environmental changes 
(obesogenic environment), such as energy-dense foods becoming more widely available in 
bigger, cheaper portions. This has led to an increased energy intake, mainly by increased 
carbohydrate intake compared to the 1970s. At the same time, aerobic fitness and energy 
expenditure have been diminishing, as a result of a more sedentary lifestyle, by for example 
increased car usage and screen entertainment [28, 29]. What the relative contribution is of 
the two factors, energy intake and energy expenditure, to the obesity epidemic is difficult to 
estimate [30].
In obesity, adipocytes are chronically relaying their hypertrophic stressed state by for 
example high leptin secretion. Therefore, resistance to chronically high adipokine levels 
occurs during obesity, both in the brain and in peripheral tissues. For example obese subjects 
suffer from leptin resistance, where leptin can no longer efficiently inhibit hunger signaling 
nor can it stimulate energy expenditure [31]. Therefore, leptin resistance contributes to a 
vicious cycle in obesity development. Resistance to other adipokines has been observed, but 
their role in obesity-related diseases is not as clear as for leptin at the moment [32]. 
Insulin resistance
Insulin resistance is a decreased responsiveness of the body to insulin signaling. The amount 
of insulin secreted from the pancreatic β-cells is based on sensing the levels of nutrients, 
primarily blood glucose levels and secondarily NEFA and amino acid levels, such as branched 
chain amino acids [33]. Insulin resistance is associated with a decreased number of insulin 
receptors on the insulin-sensitive cell membranes. Also, the downstream signaling efficiency 
of the activated insulin receptor is diminished by a decreased number of (active) signal 
transduction proteins in the insulin pathway [33]. Once insulin resistance develops, the 
pancreas secretes more insulin to maintain normal blood glucose levels (~5 mM). The insulin 
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resistant state can deteriorate further, leading to hyperglycemia despite increased levels of 
insulin. This state is called type 2 diabetes mellitus (T2DM). Finally, the chronically elevated 
insulin production will lead to a failure of the β-cells, which will cease to produce endogenous 
insulin. These patients are subsequently dependent on exogenous insulin injections [33]. 
Insulin resistance may be due to a number of possible causes, their contribution differing 
widely per individual. As the risk of T2DM is strongly related to increasing BMI, obesity is an 
important risk factor. Therefore many explanations for T2DM and insulin resistance involve 
consequences of obesity [34]. 
Due to an overabundance of digested nutrients entering the bloodstream, adipocytes will 
take up more NEFAs. It is well known that acute lipid infusion and NEFA uptake in cells will 
cause insulin resistance on the short term [35], by an acute accumulation of the intermediates 
of NEFA β-oxidation in mitochondria [36]. Therefore an important early contributor 
to adipose tissue insulin resistance could be increased NEFA uptake and subsequent 
mitochondrial processing. Adipocyte-specific knockout of genes involved in mitochondrial 
functioning resulted in a less burdened mitochondrial membrane potential. Upon feeding a 
high fat diet, these adipocyte-specific knockout mice showed decreased mitochondrial stress, 
enhanced adipose insulin sensitivity and enhanced whole-body insulin sensitivity [37, 38]. 
A later stage contributor to insulin resistance originating from adipose tissue could be 
the increasing lipid load of adipocytes becoming hypertrophic. Lipid load is correlated to 
lipid hydrolysis and NEFA release, but also to the release of certain adipokines, such as 
leptin. Increased adipocyte lipolysis would lead to increased intracellular adipocyte NEFA 
concentrations, but also to increased circulating NEFA concentrations. NEFAs could become 
lipotoxic by affecting mitochondrial functioning in adipose tissue, but also in peripheral 
tissues taking up increased amounts of NEFAs [39]. Furthermore, adipocyte hypertrophy 
also leads to hyperleptinenemia and leptin resistance. As leptin inhibits β-cell insulin release, 
leptin resistance can cause systemic hyperinsulinemia [36].
Another late stage contributor to obesity related insulin resistance might be the fact that 
advanced adipocyte hypertrophy can induce intracellular stress [34], possibly due to: 1) 
reaching the maximal mechanical expandability of the adipocytes and adipose tissue within 
the body, 2) intracellular hindrance of the expanding lipid droplet with organelles such 
as mitochondria and the endoplasmic reticulum, and/or 3) reaching the maximal oxygen 
diffusion limit of the enlarged cells. As a consequence of adipocyte intracellular stress, serine 
protein kinases will be activated and will phosphorylate serine residues of insulin receptor 
substrate 1 (IRS1) [34]. Serine phosphorylation of IRS1 will directly interfere with the kinase 
activity of the activated insulin receptor on IRS1 tyrosine residues. Insulin resistant adipocytes 
will respond less to insulin-inhibition of lipolysis and will therefore have a higher rate of basal 
lipolysis and NEFA release, which then forms a vicious cycle for increased NEFAs. 
The intracellular stress of hypertrophic adipocytes can become too great, leading to the 
secretion of immune modulating stress factors and eventually to adipocyte death. Dying 




factors [34]. This also leads to a vicious cycle of inflammation. These immune cells and 
immune factors will decrease insulin sensitivity locally, but will eventually spread via the 
circulation to peripheral tissues, thereby inducing whole-body insulin resistance. Although 
many important associations have been found between insulin resistance and adipose tissue 
related changes, the causal sequence and the relative contributions of the adipose tissue 
changes to adipose and whole-body insulin resistance have not been completely elucidated.
Although T2DM is strongly associated with obesity, the association does not have to be 
directly causative. Other causative associations exist with T2DM, unrelated to or indirectly 
related to obesity. For example, 38% of the variation in HOMA-insulin resistance can be 
explained by heritable factors in Caucasian families [40]. Genome wide association studies 
on T2DM have been done to identify which molecular mechanisms could be involved. These 
GWAS have found that most genetic variants associated to T2DM are related to pancreatic 
β-cell functioning, not to obesity [41, 42]. An unstable pancreatic β-cell functioning might 
become problematic under certain conditions, such as obesity. If the β-cell functioning of 
metabolically healthy obese patients is more robust, these obese patients might be more 
resilient to developing T2DM and will merely develop hyperinsulinemia [43]. As with 
many complex diseases, the discovered genetic variants are capable of explaining only a 
small portion of the theoretical heritability of insulin resistance. Therefore, the search for the 
“missing heritability” of insulin resistance will continue [25].
Dyslipidemia
Dyslipidemia is characterized by abnormal blood lipid levels, such as triglycerides (TG), 
phospholipids (PL), cholesterol esters (CE) and total cholesterol (TC) levels. Not only is the 
absolute concentration of blood lipids an important risk factor for CVD, the distribution 
of blood lipids over lipoprotein particles also contributes [44]. For example, cholesterol is 
present in both VLDL and LDL (built around apoB100) as well as in HDL (built around 
apoAI). The VLDL/LDL particles deliver cholesterol and the HDL particles are thought to 
remove cholesterol from peripheral tissues. If the relative balance between LDL-cholesterol 
and HDL-cholesterol has shifted towards the LDL side, reverse cholesterol transport would 
be lowered [45] leading to peripheral and vascular cholesterol accumulation as a potential 
risk factor for CVD [44]. This view has led to an interest in drugs which shift the LDL/HDL-
cholesterol ratio towards the HDL side. One of these drugs is niacin [46].
Another dyslipidemic balance that has gained interest is the omega-3 over omega-6 poly 
unsaturated fatty acid ratio (n-3/n-6 PUFA ratio) [47]. Similar to total plasma cholesterol the 
absolute PUFA quantity is the most important determinant of CVD risk [48], and similar 
to LDL/HDL cholesterol the relative distribution of n-3/n-6 PUFA has been associated with 
CVD risk [49]. The quantitative intake of PUFAs is easily met in our present-day Western type 
diet. However, the Western dietary n-3/n-6 PUFA ratio is about 1:16. This low dietary n-3/n-6 
PUFA ratio also resulted in a low n-3/n-6 PUFA ratio of the PUFAs incorporated the body’s 
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cell membranes. A shift in the blood n-3/n-6 PUFA ratio away from n-3 PUFAs has been 
shown to enhance dyslipidemia and increase LDL-cholesterol levels [48]. Epidemiological 
studies have repeatedly found that people with a higher n-3/n-6 PUFA ratio in their blood 
have a reduced risk of dying from CVD [50, 51]. Also, the addition of the n-3/n-6 PUFA 
ratio improves CVD risk estimations on top of the classical dyslipidemia criteria [47, 52].
Susceptibility to dyslipidemia can be inherited. Variation in TG and HDL-C levels can 
be explained for 31% and 43% respectively by heritable factors in a Dutch population [53]. 
The known genetic contributors are mostly directly associated with lipid metabolism in the 
liver. For example, via genetic variants affecting apolipoproteins (such as apolipoprotein A5), 
lipoprotein particle synthesis enzymes or adaptor proteins involved in the synthesis, transport 
and binding of lipoprotein particles [54]. 
Heritable factors also explain some 24% of the biological variation in n-3/n-6 PUFA ratio 
[55]. Interestingly, genome wide association studies have found an association between 
plasma cholesterol levels and genetic variants affecting FADS1 and FADS2. These genes 
encode for the rate-limiting enzymes in the synthesis of n-3 and n-6 PUFAs [56]. This genetic 
association between PUFA synthesis genes and cholesterol levels is interesting, as PUFAs can 
inhibit cholesterol biosynthesis [57]. This hints towards a mechanistic link between decreased 
(endogenously synthesized) PUFAs and the development of dyslipidemia. 
The mechanisms underlying the non-heritable causes of dyslipidemia are less clear. Diet 
quality and increased carbohydrate intake have been associated with dyslipidemia [58]. 
Obesity and insulin resistance have also been implicated in the development of dyslipidemia. 
Obesity induces increased blood NEFA levels which are substrates for liver VLDL-TG 
thereby increasing VLDL production and circulating levels of these atherogenic particles. In 
the hepatic insulin resistant state, the liver is less responsive to insulin-mediated inhibition 
of VLDL production. Therefore both obesity and insulin resistance could lead to VLDL 
overproduction and hyperlipidemia. 
Mortality of the Metabolic Syndrome
The majority of severe complications associated with the MetS are due to cardiovascular disease, 
although MetS also increases the risk of other complications, such as cancer. Cardiovascular 
diseases are mostly a consequence of atherosclerosis. Atherosclerosis is the process of the 
narrowing of arteries by accumulation of calcium, (modified) lipids and inflammatory cells 
in the arterial wall. If the narrowed artery becomes blocked, the downstream tissue becomes 
ischemic. If the atherosclerotic wall ruptures, the accumulated debris will initiate blood 
coagulation and the resulting blood clot will travel through the bloodstream.  The blood clot 
can occlude a downstream narrower artery. Depending on the location of the occluded artery, 
this can result in for example a heart attack or a stroke.




Dyslipidemia can shift the balance between cholesterol delivery and cholesterol removal by 
LDL and HDL respectively [45]. Increased levels of LDL particles will bind to proteoglycans 
on the arterial endothelial cells resulting in increased LDL particle transport across the 
arterial wall. If these lipids become oxidized and modified, this stimulates phagocytosis by 
macrophages [59]. and will attract more inflammatory cells to the site of early inflammation. 
These cells will accumulate in the arterial wall, causing atherosclerosis. If the total cholesterol 
over HDL-cholesterol doubles in a person between 40-65 years old from 4 to 8 this also 
doubles the risk to dying from a CVD [60].
The complications of insulin resistance and T2DM are characterized by glucose-induced 
damage to the retina, kidneys, neurons and the extremities, as specifically endothelial cells 
and nerve cells cannot efficiently down-regulate glucose influx during hyperglycemia [61]. 
The increased intracellular glucose level has been suggested to increase mitochondrial 
production of radical oxygen species and advanced glycosylated end-products [61]. At high 
concentrations, glucose will react with amino acid residues of proteins, thereby glycosylating 
proteins, which are an inflammatory trigger [62]. The inflamed capillary endothelial cells 
become damaged, which can initiate atherosclerosis [63]. About 5% of the Dutch population 
suffered from type 2 diabetes in 2011 and this percentage is increasing [64]. A person 
diagnosed with T2DM has an increased risk of dying from CVD within 10 years that is 
equivalent to that person aging 15 years [60].
Obesity is not lethal as such, however it significantly increases the risk for other co-
morbidities which can lead to death. Increased adipose tissue mass is strongly associated 
with increased blood pressure [21], which can damage the arteries and the heart. In the 
Netherlands, 42% of the population was overweight in 2013 and 10% was obese [65]. Obese 
subjects have about a 1.5 time higher risk of dying than normal weight subjects [66]. 
Predicting the risk of dying from CVD is most effective by measuring factors closely 
associated to death. For example, atherosclerosis is a better risk marker then dyslipidemia, 
which is a better risk marker then obesity. The further away from death, the worse the factor 
will be at predicting the risk of death. But the further away from death, the more time there 
might be to intervene with the risk of dying. 
Outline of this thesis
The research described in this thesis focuses on factors that modulate energy metabolism, 
leading to obesity and insulin resistance, with a specific focus on fatty acid metabolism. An 
introductory overview of this topic is presented in Chapter 1. In the subsequent chapters, we 
examine the role of specific genes in disturbing energy metabolism and reversely, we examine 
the effects of disturbed energy metabolism on adipose tissue characteristics, in the context of 
diet-induced obesity and insulin resistance. 
GWAS have revealed numerous single nucleotide polymorphisms (SNPs) in genes 
associated with obesity and related metabolic disorders. However, translating this genetic 
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CHAPTER 1
information to a mechanism by which the disease could arise has proven difficult. In order 
to assist scientists in reviewing possible mechanisms by which a SNP could be associated to 
a disease or disease-marker, we describe in Chapter 2 the application of a newly developed 
knowledge-based workflow for assisting users in mapping SNPs to genes. We applied this new 
workflow to a statistically strong, but mechanistically weak association of a SNP mapped to the 
HPS5 gene, which associated with branched chain amino acid (BCAA) degradation products 
[67]. We found that another gene (LDHA) is mechanistically a more plausible candidate gene 
than HPS5 and we verified this functional association experimentally. Previous research from 
our laboratory has shown that BCAA metabolism is affected in obese and diabetic individuals, 
indicating the possible relevance of the SNP mapped to LDHA in metabolic diseases. 
In Chapter 3, we investigated the mechanism by which the APOA5 gene, which has been 
shown to affect plasma triglyceride levels [68], affects energy metabolism using mice deficient 
for Apoa5. APOA5 has been proposed to function as an anchor protein on lipoprotein 
particles and to play a role in lipoprotein lipase mediated lipolysis [69]. Since Apoa5 deficient 
mice eat more food and develop severe obesity, we investigated the mechanism underlying 
the hyperphagic phenotype. Our results indicate that APOA5 may play a role in the central 
regulation of satiety.
In the second part of this thesis, we studied the impact of a disturbed energy metabolism 
on adipose tissue characteristics. Niacin is a drug that has been used to treat dyslipidemia 
in humans. Although niacin acutely inhibits fatty acid release from adipocytes, prolonged 
treatment is associated with adipocyte insulin resistance. In Chapter 4, using a transgenic 
mouse model with a human-like lipoprotein metabolism, the underlying mechanism of 
prolonged niacin treatment leading to insulin resistance was investigated. Our results show 
that niacin induced insulin resistance is due to an adaptation of PDE3B; a central regulator 
of cAMP signaling. 
Chapter 5 focuses on changes in PUFA metabolism in mouse adipose tissue after niacin 
treatment, which might play a role in the effects of niacin on CVD risk. We found that niacin 
increases PUFA synthesis and n-3 PUFA secretion into the circulation. These n-3 PUFAs 
were converted to increased levels of anti-inflammatory oxylipins, which might contribute to 
niacin’s beneficial effects on CVD.
In Chapter 6, we examined adipose tissue from extremely obese women with and without 
T2DM. In previous research from our laboratory we have found that adipose tissue from 
obese women with T2DM is in a more pro-inflammatory state both at the cellular and at the 
gene expression level. In Chapter 6 the adipose tissue was analyzed for fatty acid composition. 
We found that obese women with T2DM have more n-3 and n-6 PUFAs in their adipose tissue 
and seem to have an increased conversion of PUFAs towards pro-inflammatory leukotrienes.
Finally, we will discuss the results obtained from these studies in Chapter 7 and their 
implications in the regulation of energy and fatty acid metabolism and how they relate to the 
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Reanalysis of mGWAS results and in vitro 
validation show that lactate dehydrogenase 
interacts with branched-chain amino acid 
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The assignment of causative genes to noncoding variants identified in Genome Wide 
Association Studies (GWASs) is challenging. We show how combination of knowledge 
from gene and pathway databases and chromatin interaction data leads to reinterpretation 
of published quantitative trait loci for blood metabolites. We describe a previously 
unidentified link between the rs2403254 locus, which is associated with the ratio of 
3-methyl-2-oxobutanoate and alpha-hydroxyisovalerate levels, and the distal LDHA 
gene. We confirmed that lactate dehydrogenase can catalyze the conversion between 
these metabolites in vitro, suggesting that it plays a role in branched-chain amino acid 
metabolism. Examining datasets from the ENCODE project we found evidence that the 
locus and LDHA promoter physically interact, showing that LDHA expression is likely 
under control of distal regulatory elements. Importantly, this discovery demonstrates that 




REANALYSIS OF mGWAS INDICATED INVOLVEMENT OF LDHA IN BCAA-METABOLISM
Introduction
Due to recent advances in metabolomics technology and decreasing costs, Genome Wide 
Association Studies have now been performed on a wide range of metabolites [1-4]. These 
studies have provided new insights into how biochemical pathways are affected by genetic 
polymorphisms and have increased our understanding of the pathogenesis of metabolic 
disease [3,5]. Since variation in metabolite levels is often linked to changes in enzyme or 
transporter activity, functional annotation of the loci that are located in or close to enzyme 
coding genes has been straightforward. However, for a substantial part of the loci identified in 
mGWAS no obvious link between the metabolite and proximal enzyme coding genes exists, 
and the association with the phenotype is much harder to explain.
We developed an automated workflow for mapping the results of GWASs on pathway 
databases to assist in their interpretation. We applied the workflow on the 37 loci that have 
been reported by Suhre et al. [3] and were able to provide a new functional annotation of 
the rs2403254 (chr11.hg19:g.18325146C>T) single nucleotide polymorphism (SNP) which 
associates with the ratio of 3-methyl-2-oxobutanoate and alpha-hydroxyisovalerate levels in 
the blood. Reanalysis of this locus uncovered a functional link to the gene coding for the 
lactate dehydrogenase (LDH) A enzyme and in vitro analysis confirmed that LDH could 
convert 3-methyl-2-oxobutanoate into alpha-hydroxyisovalerate. In addition, we found 
a physical association between the rs2403254 locus and the LDHA promoter region in the 
chromatin interaction data from the ENCODE project [6-8]. Combined, our data suggest 
that LDH interacts with branched-chain amino acid metabolism and is affected by genetic 




Automated annotation of GWAS results
In order to facilitate the manual process of assigning a gene to each locus, we developed an 
automated workflow in house to generate reports containing the associated protein, enzyme, 
metabolic reaction, pathway, and disease phenotypes of each gene within a distance of 500 
kb of the locus. In detail, the reports created by our workflow were based on the dbSNP[9], 
NCBI-Gene (http://www.ncbi.nlm.nih.gov/gene), ConsensusPathDB[10], UniProtKB[11], 
OMIM[12], Gene Ontology[13], TCDB[14], ExPASy[15] and KEGG database[16]. 
The databases had been downloaded earlier from the respective ftp servers and have been 
integrated offline using MATLAB (R2010a, The Mathworks Inc., Natick, MA, USA). 
Characterization of rs2403254 locus
Chromatin accessibility and interactions were initially evaluated in the UCSC genome browser 
(http://genome.ucsc.edu). Subsequently cell-type specific DHS correlations and ChIA-PET 
(K562 Pol II) data were imported in MATLAB and superimposed on the regional LD data of 
the rs2403254 locus based on the 1000 Genomes Pilot 1 data of the CEU population (calculated 
using SNAP[17]). Since the ChIA-PET K562 Pol II data comprised two replicates, we only 
considered interactions for which the interacting regions overlapped between both replicates. 
Finally, eQTLs associated with LDHA expression as reported in the GTEx (http://www.ncbi.
nlm.nih.gov/gtex/GTEX2) and gEUVADIS[18] database were imported and added to the 
regional LD plot.
Lactate dehydrogenase activity
Enzyme kinetic measurements were done in a 96 well plate in quadruple, based on the protocol 
of Vassault et al. [19]. Briefly, substrates were dissolved in buffer solution (80 mM TrisHCl, 
0.20 mM NADH, pH 7.2 at 30°C) to the final concentrations mentioned in figure 2 in 180 µl. 
Lactate dehydrogenase was added (20 µl) containing 2.03•10-5 mg LDH per well for pyruvate, 
9.27•10-3 mg for 3-methyl-2-oxobutanoate, 9.27•10-2 mg for 3-methyl-2-oxopentanoate and 
1.63•10-2 mg for 4-methyl-2-oxopentanoate reactions. The decrease of A340 nm for NADH was 
measured every 8 sec for 6 min after which the slope was taken and using a calibration curve 
for NADH was recalculated as specific activity (U) in µmol NADH min-1 mg-1 LDH. 
Data availability
We have submitted our finding of the link between rs2403254 and LDHA to the ClinVar 
database (http://www.ncbi.nlm.nih.gov/clinvar; accession number SCV000211950).
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Results
Automated annotation of GWAS results
The automated workflow we developed was used to generate reports for each of the 37 
SNPs published by Suhre et al. [3], containing the associated protein, enzyme, metabolic 
reaction, pathway, and disease phenotypes of each gene within a distance of 500 kb of the 
locus. Inspection of the results showed that for one of the 37 SNPs, rs2403254, there was an 
alternative candidate gene that provided a more likely explanation of the association. The 
rs2403254 SNP was associated with alpha-hydroxyisovalerate levels in the blood (p=1.0∙10-
20) and showed an even stronger correlation with the ratio of 3-methyl-2-oxobutanoate and 
alpha-hydroxyisovalerate levels (p=7.9∙10-28). The rs2403254 SNP lies inside the HPS5 gene 
and had therefore been assigned to HPS5 by Suhre and colleagues. However, from inspection 
of the results from our workflow it followed that a plausible alternative candidate gene in the 
vicinity of the locus was LDHA, which codes for the A-isoform of the lactate dehydrogenase 
(LDH) enzyme. In addition, from information retrieved from the KEGG database [16] it 
followed that LDH has a broad substrate specificity and can catalyze the conversion of several 
keto and hydroxy acids, even though 3-methyl-2-oxobutanoate or alpha-hydroxyisovalerate 
were not listed as substrates (Supplemental Text S1). 
The rs2403254 locus
Closer examination of the locus showed that rs2403254 is located in a large linkage 
disequilibrium (LD) block, which lies approximately 20kb upstream of LDHA (Fig. 1). To 
investigate the presence of potential long-distance regulatory mechanisms, we first looked at 
expression Quantitative Trait Loci (eQTLs) in lymphoblastoid cell lines that were associated 
with LDHA. These eQTLs were all located downstream of the LD block and were not in strong 
LD with rs2403254. In contrast, we found that rs2403254 is an eQTL for HPS5 (p=4.4∙10-9) 
and GTF2H1 (p=8.4∙10-15), most likely because it is in strong LD (R2 > 0.8) with several SNPs 
that lie close to the transcription start sites of these genes. 
Subsequently we explored chromatin interactions and the presence of regulatory elements 
in the LD block by looking at the DNase I signal data from the ENCODE project [6-8]. 
Interestingly, several regulatory regions were present within the LD block whose DNase I 
signal had a strong cross-cell-type correlation with the LDHA promoter (Fig. 1; bottom). 
These potential distal interactions were supported by the Chromatin Interaction Analysis 
with Paired-End-Tag (ChIA-PET) sequencing data, which showed that there were significant 
chromatin interactions between the central region of the LD block and the region containing 
the LDHA promoter. Collectively, these data show that long-range regulation of LDHA by 




Figure 1: Regional Linkage Disequilibrium (LD) plot of the rs2403254 locus. The rs2403254 locus is located in a 
region of strong LD spanning over approximately 100kb. Several eQTLs have been identified that associate with 
LDHA expression, but none lie in LD with rs2403254. In contrast, chromatin interaction ChIA-PET data and cell type 
specific DNase I hypersensitive site correlations show that there are several chromatin interactions between the 
LDHA promoter and regulatory elements within the LD block.
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Experimental validation
Subsequently, we investigated whether LDH could catalyze the conversion between 
branched-chain alpha-keto and hydroxy acids. In previous studies LDH had already been 
shown to catalyze a broad range of substrates [20, 21], but because of the extremely low 
rates with which branched-chain alpha-keto and hydroxy acids were converted it was unclear 
whether this reaction was mediated by LDH or another dehydrogenase [22, 23]. We 
therefore validated our finding by assaying the activity of LDH in the presence of NADH 
and the transaminated branched-chain keto acid products 3-methyl-2-oxobutanoate (valine), 
4-methyl-2-oxopentanoate (leucine), 3-methyl-2-oxopentanoate (isoleucine) and pyruvate 
for a range of different substrate concentrations (Fig. 2). Results show that LDH was indeed 
able to convert 3-methyl-2-oxobutanoate, but it had a specificity constant kcat/Km that was 
approximately 3000 times lower than with pyruvate as substrate (Table 1). In comparison, the 
kcat/Km of the other two branched-chain alpha-keto acids was around 10 times lower than with 
3-methyl-2-oxobutanoate as substrate. Most probably 3-methyl-2-oxobutanoate is converted 
more efficiently by LDH because it is a smaller molecule, having a carbon chain of 4 atoms, 
whereas 3- and 4-methyl-2-oxopentanoate have a carbon chain of 5 atoms. Interestingly, the 
Km value for pyruvate and 3-methyl-2-oxopentanoate were very similar, while for the other 
two branched-chain alpha-keto acids it was 3 to 4 times larger. 
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Figure 2: Enzyme kinetics of rabbit muscle lactate dehydrogenase. Specific activity in µmol NADH min-1 mg-1 LDH of 
rabbit muscle lactate dehydrogenase for A) pyruvate, B) 3-methyl-2-oxobutanoate, C) 4-methyl-2-oxopentanoate 
and D) 3-methyl-2-oxopentanoate. Assay conditions were 30°C, pH 7.2, initial [NADH]=0.20 mM. 
Table 1: Kinetic parameters of rabbit muscle lactate dehydrogenase. Km and kcat are Michaelis-Menten parameters 
( v = kcat [E] [S] / (Km+[S]) ), while h, K1/2 and kcat’ are allosteric sigmoidal parameters ( v = kcat’ [E] [S]
h / (K1/2
h+[S]h) ). 
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Discussion
The discovery of the functional link between the rs2403254 locus and the LDHA gene has 
been made possible by the automated workflow we developed for annotating GWAS results, 
which allowed us to examine the set of loci reported by Suhre et al. [3] in both a quick 
and thorough manner. In recent years there has been an increasing interest in bioinformatics 
tools for the analysis, interpretation and integration of results from GWASs [24, 25]. Suhre 
and colleagues have employed the tool GRAIL from the Broad Institute [26] in their study, 
which uses textual relationships between genes to prioritize candidate genes for a given locus. 
Nonetheless, using this method the authors did not identify LDHA as a plausible candidate 
for the rs2403254 locus, most likely because alpha-hydroxyisovalerate is currently not present 
in pathway databases and its link to LDH has only been scarcely described in the literature. 
In fact, the locus was replicated in a recent meta-analysis on the same metabolomics platform 
[27], but HPS5 was still proposed as candidate gene.   
In contrast, with our approach we focused on integrating the knowledge present in 
several databases in order to produce succinct SNP reports containing relevant information 
about all neighboring genes. In the case of the rs2403254 locus the SNP report showed that 
LDHA was the closest gene with a metabolic function and that LDH was documented in 
the KEGG pathway database as an enzyme that can catalyze multiple reactions. Subsequent 
investigation of the chemical structure of alpha-hydroxyisovalerate suggested that - in 
principle - its conversion could be catalyzed by LDH. This hypothesis was further reinforced 
by the observation that the same locus had a stronger association with the ratio of alpha-
hydroxyisovalerate and 3-methyl-2-oxobutanoate levels and that alpha-hydroxyisovalerate is 
the product of 3-methyl-2-oxobutanoate after reduction of the alpha-carbonyl group.
Our results suggest that there is a functional link between LDHA and alpha-
hydroxyisovalerate levels and, more specifically, that LDH can compensate for large build-
ups of branched-chain alpha-keto acids under hypoxic conditions. In fact, the first step of 
branched-chain amino acid catabolism involves the transamination of the amino group, 
which changes the oxidation level of the adjacent carbon atom. Under anaerobic conditions 
the redox balance needs to be restored, which can be achieved through LDH by converting 
the alpha-keto acid into an alpha-hydroxycarboxylic acid (Fig. 2). This  process has been 
observed in babies who suffered from asphyxia during birth, where elevated levels of alpha-
hydroxyisovalerate were found in the urine [28]. Interestingly, also infants that suffer from 
Maple syrup urine disease, which is a defect in any of the genes coding for the components of 
the BCKDH enzyme complex, have elevated levels of alpha-hydroxyisovalerate in the urine 
[29]. This can be explained by the fact that a blockage in the second step of the branched-
chain amino acid degradation pathway causes a build-up of keto acid intermediates, which 

































Figure 3: Visualization of the valine degradation pathway and the interaction with lactate dehydrogenase. 
Abbreviations of enzyme names are shown in boldface (BCAT: branched-chain aminotransferase; BCKDH: branched-
chain alpha-keto acid dehydrogenase; LDH: lactate dehydrogenase). LDH can convert 3-methyl-2-oxobutanoate, 
which is the product of valine after transamination, into alpha-hydroxyisovalerate to balance the redox potential 
under hypoxic conditions. Under aerobic conditions 3-methyl-2-oxobutanoate can be further degraded by the 
enzymes of branched-chain amino acid catabolism. In contrast, alpha-hydroxyisovalerate cannot be metabolized 
any further and is excreted in urine.
Interestingly, in the meta-analysis of Shin et al. [27] rs2403254 was found to have the strongest 
association with the ratio of 3-(4-hydroxyphenyl)lactate and alpha-hydroxyisovalerate levels. 
3-(4-hydroxyphenyl)lactate is the product of 4-hydroxyphenylpyruvate after reduction 
of the alpha-carbonyl group, which is the product of tyrosine after transamination. Given 
their structural differences it is unlikely that 3-(4-hydroxyphenyl)lactate and alpha-
hydroxyisovalerate can be converted into one another in one or two enzymatic steps. The 
association with rs2403254 is therefore probably due to other mechanisms, such as co-
regulation of aromatic and branched-chain amino acid metabolism.
Importantly, our finding does not preclude effects of rs2403254 on HPS5 or other genes. 
In fact, in our analysis we found that rs2403254 is an expression QTL for HPS5 and GTF2H1, 
which shows that multiple genes can be affected by a single SNP. However, neither of these 
genes provide a biochemical explanation of the phenotype, namely, why rs2403254 is 
associated with the ratio of 3-methyl-2-oxobutanoate and alpha-hydroxyisovalerate levels. 
The absence of eQTLs for LDHA in the databases that we enquired seems to confirm that 
distal eQTLs are more difficult to identify and demonstrates the additional value of chromatin 
interaction data to establish SNP-gene interactions.
2
35
REANALYSIS OF mGWAS INDICATED INVOLVEMENT OF LDHA IN BCAA-METABOLISM
In conclusion, we have uncovered a novel functional link between lactate dehydrogenase 
and the branched-chain keto acid intermediate of valine metabolism by reanalyzing published 
mGWAS results using automated workflows for integrating information from pathway 
databases.
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Text S1: SNP report of the rs2403254 locus for LDHA. Similar gene-reports were generated for all genes within a 
500 kbp distance of rs2403254, as retrieved from NCBI-Gene, ConsensusPathDB, UniProtKB, OMIM, Gene Ontology, 
TCDB, ExPASy and KEGG database.
--------------------------------------------------------------------------------------
SNP  rs2403254   Chr 11   18325146
--------------------------------------------------------------------------------------
  
Distance to locus: -90790    LD R2 of rs2403254 with intragenic SNP rs3758683: 0.11936
     Gene: 3939 (LDHA)   Chr 11   18415936-18429765  (+)
         23516535   the role played by ERRalpha in the regulation of lactate dehydrogenases A and B
         23404405   Lactate dehydrogenase A is overexpressed in pancreatic cancer.
         23266049   Data indicate that serum lactic dehydrogenase (S-LDH) appears to be a significant 
independent prognostic index in patients with metastatic nasopharyngeal carcinoma (NPC).
         23184277   Increased LDH5 expression is associated with lymph node metastasis in oral 
squamous cell carcinoma.
         23166385   Elevated lactate dehydrogenase level is associated with recurrent or refractory 
aggressive lymphoma.
         22961700   LDHA plays an important role in the progression of esophageal squamous cell 
carcinoma by modulating cell growth
         22948140   Cells expressing either PDK1 or LDHA maintained a lower mitochondrial membrane 
potential and decreased reactive oxygen species production with or without exposure to toxins.
         22923663   Lactic acid induces myofibroblast differentiation via pH-dependent activation of 
transforming growth factor beta.
         22897481   Studies indicate the mechanisms by which lactate dehydrogenase A (LDHA) promotes 
tumor growth and metastasis.
         22593701   Data suggest that serum lactate dehydrogenase (LDH) kinetics might reflect disease 
behaviour in extracranial metastatic and primary sites without need for comprehensive imaging studies 
and is a quite inexpensive diagnostic test.
         22429998   We demonstrate that LDH-A reduction can suppress the tumorigenicity of intestinal-
type gastric cancer (ITGC) cells by downregulating Oct4 both in vitro and in vivo.
         22360420   A protein encoded by this locus was found to be differentially expressed in 
postmortem brains from patients with atypical frontotemporal lobar degeneration.
         22127970   Case Report: describe an elderly patient with physical therapy-induced 
rhabdomyolysis complicated by acute kidney injury associated with reduced skeletal muscle LDH-A 
activity.
         21969607   LDH-A is tyrosine phosphorylated and activated by FGFR1 in cancer cells.
         21858537   Results show that S-100B, MIA and LDH levels were significantly higher in patients 
with advanced melanoma than in disease-free patients or healthy controls.
         21632858   Serum LDH and tissue LDH5 levels are complementary features that help to 
characterize the activity of LDH in colorectal cancer and have a potent value in predicting response 
to chemotherapy.
         21452021   LDH-A reduction resulted in an inhibited cancer cell proliferation, elevated 
intracellular oxidative stress, and induction of mitochondrial pathway apoptosis.
         21249322   High LDH is associated with M1b prostate cancer.
         20951115   Presented are QM/MM calculations that show differences in geometries of active 
sites of M(4) and H(4) isoforms of human LDH ligated with oxamate, pyruvate or L-lactate.
         20828817   High lactate dehydrogenase is associated with acute adult T-cell leukemia/
lymphoma.
         20385008   LDH5 is overexpressed in non-small cell lung cancer and could serve as a marker 
for malignancy. LDH5 correlates positively with the prognostic marker transketolase like 1 protein.
         19923867   LDH5 is highly expressed in squamous cell head and neck cancer and is linked with 
local relapse, survival and distant metastasis.
         19847924   Observational study and genome-wide association study of gene-disease association. 
(HuGE Navigator)
         19838163   Correlation of LDH-5 expression with clinicopathological factors and with the 
expression of Bcl-2, Bcl-XL, Mcl-1 and GRP78 was examined in pigmented lesions, including nevi and 
melanoma at different stages of progression
         19668225   ErbB2 promotes glycolysis at least partially through the HSF1-mediated 
upregulation of LDH-A.
         19276158   LDH-A knockdown in the background of FH knockdown results in significant reduction 
in tumor growth in a xenograft mouse model.
         19021062   LDH5 is highly upregulated in B-cell non-Hodgkin lymphomas and is in direct 
relation to factor HIF1alpha and HIF2alpha expression. LDH5 expression is linked with activated 
VEGFR2/KDR expression in both lymphoid lesions.
         18821170   The expression of LDH and its isoenzymes in pleural effusions reflects the host 
reaction in pleural space and, in non-small-cell lung cancer, may also feature the anaerobic phenotype 
of cancer cells.
         18814027   Modulation of LDH expression involves alpha6beta4 integrin-FAK-p38MAPK pathway.
         18534967   LDL-M is released into blood fo patients exposed to myocardial ischemia 
reperfusion.
         18521687   The results of the current study show that LDH-5 expression may be a useful 
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prognostic factor for patients with gastric carcinoma.
         17483170   biophysical study of ligand binding and protein dynamics in lactate dehydrogenase
         17178662   LDH1 was decreased in essential thrombocythemia. This isoenzymatic pattern could 
be expression of a metabolic adaptation.
         17178662   LDH5 was reduced in idiopathic myelofibrosis. This isoenzymatic pattern could be 
expression of a metabolic adaptation [LDH5]
         16766262   Reduction in LDH-A activity resulted in stimulation of mitochondrial respiration 
and decrease of mitochondrial membrane potential.The tumorigenicity of the LDH-A-deficient cells was 
severely diminished.
         16132575   Lactate dehydrogenase 5 content in tumor cells is directly related to an up-
regulated hypoxia inducible factor pathway and is linked with an aggressive phenotype in colorectal 
adenocarcinomas.
         15240094   These data indicate that LDH-A is induced through a non-genomic pathway of 
estrogen action.
         12712614   The activity of this enzyme was studied in tissues, erythrocytes, and blood 
plasma of patients with peptic ulcer both in its uncomplicated course and in the development of 
complications.
         12629811   The study of this protein in a sportsman is significant for assessment of training 
efficiency.
         12555229   an LDHA exon5 haplotype confers increased risk for paradoxically decreased minute 
volume respiratory response to CO2 challenge but not to panic disorder
         Pathway: Pyruvate metabolism - Homo sapiens (human)   (database: KEGG)
         Pathway: Glycolysis / Gluconeogenesis - Homo sapiens (human)   (database: KEGG)
         Pathway: Propanoate metabolism - Homo sapiens (human)   (database: KEGG)
         Pathway: HIF-1 signaling pathway - Homo sapiens (human)   (database: KEGG)
         Pathway: Cysteine and methionine metabolism - Homo sapiens (human)   (database: KEGG)
         Pathway: Cori Cycle   (database: Wikipathways)
         Pathway: Glycolysis and Gluconeogenesis   (database: Wikipathways)
         Pathway: hypoxia-inducible factor in the cardivascular system   (database: BioCarta)
         Pathway: TCR   (database: NetPath)
         Pathway: Pyruvate metabolism   (database: Reactome)
         Pathway: Validated targets of C-MYC transcriptional activation   (database: PID)
         Pathway: Pyruvate metabolism and Citric Acid (TCA) cycle   (database: Reactome)
         Pathway: The citric acid (TCA) cycle and respiratory electron transport   (database: 
Reactome)
         Pathway: Methionine Cysteine metabolism   (database: INOH)
         Pathway: Propanoate metabolism   (database: INOH)
         Pathway: Glycolysis Gluconeogenesis   (database: INOH)
         Pathway: EGFR1   (database: NetPath)
         Pathway: Pyruvate metabolism   (database: INOH)
         Pathway: pyruvate fermentation to lactate   (database: HumanCyc)
         Pathway: HIF-1-alpha transcription factor network   (database: PID)
         Pathway: hypoxia-inducible factor in the cardivascular system   (database: PID)
         Protein: LDHA (P00338)   L-lactate dehydrogenase A chain;
             EC: 1.1.1.27   L-lactate dehydrogenase.       (S)-lactate + NAD(+) = pyruvate + NADH.
             GO: 0004459   L-lactate dehydrogenase activity
             GO: 0005515   protein binding
             GO: 0005634   nucleus
             GO: 0005739   mitochondrion
             GO: 0005829   cytosol
             GO: 0005929   cilium
             GO: 0006090   pyruvate metabolic process
             GO: 0006096   glycolytic process
             GO: 0021762   substantia nigra development
             GO: 0031668   cellular response to extracellular stimulus
             GO: 0044237   cellular metabolic process
             GO: 0044281   small molecule metabolic process
             GO: 0070062   extracellular vesicular exosome
             KO: K00016   L-lactate dehydrogenase [EC:1.1.1.27]
                 ReactionKEGG: R00703   (S)-Lactate + NAD+ <=> Pyruvate + NADH + H+
                 ReactionKEGG: R01000   2-Hydroxybutanoic acid + NAD+ <=> 2-Oxobutanoate + NADH + H+
                 ReactionKEGG: R03104   3-Mercaptolactate + NAD+ <=> Mercaptopyruvate + NADH + H+
         OMIM: 150000 LACTATE DEHYDROGENASE A; LDHA
             OMIM: 612933 GLYCOGEN STORAGE DISEASE XI; GSD11
 
footnotes:
- Linkage disequilibrium R2 is based on founders in HapMap r27 CEU population
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Mutations in apolipoprotein A5 (APOA5) have been associated with hypertriglyceridemia 
in humans and mice. This has been attributed to a stimulating role for APOA5 in 
lipoprotein lipase-mediated triglyceride hydrolysis and hepatic clearance of lipoprotein 
remnant particles. However, due to the low APOA5 plasma abundance, we investigated an 
additional signaling role for APOA5 in high fat diet (HFD) induced obesity. 
Wildtype (WT) and Apoa5−/− mice on chow diet showed no difference in bodyweight or 
24h food intake (Apoa5−/−, 4.5±0.6g, WT, 4.2±0.5g), while on HFD Apoa5−/− mice ate more 
in 24h (Apoa5−/−, 2.8±0.4g, WT, 2.5±0.3g, p<0.05) and became more obese than WT mice. 
Also, intravenous injection of APOA5-loaded VLDL-like particles lowered food intake 
(VLDL-control, 0.26±0.04g, VLDL+APOA5, 0.11±0.07g, p<0.01). In addition, the HFD 
induced hyperphagia of Apoa5-/- mice was prevented by adenovirus-mediated hepatic 
overexpression of APOA5. Finally, intracerebroventricular injection of APOA5 reduced 
food intake compared to injection of the same mouse with artificial cerebral spinal fluid 
(aCSF, 0.40±0.11g, APOA5, 0.23±0.08g, p<0.01). 
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Introduction
Elevated plasma triglyceride (TG) levels and prolonged circulation of lipoprotein remnants 
are independent risk factors for cardiovascular disease [1-5]. In the post absorptive state, 
hypertriglyceridemia is a consequence of aberrant kinetics of VLDL, including hepatic 
overproduction and/or delayed clearance [6]. Apolipoprotein A5 (APOA5) has classically 
been described to be involved in the regulation of TG-rich lipoprotein metabolism [7]. 
APOA5 is a potent stimulator of lipoprotein lipase (LPL) [8, 9] and facilitates lipoprotein 
remnant clearance in a LDL-receptor dependent manner [10]. The function of APOA5 in 
lipid metabolism is supported by the fact that non-obese carriers of the APOA5 -1131T>C 
polymorphism have a disturbed postprandial lipidemic response after a high fat meal [11, 
12]. However, even though in vitro and animal studies suggest that APOA5 accelerates LPL 
mediated TG metabolism and the fact that APOA5 levels are positively associated with plasma 
TG levels, APOA5 does not directly affect postprandial VLDL kinetics in mild dyslipidemics 
or type 2 diabetics [13, 14].
In humans, the plasma concentration of APOA5 is low (114 to 258ng⋅ml-1  in normolipidemic 
subjects [15, 16]), possibly due to its low excretion rate [17, 18]. On a molar basis, APOA5 
plasma levels are 1,000 and 10,000 fold lower when compared to Apolipoprotein B (APOB) 
and APOA1, respectively. Because of the low plasma concentration [19] and in light of the 
low secretion rate, APOA5 has been suggested to play a role in intracellular lipid metabolism. 
Intracellular APOA5 is associated with lipid droplets in liver [20] and adipocytes [21]. 
Interestingly, APOA5 shows a high protein similarity to perilipin-1 (PLIN1), a well-studied 
inhibitor of hormone sensitive lipase (HSL) activity [22]. Recently, intracellular APOA5 
has been shown to co-localize with perilipin-1 in adipose tissue, and to actively regulate TG 
uptake, and thus may be involved in the development of obesity [21].
In addition to dyslipidemia, and in support of a role of APOA5 in the development of 
obesity, APOA5 gene variants have been associated with a greater degree of obesity in a 
number of epidemiological studies involving Caribbean Hispanics [23], pediatric patients 
[24] and Brazilian elderly [25]. In part, this could be due to the proposed role of APOA5 in 
circulating lipid metabolism. Interestingly, it may also be due to altered food intake patterns, 
as the APOA5 -1131T>C gene variant has been shown to be associated with higher fat intake 
[26] and to modulate the effects of dietary fat intake on body mass index and obesity risk 
[27, 28] and dyslipidemia [29].
The aim of this study was to assess the role of APOA5 in the regulation of food intake. 
First, we confirmed that Apoa5−/− mice are dyslipidemic and have an impaired lipid clearance. 
In addition, we further demonstrate that Apoa5−/− mice become more obese, and develop 
hepatic steatosis and become more insulin resistant on a high fat diet (HFD) than WT mice, 
due to a hyperphagic phenotype. Furthermore, the hyperphagic phenotype of Apoa5−/− mice 
is reduced upon adenoviral vector mediated overexpression of APOA5. Moreover, systemic 
(intravenous) as well as central (lateral ventricle) administration of APOA5 reduced food 
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intake by 60% and 45%, respectively, suggesting that APOA5 inhibits food intake, at least 
partly, via a central mechanism.
Materials and Methods
Animals and diets
Male wild type (WT) C57Bl/6Jico mice were obtained from Charles River laboratories 
(Charles River, Maastricht, The Netherlands) at an age of 10 weeks. After at least 2 weeks 
of acclimatization, mice were fed a HFD (45% energy as fat, 4.73kcal⋅g-1, D12451, Research 
Diet Services, Wijk bij Duurstede, The Netherlands). Apoa5−/− mice [30] were bred in-house 
at the Leiden University Medical Center and back-crossed on the C57Bl/6Jico background 
for at least 8 generations prior to homozygous breeding. Absence of the Apoa5−/− gene was 
confirmed by isolated tail DNA PCR (forward; TGGAGGGTCAAAGAAGGATG, reverse; 
GGTTGCTGGTCACAGGATTT). Animals were housed in a controlled environment (21◦C, 
40-50% humidity) under a 12h photoperiod (07:00–19:00). Food and tap water was available 
ad libitum during the whole experiment, unless otherwise indicated. In all experiments, male 
mice were used. All animals were weighed at least once every week. All animal experiments 
were performed in accordance with the regulations of Dutch law on animal welfare and the 
institutional ethics committee for animal procedures from the Leiden University Medical 
Center, Leiden, The Netherlands approved the protocol.
Plasma and liver lipid analysis
Plasma was obtained via tail vein bleeding and assayed for TC and TG, using the commercially 
available enzymatic kits 236691 and 11488872 (Roche Molecular Biochemicals, Indianapolis, 
IN, USA), respectively. Free fatty acids (FA) were measured using NEFA-C kit from Wako 
Diagnostics (Instruchemie, Delfzijl, the Netherlands). Human APOA5 levels were determined 
using a previously described ELISA [31].
Lipids were extracted from livers according to a protocol modified from Bligh and 
Dyer [32]. In short, a small piece of liver was homogenized in ice-cold methanol. After 
centrifugation, lipids were extracted by addition of 1,800μl of CH3OH-CHCl3 (3:1 vol/vol) to 
45μl of homogenate. The organic phase was dried and dissolved in 2% Triton X-100. Hepatic 
TG and TC concentrations were measured using commercial kits, as described above. Liver 
lipids were expressed per milligram of protein, which was determined using the Pierce BCA 
protein assay kit (Thermo Scientific, Rockford, IL, USA).
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Lipid clearance analysis
Glycerol tri(9,10(n)[3H]oleate ([3H]TO) and [1α,2α(n)-14C]cholesteryl oleate ([14C]CO) 
double radiolabeled VLDL-like emulsion particles (mean diameter 80nm) were prepared as 
described before [33]. Mice were anesthetized with 6.25mg⋅kg-1  Acepromazine (Alfasan, 
Woerden, The Netherlands), 6.25mg⋅kg-1 Midazolam (Roche, Mijdrecht, The Netherlands) 
and 0.31mg⋅kg-1 Fentanyl (Janssen-Cilag, Tilburg, The Netherlands) prior to particle injection 
via the tail vein. At time points 2, 5, 10 and 15min post-injection, blood was taken to determine 
clearance rates. After 15 minutes mice were sacrificed and organs were harvested to determine 
[3H]TO and [14C]CO uptake.
Determination of adipocyte differentiation capacity
Adipose tissue from the reproductive and subcutaneous region were harvested and kept in 
PBS. The tissue was minced and digested in 0.5g⋅l-1 collagenase in HEPES buffer (pH 7.4) 
with 20g⋅l-1 of dialyzed bovine serum albumin (BSA, fraction V, Sigma, ST Louis, USA) for 1h 
at 37°C. The disaggregated adipose tissue was filtered through a nylon mesh with a pore size 
of 236µm and the stromal vascular cells were isolated. Preadipocytes were differentiated in 
an adipogenic medium and differentiation capacity was determined as previously described 
[34].
Indirect calorimetry/metabolic cage analysis
WT and Apoa5−/− mice were subjected to indirect calorimetry/metabolic cage analysis 
(Phenomaster, TSE Systems, Bad Homburg, Germany). A period of 48 hours of acclimatization 
was included prior to the start of the experiment. Oxygen consumption (VO2) and carbon 
dioxide production (VCO2) were determined at 9 minute intervals. Respiratory exchange 
ratio (RER) was calculated as the ratio between VCO2 and VO2. Energy expenditure (EE), fat 
oxidation (FAox) rate and carbohydrate oxidation (CHox) rate were calculated as previously 
described [35]. Food intake was monitored in real time. Data from the light and dark phase 
were averaged and tested separately to distinguish periods of high and low physical activity. In 
total the measurement period lasted 7.5 days (chow≈3 days and HFD≈4.5 days). The switch to 
the HFD was performed inside the metabolic cage system at 14:00 for all animals. For the long 
term experiment, mice were fed a HFD for a period of 4 weeks prior to analysis.
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Adenovirus vector mediated overexpression of human APOA5 in 
Apoa5−/− mice
A separate group of Apoa5−/− mice were used for adenoviral vector gene transfer, and subjected 
to indirect calorimetry/metabolic cage analysis during the initial week of high fat feeding. A 
period of 24 hours of acclimatization was included prior to the start of the experiment and 
baseline measurements were performed for each individual animal. Subsequently, animals 
were randomized based on body mass and injected intravenously (vena caudalis) with mock 
LacZ or human APOA5 expressing adenovirus vectors (≈2⋅109pfu). Calorimetric analysis was 
continued for 4 days after injection until the expected peak in transgenic expression [36, 
37]. Since adenovirus vector mediated gene expression in itself may affect energy balance 
[38-40] data were analyzed per animal separately in a paired comparison setting (i.e. pre-
injection vs. post-injection). Differences in the change in food intake over the 4 days were 
compared between groups.
Intravenous APOA5 injection and food intake test
WT mice were fed a high fat diet for a period of 1 week prior to analysis to ascertain 
habituation to the high fat diet. All mice were food restricted for 6 hours prior to injection, 
starting at 12:00, to induce the drive for food intake. To assess the effect of elevated circulating 
APOA5 levels on food intake, VLDL emulsion particles [41] were loaded with human 
APOA5 (100ng⋅µl-1, Abnova, Jhongli, Taiwan). Human APOA5 protein was produced in 
an in vitro wheat germ expression system, which generally results in negligible endotoxin 
levels (Personal communication, V. Yu, Abnova, Jhongli, Taiwan). Analysis of the Sepharose 
purified preparation by SDS-PAGE and Coomassie staining revealed a single band. Non-
loaded control and APOA5 loaded emulsion particles were intravenously injected in the tail 
vein at a dose of 6µg per mouse and injected 6h after food restriction. After injection, food 
intake was recorded up to 120 minutes post injection and expressed as gram food consumed 
per unit of 60 minutes.
Lateral ventricle cannulation and ICV APOA5 injection and food intake 
test
WT mice were fed a high fat diet for a period of 1 week prior to analysis to ascertain habituation 
to the high fat diet. To assess the effect of central administration of APOA5 on food intake, a 25 
gauge guide cannula was implanted into the left lateral ventricle as previously described [42, 
43]. Similar to the IV injection experiment, mice were food restricted to induce the drive for 
food intake. All animals received a successive 1µl bolus injection of artificial cerebrospinal 
fluid (aCSF, Harvard Apparatus, Holliston, MA, USA) (7d post-surgery), APOA5 (10d post-
surgery, 8ng/mouse) and neuropeptide Y (NPY, 14d post-surgery, 5µg/mouse) under light 
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isoflurane anesthesia. After injection, food intake was recorded during the first 120 minutes 
post injection and expressed as gram food eaten per unit of 60 minutes. Correct placement of 
the cannula was assessed in all mice in the fed state at 14d post-surgery by a bolus injection of 
neuropeptide Y at 0900 a.m. Cannulation was assumed to be correct if the animal consumed 
more than 300mg of food within 1 hour post NPY injection. One animal did not meet this 
criterion and was excluded from the experiment.
Hyperinsulinemic-euglycemic clamp in conscious mice
WT and Apoa5−/− mice were subjected to hyperinsulinemic-euglycemic clamp analysis as 
previously described [44]. In short, all mice were equipped with a single catheter in the right 
jugular vein for infusion. After surgery, mice recovered for a period of 8 days prior to the 
clamp analysis, in individual cages. Food intake and body weight returned to preoperative 
levels within 2-3 days. Food was removed 9 hours before the start of the experiment, but the 
animals had free access to water. Clamp quality control was determined by calculating the 
coefficient of variation (COV) of the glucose infusion rate (GIR) and plasma glucose levels 
over the last 30 minutes of the clamp. COV of the GIR and glucose levels were determined to 
be below 2% for both genotypes.
Statistics
All data are represented as mean ± standard deviation. Energy intake data was tested by 
unpaired t-test for normally distributed data or paired t test in case of the adenoviral and icv 
experiment. Threshold for statistical significance was set at 5%. Tests were performed using 




High fat fed Apoa5−/− mice are hyperlipidemic and have severely 
impaired lipid clearance
Plasma was isolated from food restricted Apoa5−/− and WT mice fed a HFD for 10 weeks, 
after which plasma cholesterol, TG, phospholipid and free fatty acid levels were determined. 
Apoa5−/− mice were hyperlipidemic (Table 1) and in line with these data, Apoa5−/− mice showed 
severely impaired lipid clearance. The plasma decay of injected [3H]TO and [14C]CO-labeled 
emulsion particles was slower in Apoa5−/− mice for the TO label (Figure 1 A, B) as well as the 
CO label (Figure 1 C, D), due to a significantly lower uptake in organs with a high metabolic 
activity (liver, heart, muscle, brown adipose tissue). In addition, CO label uptake was also 
lower in liver and brown adipose tissue, but not in heart and muscle. These data confirm 
previously published data (10;30) and demonstrate that the hyperlipidemic phenotype of 
Apoa5−/− mice is associated with an impaired lipid partitioning.
Table 1: Plasma lipid levels of HFD fed Apoa5-/- and WT control mice. Data represent mean values ± SD, **=p<0.01.
Apoa5-/- WT
Triglyceride(mmol/L) 5.7±2.8 1.1 ± 0.2**
Cholesterol (mmol/L) 6.8 ± 1.1 4.0 ± 0.6**
Phospholipids (mmol/L) 7.1 ± 1.0 4.3 ± 0.5**
Free fatty acids (mmol/L) 1.9 ± 0.9 1.0 ± 0.3**
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Figure 1: Plasma decay curve (A) and tissue specific retention (B) of the 3H-TO label and the decay curve (C) and 
tissue specific retention (D) label of the 14C-CO label after mass lipid injection in Apoa5−/− and WT mice. Data 
represent mean values ± SD, *=p<0.05, **=p<0.01.
High fat diet feeding aggravated obesity development in Apoa5−/− mice
Bodyweight was monitored in WT and Apoa5−/− mice fed a HFD. Diet induced weight gain 
was more pronounced in Apoa5−/− mice, which thereby became more obese compared to 
WT (Figure 2). White adipose tissue mass was significantly higher in Apoa5−/− mice in both 
the reproductive (Apoa5−/−, 2.4±0.3g, WT, 1.7±0.5g, p<0.01) and subcutaneous (Apoa5−/−, 
1.7±0.6g, WT, 1.1±0.3g, p<0.01) white adipose tissue depot. Due to the large infiltration of 
pancreatic tissue, the mesenteric fat depot could not be isolated in a reproducible manner 
[45]. Heart, liver, spleen, lung, or kidney mass did not differ between genotype (data not 
shown). Since APOA5 has been described to regulate fatty acid uptake in adipocytes [21] and 
thus possibly affect adipogenesis, the differentiation capacity of pre-adipocytes isolated from 
the reproductive and subcutaneous fat pads of HFD fed Apoa5−/− and WT mice was studied 
by Nile red assay. Differentiation capacity did not differ between genotypes for either of the 
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isolated fat pads (p=0.70 and p=0.69 for reproductive and subcutaneous fat, respectively 
(Supplemental Figure S1). Together, these data demonstrate that HFD fed Apoa5−/− mice 
become more obese than WT mice and that this is not due to an intrinsic difference in the 
adipogenic capacity of the white adipose tissue.
Figure 2: Weight development of Apoa5−/− mice and WT controls during high fat diet intervention. Data represent 
mean values ± SD, *=p<0.05, **=p<0.01.
Apoa5−/− develop aggravated hepatic steatosis and insulin resistance 
upon HFD feeding
Ectopic fat accumulation in the liver of Apoa5−/− and WT control mice was assessed. Although 
total hepatic mass did not differ between groups, hepatic TG content was 50% higher in HFD 
fed Apoa5−/− mice (Apoa5−/−, 0.47±0.16µmol⋅mg-1 protein, WT, 0.31±0.17µmol⋅mg-1 protein, 
p=0.056). Hepatic cholesterol and phospholipid accumulation did not differ between groups 
(data not shown).
Since HFD fed Apoa5−/− mice become more obese and develop hepatic steatosis upon HFD 
feeding, tissue specific insulin sensitivity was determined by hyperinsulinemic-euglycemic 
clamp analysis in conscious mice (Supplemental Figure S2). GIR was lower in Apoa5−/− mice 
(Apoa5−/−, 335±64µmol⋅ (kg⋅min)−1, WT,  408±60µmol⋅(kg⋅min)−1, p<0.05, (Supplemental 
Figure S2a)), indicating a reduction in insulin sensitivity. In addition, the hyperinsulinemic 
circulating glucose level at stable GIR was significantly higher in Apoa5−/− mice (Apoa5−/−, 
6.6±1.2mmol⋅l−1, WT, 5.5±0.7mmol⋅l−1, p<0.05 (Supplemental Figure S2b)). To correct for 
this difference in circulating glucose pool, metabolic clearance rates (MCR) were determined. 
MCR was significantly reduced in Apoa5−/− mice (Apoa5−/−, 77.0±15.4ml⋅(kg⋅min)−1WT, 
101.0±18.1ml⋅(kg⋅min)−1, p<0.05 (Supplemental Figure S2c)). Collectively, these data show 
that Apoa5−/− mice, in addition to obesity, develop hepatic steatosis and insulin resistance 
when fed a HFD.
3
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Apoa5−/− mice are hyperphagic when fed a high fat diet
Given the association of APOA5 with fat intake (27;28), we determined whether the change in 
energy balance in Apoa5-/- mice was due to a defect in oxidative metabolism (which may arise 
from the reduced lipid clearance capacity) or food intake (FI). At the start of the experiment, 
when animals were fed a chow diet, bodyweight did not differ significantly between groups 
(Apoa5−/−, 25.3±0.8g, WT, 26.2±1.4g, p=0.2). Furthermore, FI measured over a period of 24 
hours did not differ between groups when animals were fed a chow diet (Apoa5−/−, 4.5±0.6g, 
WT, 4.2±0.5g). In addition, respiratory exchange ratio (RER) and energy expenditure (EE) 
were similar between groups (Data not shown). 
After the chow period, all animals were switched to the HFD (Figure 3). During the first 
24 hrs after the switch to the HFD, FI was significantly higher when compared to the chow 
diet in both groups (Apoa5−/−, 4.7±0.3g, WT, 4.7±0.1g, p<0.01 for both groups vs. chow), but 
did not differ between groups (p=0.20). After that, FI declined in both groups, but remained 
higher in the Apoa5−/− group. Food intake during the last 24 hours was significantly higher 
in Apoa5−/− mice during the dark period (Apoa5−/−, 2.1±0.3g, WT, 1.9±0.7g, p<0.05) but did 
not differ between groups during the light period (Apoa5−/−, 1.2±0.5g, WT, 1.1±0.4g). Total 
FI during the first 96 hours of HFD intervention was higher in the Apoa5−/− group (Apoa5−/−, 
16.5±1.2g, WT, 14.2±0.7g, p<0.01). The HFD induced a gradual shift from carbohydrate to fat 
metabolism in both groups. RER and absolute carbohydrate oxidation declined and absolute 
fat oxidation increased, but this switch was less pronounced in Apoa5-/- mice (Figure 3). 
Similar results were found after 4 weeks of HFD intervention, where food intake was 
significantly higher in Apoa5−/− mice during a period of 24 h (Apoa5−/−, 2.8±0.4g, WT, 
2.5±0.3g, p<0.05). Oxidative fat metabolism was still reduced in Apoa5−/− mice compared 
to controls (Supplemental Table S1). These data show that HFD fed Apoa5−/− mice remain 
























































Figure 3: Indirect calorimetry data from Apoa5−/− (dashed line) and WT (solid line) mice during the first week of high 
fat diet intervention in the light (L) and dark (D) periods of the day. A) Energy intake  (EI),B)  Respiratory exchange 
ratio (RER), C) Carbohydrate oxidation (CHox) and D) Fat oxidation (FAox). All graphs depict the smoothed average 
± SEM.
Adenovirus mediated gene transfer of APOA5 to Apoa5−/− mice reduces 
food intake
To assess whether hepatic expression of APOA5 rescues the hyperphagic phenotype, Apoa5−/− 
mice were injected with adenovirus vectors expressing either LacZ or human APOA5. At 
the time of injection, body mass did not differ significantly between the groups (APOA5, 
22.7±1.8g, LacZ, 24.2±3.0g, p=0.3). Basal FI, determined at day 0, did not differ between 
groups during the light (APOA5, 0.66±0.23g, LacZ, 0.53±0.16g, p=0.2) or dark period (APOA5, 
1.43±0.50g, LacZ, 1.54±0.23g, p=0.6). At the fourth day after virus injection, FI was compared 
to basal levels in both groups. In LacZ mice, FI was significantly higher compared to basal 
levels during the light (0.80±0.23g, p<0.01) as well as the dark period (2.01±0.72g, p<0.01), 
whereas in APOA5 injected animals, FI during the light and dark period was similar to basal 
values (Light, 0.85±0.39g, p=0.08 and dark period 1.41±0.59g, p=0.46, respectively). Hepatic 
overexpression of APOA5 resulted in human APOA5 plasma levels of 57.6±16.6µl⋅ml-1. These 
data show that APOA5 overexpression is sufficient to reduce food intake.
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Peripheral and central APOA5 protein administration reduce food 
intake
To determine whether hepatic Apoa5 expression, or increased circulating APOA5 protein 
levels mediates reduction in food intake (FI), APOA5 protein was loaded onto VLDL like 
emulsion particles and injected intravenously in WT mice. Injection of APOA5-loaded 
emulsion particles significantly reduced food intake (-60%) during the first 60 minutes 
post injection as compared to unloaded (control) emulsion particles (control, 0.26±0.04g, 
APOA5, 0.11±0.07g, p<0.01, Figure 4A). During the second hour after the injection, APOA5-
loaded emulsion particles did not lower food intake compared to control particles (control, 
0.18±0.11g, APOA5, 0.13±0.08g). These data show that increased circulating APOA5 protein 
levels are capable of reducing food intake.
A peripheral increase of circulating APOA5 protein may affect FI via upregulation of LPL 
mediated lipolysis (45) or a direct peripheral to central signaling pathway. To determine 
whether APOA5 protein is capable to reduce FI directly via a central mechanism, aCSF (as 
a negative control) or aCSF+APOA5 protein was injected into the lateral ventricle of food 
deprived WT mice (Figure 4B). APOA5 injection significantly lowered FI during the first 60 
minutes post injection (40-50%) compared to aCSF (aCSF, 0.40±0.11g, APOA5, 0.23±0.08g, 
p<0.01) (Figure 4B). FI tended to be reduced during the second hour after APOA5 injection 
(aCSF, 0.17±0.06g, ApoA5, 0.11±0.10g, p=0.1). These data show that central APOA5 protein 
administration directly reduces food intake, even at nano-molar concentrations and suggest 
that the food intake-reducing effect of APOA5 may be regulated, in part, via a central 
mechanism.
Figure 4: Food intake during the first 60 min. after (A) intravenous injection of unloaded VLDL-like emulsion particles 
(white bars) or APOA5 loaded VLDL-like emulsion carrier particles (black bars) and (B) intracerebroventricular 





Here, we confirm previous reports that APOA5 plays a central role in lipid metabolism 
and energy balance. Apoa5−/− mice are hypertriglyceridemic and hypercholesterolemic and 
display impaired lipid partitioning. Furthermore, Apoa5−/− mice develop obesity, hepatic 
steatosis and insulin resistance when fed a HFD. In addition, we show that Apoa5−/− mice 
are hyperphagic, and that adenoviral overexpression of APOA5 reverses this phenotype. 
Furthermore, intravenous as well as central injection of purified APOA5 protein reduced 
food intake in WT mice (60% and 45%, respectively), suggesting a central effect of APOA5 on 
the regulation of food intake. Collectively, we confirm that APOA5 plays a crucial role in lipid 
clearance but we also demonstrate a novel role of APOA5 in the regulation of food intake. 
Therefore, we speculate that peripheral to central translocation of APOA5 is a satiety signal 
acting perhaps independently of the effects of APOA5 on LPL-mediated lipolysis.
Food intake is known to be variable and time dependent in C57Bl/6 mice switched to a HFD 
[46]. After an initial phase of hyper caloric intake, food intake decreases and hypothalamic 
expression of pro- opiomelanocortin (POMC) is up regulated, possibly as a defensive 
mechanism against the development of obesity [46]. Here, we confirm that food intake upon 
high fat feeding was only transiently elevated in control C57Bl/6 mice. In contrast, food intake 
was significantly higher in Apoa5−/− mice upon HFD intervention when compared to controls, 
and, interestingly, the decline in food intake was largely absent in Apoa5−/− mice. Food intake 
of Apoa5−/− mice remained higher compared to both WT mice and baseline values for a period 
of at least 5 weeks. In addition to hyperphagia, the oxidative metabolism of Apoa5−/− mice was 
characterized by a low rate of fat oxidation. It is, however, unlikely that the increased obesity 
grade in the Apoa5−/− mice is due to a reduced fat oxidation, as peak oxidation rates (during 
the light period, after 4 weeks of HFD feeding) did not differ from controls. Together, these 
data clearly show that, compared to controls, Apoa5−/− mice have a higher caloric intake when 
fed a HFD, but do not match fat oxidation to this excess, ultimately leading to a more positive 
fat balance, and thus obesity.
To assess the hyperphagic phenotype in more detail, human APOA5 was overexpressed in 
the liver via an adenovirus. Four days after APOA5 virus injection, the hyperphagic phenotype 
of Apoa5-/- mice was prevented compared to LacZ virus injected animals. The established 
human APOA5 plasma concentration was substantially higher (100-300 fold) than the 
endogenous mouse APOA5 concentration, which is in the same range as earlier experiments 
[8, 47]. Thus, supraphysiological APOA5 levels reduced food intake. Subsequently, we 
investigated whether low plasma levels of APOA5 could also reduce food intake. Therefore 
protein free VLDL like emulsion particles were loaded with 6µg purified APOA5 and injected 
intravenously to mimic the postprandial hypertriglyceridemic situation. Addition of APOA5 
to the VLDL particles resulted in a large, but transient reduction in food intake, which is in 
line with a putative function of APOA5 as a satiation signal. These data show that APOA5 
is involved in the regulation of food intake, either directly via a central mechanism and/or 
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indirectly by its known effect on peripheral lipolysis. The liberation of free fatty acids at the 
vessel wall during peripheral lipolysis may in itself induce meal termination, as hypothalamic 
sensors monitor energy status and adjust food intake [48]. Recent studies showed that central 
administration of oleic acid results in a reduction of food intake [45] in a melanocortin-4-
receptor (MC4R) dependent manner, and that this is dependent on nutritional status [49]. 
Therefore, it could be that the effect of APOA5 on food intake is indirect and involves the 
stimulation of peripheral lipolysis, and subsequent transport of fatty acids to the brain. In 
previous studies, however, it has been shown that although APOA5 levels rise concomitantly 
with TG levels in the postprandial period, this does not affect postprandial VLDL kinetics 
[13, 14], arguing that the satiating effect of APOA5 may be independent of its effect on 
lipolysis.
Human cerebrospinal fluid (CSF) contains spherical lipoproteins that resemble HDL in 
plasma [50, 51]. Furthermore, it has been described that active endocytosis of lipoproteins 
occurs at the blood brain barrier [52]. A number of apolipoproteins have been identified 
in human CSF. APOE and APOA1 are the major apolipoproteins; with APOA2, A4, C1, D, 
C2, C3, C4, J and H present as well [50, 51, 53]. Interestingly, it has been shown that the 
concentration of APOA4 in CSF increases as a result of lipid feeding [54]. To be able to act 
as a nutritional sensor, the peripheral-to-central transition of the signal must be rapid. The 
transcytosis time of lipoprotein particles at the blood brain barrier has been shown to be short 
(≈15 minutes). Thus, if lipoprotein bound APOA5 acts as a satiety signal, the transition time 
is likely not rate limiting in the potential of APOA5 to mediate satiation.
Interestingly, central APOE is involved in food intake in rats via a melanocortin 3/4 receptor 
dependent mechanism [55]. Furthermore, APOA4, the closest structural homolog of APOA5, 
has also been shown to be expressed in the hypothalamus [56] and to decrease food intake in 
a cholecystokinin dependent manner [57], also partly via a melanocortin regulated central 
mechanism [54, 58]. These findings indicate that the effect of APOA4 and APOE on food 
intake may share a common signaling route. APOA5 is often described as being exclusively 
expressed in the liver [59, 60]. However, a recent report demonstrated that APOA5 is 
expressed in the duodenum and colon in mice and human subjects, and that this expression 
can be modulated by fatty acids as well as fibrates [61]. Furthermore, active transcription of 
Apoa5 in the brain has been shown in birds [62] and mice [63]. More specifically, in mice, 
central transcription of Apoa5 was determined to be located at the hypothalamus [64]. In 
humans, microarray analysis of post mortem brain material revealed that APOA5 is expressed 
in the brainstem and near the paraventricular nuclei of the hypothalamus [65]. To assess 
whether the hyperphagic food intake of Apoa5−/− mice could be a direct consequence of the 
loss of central APOA5 signaling rather than a consequence of impaired peripheral lipolysis, 
purified APOA5 was injected in the lateral ventricle of HFD fed mice. Central administration 
of purified APOA5 also largely reduced food intake. Although we cannot formally exclude 
the presence of contaminants in the commercially produced APOA5, the endotoxin-free 
production of the protein and the further 12-fold dilution in aCSF, make it unlikely that the 
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observed effect of ICV administered APOA5 on food intake is non-specific. Possibly, APOA5 
mediates energy balance by its association with lipid particles, some of which are able to be 
transported across the blood brain barrier. It has been shown that in particular LDL and HDL 
can cross the blood brain barrier via receptor mediated transport [66, 67]. A possible site 
of peripheral to central translocation of APOA5 containing lipoproteins could be the median 
eminence of the basal hypothalamus, adjacent to the arcuate nucleus [68]. The arcuate 
nucleus is crucially involved in the regulation of energy balance and is subject to plastic 
remodeling when dietary fat content is modulated [69]. Interestingly, low, but significant, 
APOA5 protein levels have been detected at the lateral ventricle wall in humans [70], which 
is directly adjacent to the arcuate nucleus.
Interestingly, the inhibiting effect of APOA5 on food intake after intracerebroventricular 
injection was already achieved at a dose of 8ng/mouse. This dose was approximately 500 fold 
lower compared to the doses of APOE [55] and APOA4 [54] that are able to reduce food 
intake. As mentioned before, APOE and APOA4 decrease food intake in a dose dependent 
manner, which is mediated by the melanocortin system [55, 56]. Since the anorexigenic 
effects of central oleic acid injection are also mediated via the melanocortin system [45], 
it is possible that the effect of APOE, APOA4 and APOA5 on food intake are mediated 
by a regulation of brain lipid metabolism rather than by a direct effect of the individual 
apolipoproteins themselves. This is further strengthened by the observation that LDL receptor 
knock out (Ldlr−/−) mice become more obese compared to controls when fed a 60% HFD [71] 
and that the LDL receptor mediates, at least in part, the effect of APOE on obesity [72]. 
Interestingly, similar to Apoa5−/− mice, Ldlr −/− mice do not reduce their caloric intake when 
switched from a chow to a HFD [71].
In summary, we demonstrate that Apoa5−/− mice are hyperphagic and become more obese 
and insulin resistant on a HFD when compared to WT mice. Furthermore, we show that 
APOA5 reduces food intake after central administration. Peripheral injected APOA5 reduces 
food intake by 60% while ICV injection reduced food intake by 40%, suggesting that the 
effect of APOA5 on food intake may, at least in part, be mediated via a central mechanism. 
We propose that the low circulating levels of APOA5 seen in rodents and humans signify a 
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APOLIPOPROTEIN A5 DEFICIENCY IMPAIRED CENTRAL FOOD INTAKE REGULATION
Supplemental data
Table S1: Indirect calorimetry data from long term HFD fed Apoa5−/− and WT controls. Data represent mean ± SD, 
*p < 0.05
Light period Dark period
Apoa5-/- WT Apoa5-/- WT
Respiratory exchange rate 0.798 ± 0.011 0.793 ± 0.011 0.847 ± 0.010 0.830 ± 0.010*
Energy expenditure (kcal/h) 0.583 ± 0.052 0.554 ± 0.031 0.657 ± 0.045 0.656 ± 0.026
Carbohydrate oxidation rate (mg/h) 54.3 ± 11.2 47.1 ± 5.7 88.7 ± 8.8 79.0 ± 8.3
Fat oxidation rate (mg/h) 40.0 ± 1.9 39.8 ± 3.6 34.2 ± 4.2 37.9 ± 2.2*
Activity (beam breaks) 118 ± 26 130 ± 36 284 ± 90 476 ± 140*
Figure S1: Data representing the differentiation capacity of adipocytes from reproductive and subcutaneous fat 
depots. Data represent mean ± SD.
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Figure S2: Glucose infusion rates (A), plasma glucose levels (B) and hyperinsulinemic metabolic clearance rate 
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The lipid lowering effect of niacin has been attributed to the inhibition of cAMP 
production in adipocytes, thereby inhibiting intracellular lipolysis and release of non-
esterified fatty acids (NEFA) to the circulation. However, long term niacin treatment leads 
to a normalization of plasma NEFA levels and induces insulin resistance, for which the 
underlying mechanisms are poorly understood. The current study addressed the effects 
of long term niacin treatment on insulin-mediated inhibition of adipocyte lipolysis and 
focused on the regulation of cAMP levels. APOE*3-Leiden.CETP transgenic mice treated 
with niacin for 15 weeks were subjected to an insulin tolerance test and showed whole 
body  insulin resistance. Similarly, adipocytes isolated from niacin treated mice were 
insulin resistant and, interestingly, exhibited an increased response to cAMP stimulation 
by 8Br-cAMP, β1 and β2-adrenergic stimulation. Gene expression analysis of the insulin 
and β-adrenergic pathways in adipose tissue indicated that all genes were down-regulated, 
including the gene encoding the cAMP degrading enzyme phosphodiesterase 3B (PDE3B). 
In line with this, we showed that insulin induced a lower PDE3B response in adipocytes 
isolated from niacin treated mice. Inhibiting PDE3B with cilostazol increased lipolytic 
responsiveness to cAMP stimulation in adipocytes. These data show that long term niacin 
treatment leads to a down-regulation of PDE3B in adipocytes which could explain part 
of the observed insulin resistance and the increased responsiveness to cAMP stimulation.
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Introduction
Niacin, also known as vitamin B3, is required for the synthesis of the co-factor nicotinamide 
adenine dinucleotide (NAD+) and is therefore essential for oxidative phosphorylation in energy 
metabolism [1]. It has been used for more than 50 years for the treatment of dyslipidemias, as 
it decreases plasma triglycerides, LDL-cholesterol and hepatic VLDL triglyceride production 
[2], in addition to increasing HDL-cholesterol. Supplementation with niacin was shown to 
decrease risk of cardiovascular disease and atherosclerosis in dyslipidemic humans [3] and in 
dyslipidemic mouse models [4], using the APOE*3-Leiden.cholesteryl ester transfer protein 
(CETP) transgenic female mouse. 
The molecular mechanism by which niacin conveys its lipid-lowering effects is mostly 
unknown. The receptor for niacin, HCA2 (formerly known as GPR109A) has been shown to 
play an important role in acute anti-lipolytic effects [5, 6], but is not required for the long 
term lipid-lowering effects [6]. This receptor is expressed mostly in spleen, immune cells and 
adipose tissue [7] where binding of niacin leads to the release of a Gα-inhibitory subunit that 
inhibits production of the secondary messenger cyclic AMP by adenyl cyclase (AC). Niacin 
is known to inhibit lipolysis in adipocytes via this reduction of cAMP [8], which leads to a 
reduced protein kinase A (PKA) activation and thus less phosphorylation and activation of 
the lipolytic enzyme hormone sensitive lipase (HSL) [9]. By inhibiting lipolysis, less NEFAs 
are released by adipocytes thus making less substrate available for VLDL-Triglyceride (TG) 
production in the liver. Niacin may therefore lower lipid levels via its anti-lipolytic effect. 
However, during niacin administration the initial drop in NEFA and glycerol is followed 
within hours by a rebound and normalization of NEFA and glycerol levels and adipose tissue 
lipolysis rates [2, 6, 10-12]. 
In addition, long term niacin administration leads to insulin resistance in liver, adipose 
and muscle tissue [13, 14] for which the underlying mechanisms are poorly understood. 
In adipocytes, binding of insulin to its receptor leads to phosphorylation and activation of 
protein kinase B (PKB/Akt) and phosphodiesterase 3B, breaking down cAMP which in turn 
reduces NEFA release from the cells.  
We hypothesized that long term niacin treatment modulates insulin signaling by acting 
at the level of PDE3B. Oh et al. [10] have previously shown that 24h treatment with niacin 
induces insulin resistance and reduces expression of PDE3B in adipose tissue, hinting towards 
a possible role for PDE3B. In this study we functionally tested in APOE*3-Leiden.CETP 
transgenic female mice whether long term niacin-induced down regulation of the enzyme 
PDE3B would lead to less PDE3B activity when stimulated by insulin, which would explain 





In contrast to wildtype mice, female APOE*3-Leiden.CETP mice [15] have a human-like 
lipoprotein profile, which makes them exquisitely suited to test hypolipidemic drugs, such 
as niacin [4]. This mouse model was bred at the Leiden University Medical Center. At 
age 15 ± 1 week, mice were fed a western type diet (Diet T with 0.1% cholesterol, which 
consisted of 17 kcal% protein, 43 kcal% carbohydrate and 41 kcal% fat; AB Diets, Woerden, 
the Netherlands) with or without niacin (0.3% w/w, Sigma Aldrich, St Louis, MO, USA). 
Body weight was registered weekly. Animals were housed in a controlled environment (21°C, 
40-50% humidity) with a daily 12h photoperiod (07h00-19h00). Food and tap water were 
available ad libitum during the whole experiment. All experiments were performed after a 15 
week dietary intervention period. All animal experiments were performed in accordance with 
the regulations of Dutch law on animal welfare. The institutional ethics committee for animal 
procedures from the Leiden University Medical Center, Leiden, The Netherlands approved 
the protocols.
Intraperitoneal insulin tolerance test
Food was withdrawn from all animals  at 08h00 for a period of 6.5 hours. Subsequently, all 
animals received a single intra-peritoneal (ip) injection with insulin (0.2 U/kg, Novo-Nordisk, 
Bagsværd, Denmark) and blood samples were taken every 30 min for a period of 2 hours. 
Blood samples were taken from the tail tip into chilled paraoxon-coated capillaries and placed 
on ice to prevent ex vivo lipolysis. 
Organ collection
All animals were sacrificed and organs were collected in the fed state between 08h00 and 
9h30 unless otherwise indicated. Blood was collected by cardiac punction and plasma was 
collected after centrifugation. Fresh subcutaneous (sWAT), gonadal (gWAT) and visceral 
(vWAT) white adipose tissue were harvested and used for determination of morphometry 
and lipolysis experiments as described below. In addition, a portion of the gWAT was frozen 
for qPCR and cAMP measurement. Liver and adrenal glands were harvested quantitatively 
and weighed prior to freezing. All tissues were stored at -80°C prior to further analysis.
Plasma and liver parameters
Commercially available kits were used to determine plasma levels of triglycerides (1488872, 
Roche Molecular Biochemicals, Indianapolis, IL, USA), total cholesterol (236691 Roche 
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Molecular Biochemicals), phospholipids (Instruchemie, Delftzijl, The Netherlands), NEFAs 
(Wako Chemicals, Neuss, Germany), glucose (Accucheck, Roche, The Netherlands) and 
insulin (Crystal Chem Inc., Downers Grove, IL, USA), according to the manufacturer’s 
instructions.
Adipocyte morphometry
Adipose tissue from the gWAT, sWAT and vWAT  were minced and digested in 0.5 g/l 
collagenase in HEPES buffer (pH 7.4) with 20 g/l of dialyzed bovine serum albumin (BSA, 
fraction V, Sigma Aldrich) for 1 h at 37°C. The disaggregated WAT was filtered through a 
nylon mesh with a pore size of 236 μm. For the isolation of mature adipocytes, cells were 
obtained from the surface of the filtrate and washed several times. Cell size and volume of 
mature adipocytes was determined from micrographs (± 1000 cells/WAT sample) using image 
analysis software that was developed in-house in MATLAB (MathWorks, Natick, MA, USA).
Lipolysis experiments in isolated adipocytes
Adipocytes were incubated in DMEM/F12 with 2% (w/w) BSA in 96 well plates with ~10,000 
adipocytes in 200 µl per well in the presence of #1) No additional reagents, #2) 10-3 M of 
the PDE3B sensitive cAMP analogue 8Bromo-cAMP, #3) 10-3 M 8Br-cAMP + 10-10 M insulin 
(Novo-Nordisk), #4) 10-6 M of the selective β2-adrenergic agonist terbutaline, #5) 10
-6 M of the 
selective β1-adrenergic agonist dobutamine. The wells of the adipocytes from niacin treated 
mice contained 10-6 M niacin, while control adipocyte medium did not contain niacin.  Basal 
lipolysis rates were determined in incubations without these reagents. PDE3B responsiveness 
in adipocytes from control and niacin treated mice was assayed by lipolysis assay using the 
selective PDE3 inhibitor cilostazol (all obtained from Sigma Aldrich).  under the following 
additional conditions: #6-8) 10-6 or 10-5 or 10-4 M cilostazol, #9-11) 10-3 M 8Br-cAMP + 10-6 
or 10-5 or 10-4 M cilostazol. The adipocytes were incubated for two hours at 37°C, after which 
100 μl of lipolysis assay medium was frozen at -20°C. At the day of analysis, 10 μl of lipolysis 
assay medium was mixed with 100 μl of Free Glycerol Reagent (F6428, Sigma Aldrich) and 
0.5μl Amplex UltraRed Reagent (A36006, Invitrogen, Carlsbad, CA, USA). After 10 min of 
incubation in the dark, the fluorescence was excited at 530 nm and measured at 590 nm on a 
Fluorometer (SpectraMAX Gemini, Molecular Devices, CA, USA).
Adipose tissue cAMP measurement
cAMP concentrations were measured in 50 mg of gWAT, using the cAMP direct immunoassay 




RNA was isolated from gWAT using the Nucleospin RNA/Protein kit (MACHEREY-
NAGEL GmbH & Co. KG, Düren, Germany). Subsequently, 1μg of RNA was used for cDNA 
synthesis by iScript (BioRad, Hercules, CA, USA), which was purified by the Nucleospin Gel 
and PCR clean-up kit (Machery Nagel). Real-Time PCR was carried out on the IQ5 PCR 
machine (BioRad) using the Sensimix SYBR Green RT-PCR mix (Quantace, London, UK) 
and QuantiTect SYBR Green RT-PCR mix (Qiagen, Venlo, the Netherlands). Target mRNA 
levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh) mRNA levels. 
Primer sequences are listed in table 1.  
Table 1: Mouse qPCR primer sequences all with an optimal temperature at 60°C.











All data in figures are represented as mean ± standard error of the mean. The mean of all data 
was tested between groups for differences by unpaired T-Test for normally distributed data. 
A repeated measures ANOVA was used when indicated. Threshold for significance was set 
at 5%. Tests were performed using GraphPad Prism version 5.00 for Windows, GraphPad 
Software, San Diego, CA, USA).
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Results
Niacin does not alter body composition
We have applied a humanized mouse model, which has previously been shown [4] to react 
to niacin on plasma lipid parameters, atherosclerosis and body weight in a similar manner 
as dyslipidemic humans. After fifteen weeks of niacin treatment body weight (Table 2) and 
weight gain (not shown) did not differ between the niacin treated and control mice. Adipose 
tissue depots were similar in weight, whereas the adrenal glands were heavier after niacin 
treatment (Table 2). Liver cholesterol content was significantly lower in niacin treated mice 
(Table 2). 
Niacin lowers plasma lipids, but increases fasting glucose and insulin
Long term niacin treatment resulted in the expected decrease of non-fasting plasma total 
cholesterol, triglycerides and phospholipids (Table 2). In contrast to short term niacin 
treatment, long term niacin treatment did not lower NEFA levels [2], but slightly lowered 
glycerol levels as compared to control mice (Table 2). Glucose and insulin concentrations 
were significantly higher after niacin treatment (Table 2), suggesting insulin resistance. 
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Table 2: Body composition, liver and plasma metabolic parameters and adipocyte sizes of mice treated 15 weeks 
with or without 0.3% niacin in the diet. Fasting values were determined after 6.5h without feeding from 08h00 until 
14h30.  *p≤0.05, **p≤0.01. 
 Control Niacin  
Mean±SD  Mean±SD N p-value
Body composition 
Body weight (g) 28.9±2.6 29.3±5.3 13 NS
Gonadal adipose tissue (g) 0.48±0.19 0.54±0.34 13 NS
Visceral adipose tissue (g) 0.40±0.11 0.48±0.28 13 NS
Subcutaneous adipose tissue (g) 0.32±0.09 0.39±0.23 13 NS
Adrenal glands (mg) 3.9±1.2 5.1±1.0 13 *
Liver (g) 1.44±0.34 1.28±0.24 13 NS
Liver lipids
Cholesterol (nmol/mg protein) 163±67 96±29 13 **
Triglycerides (nmol/mg protein) 851±382 651±213 13 0.11
Phospholipids (nmol/mg protein) 165±42 148±23 13 NS
Plasma lipids, glucose and insulin
Fed state cholesterol (mM) 13.0±4.9 5.1±1.4 13 **
Fed state triglycerides (mM) 4.11±2.66 0.94±0.19 13 **
Fed state phospholipids (mM) 4.02±0.88 2.94±0.53 13 **
Fasting NEFA (mM) 1.1±0.3 1.0±0.2 12 NS
Fasting glycerol (mM) 0.92±0.29 0.74±0.14 12 0.08
Fasting glucose (mM) 9.1+0.9 10.6+0.9 12 *
Fasting insulin (ng/ml) 0.49+0.21 0.82+0.39 12 *
Adipocyte mean volume 
Gonadal (pl) 342±98 334±140 13 NS
Visceral (pl) 152±39 190±97 13 NS
Subcutaneous (pl) 167±43 158±60 13 NS
Niacin induces insulin resistance in vivo
To verify the development of in vivo insulin resistance upon long term niacin treatment 
we performed an insulin tolerance test. Insulin stimulates glucose uptake in muscle and 
adipose tissue and suppresses WAT glycerol release. After an ip injection of insulin, blood 
was drawn and at indicated times glucose (Fig. 1A), glycerol (Fig. 1B) and insulin (Fig. 1C) 
were measured. Glucose levels dropped and insulin levels rose in both groups. As glucose 
levels were already higher due to niacin treatment at t=0, the percentage change in glucose, 
glycerol and insulin levels from the t=0 values were calculated (data not shown). A repeated 
measures ANOVA of the percentage change in insulin values indicated no significant effect of 
niacin, while a similar analysis of glucose values showed significant treatment differences. At 
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60 min, the percentage change in glucose was smaller for niacin treated animals, indicating 
insulin resistance on a whole body level. Insulin induced a decrease in glycerol levels in the 
control group, but failed to do so in the niacin treated group, indicating adipose tissue insulin 
resistance.
Figure 1: Intraperitoneal insulin tolerance tests of mice treated with or without niacin. After 0.2U/kg insulin 
injection A) glucose, B) glycerol and C) insulin concentrations were measured during 2 h. All values are means±SEM. 
N=12 mice per group, *p≤0.05 compared to control treatment, **p≤0.01 compared to niacin treatment, #p≤0.05 
compared to niacin treatment, when calculated as percentage change from t=0 level. 
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Niacin reduces the anti-lipolytic effect of insulin in isolated adipocytes
To study whether long term niacin treatment also alters the response to insulin at the level of 
adipocyte lipolysis, we isolated gWAT adipocytes from control and niacin treated mice and 
performed an ex vivo lipolysis assay. Basal lipolysis (i.e. unstimulated lipolysis) did not differ 
between the niacin treated and control mice (Fig. 2A). 8Br-cAMP stimulated glycerol release 
was higher in adipocytes from niacin treated mice compared to control treatment. The anti-
lipolytic effect of insulin, reflected by the percentage lipolysis suppression by insulin of 8Br-
cAMP stimulated lipolysis, was significantly smaller in the niacin treated adipocytes (Fig. 2B). 
This implies a reduced insulin response of adipocytes from niacin treated mice.
Niacin increases the lipolytic effect of β-adrenergic stimulation in 
isolated adipocytes
Similar to testing the response of adipocyte lipolysis to inhibition by insulin, β1 and β2-
adrenergic stimulation of gonadal adipocyte lipolysis was tested. Gonadal adipocytes from 
niacin treated mice exhibited a greater response to both the β1-agonist dobutamine and the 
β2-agonist terbutaline, as well as the secondary lipolytic messenger 8Br-cAMP (Fig 2A). These 
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Figure 2: Isolated adipocyte responsiveness to lipolysis stimulation and inhibition. A) Glycerol concentration in ex 
vivo gonadal adipocyte medium after 2 h incubation with different reagents. B) Suppression of gonadal adipocyte 
lipolysis by 10-10 M insulin (100 – 100*(8Br-cAMP+Ins / 8Br-cAMP)). C) gWAT mRNA fold change of niacin treatment 
compared to control treatment. Insr (Insulin receptor), Irs1 (Insulin receptor substrate 1), Pde3b (Phosphodiesterase 
3B), Adrb1,2,3 (β-Adrenoceptor 1,2,3), Arrb1 (β-arrestin 1), Hsl (Hormone sensitive lipase). All values are 
means±SEM. N=13 mice per group, *p≤0.05, **p≤0.01, ***p≤0.001.
Niacin down-regulates genes involved in both the insulin and the 
β-adrenergic signaling pathways that regulate lipolysis
Expression of genes involved in the insulin and/or β-adrenergic pathways, were analyzed by 
qPCR in gWAT. The niacin treated adipose tissues showed a down-regulation of the insulin 
signaling cascade: mRNA levels of the insulin receptor (Insr), insulin receptor substrate-1 
(Irs1) and Pde3b were down-regulated by 45%, 97% and 53%, respectively, compared to 
control (Fig. 2C). Also mRNA levels of the lipolytic enzyme hormone sensitive lipase (Hsl) 
were down-regulated (62%) in the niacin treated mice. Furthermore, all β-adrenergic receptor 
genes were significantly down-regulated. The β1-adrenoceptor (Adrb1) was down-regulated 
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by 68%, Adrb2 by 74% and Adrb3 by 88%. The intracellular adrenergic adaptor β-Arrestin1 
(Arrb1) was also down-regulated by 42%. These data indicate a decreased gene expression of 
the insulin and β-adrenergic receptors, and their post-receptor signaling pathways to lipolysis. 
Niacin treated adipocytes display less PDE3B capacity 
As the down-regulation of the β-adrenoceptors was not consistent with the observed increased 
β-adrenergic response, we investigated whether the increased β-adrenergic response was 
the result of post-receptor signaling changes. Therefore we first tested the basal levels of 
the lipolytic post-receptor mediator cAMP. The cAMP concentration of non-fasted gWAT 
showed no difference after long term niacin treatment (control: 19.9±6.5, niacin:  21.6±8.2 
pmol/g adipose tissue, p=0.63). 
We then focused on the post receptor enzyme PDE3B, catalyzing cAMP hydrolysis, whose 
gene expression was down-regulated after niacin treatment. PDE3B is the most predominant 
PDE3 isoform in adipose tissue [16] which is activated by insulin. The role of PDE3B in 
lipolysis was characterized in gWAT adipocytes using the PDE3 selective inhibitor cilostazol 
(Fig 3). Adding cilostazol to unstimulated adipocytes in basal medium did not increase 
lipolysis, indicating that under basal conditions PDE3B was not active. However, when 
8Br-cAMP stimulated adipocytes were subjected to increasing concentrations of cilostazol, 
there was a sharp rise in lipolysis. Therefore, inhibiting PDE3B capacity can increase the 
responsiveness to cAMP stimulation, e.g. by catecholamines. Futhermore, lipolysis of 
adipocytes from niacin treated mice was stimulated to a lesser degree by 10-4 M cilostazol 
then control treated mice. A repeated measures ANOVA indicated a significant interaction 
(p<0.0001) between the concentration of cilostazol and the 8Br-cAMP stimulated control/
niacin adipocytes. This implied a lower responsiveness (slope) of PDE3B to its inhibitor in 
adipocytes from niacin treated mice, independent of insulin signaling.
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Figure 3: PDE3B capacity of isolated adipocytes after lipolysis stimulation and inhibition. Glycerol concentration in 
ex vivo gonadal adipocyte medium after 2 h incubation with PDE3B inhibitor cilostazol. A) Responsiveness of basal 
and 8Br-cAMP stimulated lipolysis to PDE3B inhibition by different cilostazol concentrations. B) PDE3B capacity as 
glycerol release after PDE3B activation by 10-10 M Insulin compared to PDE3B inhibition by 10-4 M cilostazol (Δ = 
8Br-cAMP+Ins+Cilo - 8Br-cAMP+Ins) tested in ex vivo adipocytes from control and niacin treated mice. All values 
are means±SEM.  N=10 mice per group, *p≤0.05, **p≤0.01 compared to niacin treatment, ##p≤0.01, ###p≤0.001 
compared to Cilo 10-6 M level.
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Figure 4: Molecular mechanism of niacin action in adipocytes. Adrenergic stimulation of adipocytes will activate 
AC to produce cAMP. This rise in cAMP will both activate lipolysis via PKA & HSL and will activate PDE3B leading 
to a negative feedback loop degrading cAMP. Insulin will activate IRS1 and PKB, also leading to PDE3B activation, 
thereby inhibiting lipolysis. Prolonged niacin leads to down regulation of the β-adrenergic and insulin pathway, but 
concomitantly to a down-regulation of PDE3B. Whether this is a direct or indirect effect is unknown. The diminished 
PDE3B capacity dampens the negative feedback loop, resulting in an increased responsiveness to adrenergic and 
cAMP stimulation of lipolysis, as well as decreased responsiveness to insulin inhibition of lipolysis.
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Discussion
The present paper shows that long term niacin induces insulin resistance in APOE*3-Leiden.
CETP female transgenic mice fed a Western type diet. The insulin resistance by niacin has been 
shown before in dyslipidemic patients and is confirmed in our humanized mouse model, both 
in vivo on glucose and glycerol metabolism and ex vivo in isolated adipocytes on lipolysis. 
The niacin induced insulin resistance was associated with a reduction in the expression 
of key insulin signaling genes (i.e. Insr and Irs1) in WAT. This indicates that niacin down-
regulates the insulin signaling pathway at the transcriptional level which led to the reduced 
anti-lipolytic effect of insulin. In contrast, gene expression of all β-adrenergic receptors, 
as well as Hsl and Arrb1 were down-regulated in white adipose tissue, while an increased 
adrenergic lipolytic effect was observed. This might be due to desensitization after niacin-
induced prolonged stress [10, 17-20]. Prolonged stress leads to increased adrenal gland size 
[21], also evident in our study. Decreased β-adrenoceptor gene expression combined with 
an increased β-adrenergic responsiveness suggests that the effects of niacin on β-adrenergic 
stimulation are due to post-receptor signaling mechanisms that enhance cAMP stimulation 
and thus lipolysis. 
Interestingly, 8Br-cAMP, which acts at the post-receptor level, induced lipolysis to a higher 
extent in niacin treated mice, which strengthens the hypothesis that a post-receptor signaling 
mechanism is affected by niacin. The adipocyte lipolysis assays were not confounded by a 
difference in weight of the gWAT depots, nor in adipocyte mean cell volume (Table 1), which 
in itself might change responsiveness to reagents. It was shown by Oh et al. [10] that 24 h 
niacin infusion lowered the expression level of Pde3b in gWAT to a similar extent (-57%) 
as compared to our study (-53%). PDE3B regulates intracellular cAMP levels and is the key 
enzyme involved in the anti-lipolytic action of insulin. Moreover, by modulating cAMP levels 
PDE3B may interact with β-adrenergic signaling. Oh and co-workers suggested that the 
reduction in Pde3b may be an indirect effect of niacin, that serves as a counter-regulatory 
mechanism to increase the cellular cAMP/AMP ratio in order to maintain basal lipolytic rate. 
In the current paper we show that the reduction of expression of Pde3b in adipose tissue 
by niacin is accompanied by a reduced anti-lipolytic effect of insulin. We further show by 
using the selective PDE3 inhibitor cilostazol in an adipocyte lipolysis assay that the PDE3B 
responsiveness in adipocytes isolated from long term niacin treated mice was diminished. 
We also showed that cilostazol increased 8Br-cAMP-stimulated lipolysis in a concentration 
dependent manner in adipocytes from control mice, whereas it did not have an effect on 
unstimulated cells. 
These data suggest that in adipocytes PDE3B will only degrade cAMP when the lipolytic 
cascade is stimulated. These observations could explain the increased responsiveness to 
β-adrenergic or 8Br-cAMP stimulation in niacin treated adipocytes. In the unstimulated 
basal condition PDE3B was not activated, which corresponds to the unchanged adipocyte 
lipolysis rate and basal adipose tissue cAMP levels between control and niacin treated mice. 
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In line with this, plasma NEFA levels did not differ between the groups at the start of the ip 
insulin tolerance test, indicating that in vivo adipose lipolysis was also similar between the 
groups, despite decreased Pde3b expression.
We propose a molecular mechanism for long term niacin treatment occurring in adipocytes 
(Fig. 4): Lipolysis is regulated by hormone sensitive lipase, which is controlled by cAMP 
levels.  Production of cAMP can be stimulated via β-adrenergic pathways or inhibited by 
PDE3B which is activated by the insulin signaling cascade. PKA is activated by cAMP, which 
can activate PDE3B creating a negative feedback loop [22-24] (Fig. 4). Long term niacin 
treatment leads to down-regulation of PDE3B (Fig. 4). This down-regulation of PDE3B is 
also accompanied by a down-regulation of the rest of the insulin signaling pathway, leading to 
reduced insulin responsiveness in the adipocyte. In addition, as the PDE3B responsiveness is 
smaller in adipocytes from niacin treated mice, stimulated cAMP levels in the niacin treated 
mice -after b-adrenergic stimulation- will be degraded to a lesser extent, leading to a net 
higher lipolysis. 
In this study we have focused on adipocyte insulin response after long term niacin treatment. 
But the sequence of events leading up to adipocyte insulin resistance and decreased Pde3b 
expression remain unclear, as does the possible role of adipocyte insulin resistance in the 
development of whole body insulin resistance. Moreover niacin has been shown to increase 
plasma adiponectin, an important insulin sensitizing hormone. The increase in adiponectin 
plasma levels after niacin treatment were shown to correlate to the decrease in insulin 
resistance [25], indicating a possible compensatory insulin sensitizing effect. We however 
did not detect an increase of adiponectin gene expression in gWAT after niacin treatment 
(data not shown). Whether niacin acutely interferes with the insulin receptor cascade remains 
to be investigated, although PDE3B capacity was not affected in control adipocytes exposed 
to niacin for two hours (data not shown). Choi et al. have shown a reduced phosphorylation 
of PKB/Akt in adipose tissue after 1.5h infusion of niacin [26], which leads to a lower insulin 
response. Niacin thus seems to induce decreased adipocyte insulin responsiveness via more 
than one mechanism. 
In conclusion, long term niacin treatment resulted in insulin resistance and increased 
β-adrenergic responsiveness which may in part be explained by a niacin induced down-
regulation of PDE3B.
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Prolonged niacin treatment elicits beneficial effects on the plasma lipid and lipoprotein 
profile that are associated with a protective cardiovascular disease (CVD) risk profile. 
Acute niacin treatment inhibits non-esterified fatty acid (NEFA) release from adipocytes 
and stimulates prostaglandin release from skin Langerhans cells, but the acute effects 
diminish upon prolonged treatment, while the beneficial effects remain. To gain insight in 
the prolonged effects of niacin on lipid metabolism in adipocytes, we used a mouse model 
with a human-like lipoprotein metabolism and drug response (female APOE*3-Leiden.
CETP mice) treated with and without niacin for 15 weeks. The gene expression profile of 
gonadal white adipose tissue (gWAT) from niacin treated mice showed an up-regulation 
of the “biosynthesis of unsaturated fatty acid (PUFA)” pathway, which was corroborated 
by qPCR and analysis of the FA ratios in gWAT. Also, adipocytes from niacin treated 
mice secreted more of the PUFA docosahexaenoic acid (DHA) ex vivo. This resulted in 
an increased DHA/arachidonic acid (AA) ratio in the adipocyte FA secretion profile and 
in plasma of niacin treated mice. Interestingly, the DHA metabolite 19,20-dihydroxy 
docosapentaenoic acid (19,20-diHDPA) was increased in plasma of niacin treated mice. 
Both an increased DHA/AA ratio and increased 19,20-diHDPA are indicative for an anti-
inflammatory profile and may indirectly contribute to the atheroprotective lipid and 
lipoprotein profile associated with prolonged niacin treatment.
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Introduction
Niacin (vitamin B3) treatment reduces cardiovascular disease and atherosclerosis development 
[1]. These beneficial effects are mediated, in part, by lowering circulating levels of LDL-
cholesterol, VLDL-TG and lipoprotein(a) [2] as well as by increasing HDL-cholesterol [3]. 
In addition, prolonged niacin treatment also decreases plasma, adipose tissue and vascular 
inflammation [4, 5], which might contribute to reducing CVD. The induction of these 
beneficial effects after prolonged niacin treatment are in striking contrast to the unwanted 
acute niacin effects. 
Acutely, niacin binds to the inhibitory hydroxycarboxylic acid receptor 2 (HCA2) (previously 
known as GPR109A). In adipocytes this leads to an inhibition of adipocyte lipolysis followed 
by an acute reduction of plasma non-esterified fatty acid (NEFA) levels. Lowering NEFA 
levels causes metabolic stress [6, 7], which increases stress hormone levels [8-12] after 
niacin treatment. In the skin Langerhans cells and keratinocytes, acute niacin binding to the 
HCA2 receptor leads to a release of arachidonic acid (AA) and subsequent cyclooxygenase-
mediated oxylipin synthesis (mostly prostaglandins) causing flushing [13] and a decrease 
in blood pressure [14]. Intriguingly, these acute effects decrease upon prolonged niacin 
treatment. Adipocyte lipolysis normalizes [15, 16] and flushing diminishes [17]. 
The fact that certain acute niacin effects decrease over time whereas the beneficial lipid 
lowering and anti-inflammatory effects remain, suggests differences between the induction of 
intracellular signaling pathways upon acute and prolonged niacin treatment. In the current 
study we set out to characterize changes in signaling regulation upon prolonged niacin 
treatment. We specifically investigated effects of niacin on adipose tissue as adipose tissue 
has been shown to be the most affected organ at the gene expression level after 7h of niacin 
treatment [18]. 
We treated mice with 0.3% niacin mixed through the diet and isolated gonadal white 
adipose tissue (gWAT) after 15 weeks of intervention. The mice used in this study were 
female APOE*3-Leiden.CETP mice [19] which-in contrast to wild type mice-have a human 
like lipoprotein profile and respond similarly to atheroprotective drugs like niacin [20]. A 
microarray was used to compare gene expression profiles in the adipose tissue. We applied 
bio-informatic and statistical analyses to the gene expression data and showed that prolonged 
niacin treatment led to an increase in the pathways unsaturated FA synthesis. To investigate 
whether PUFA levels and possible derivatives thereof (i.e. oxylipins) were functionally affected 
we determined the fatty acid (FA) composition in the adipose tissue by gas chromatography 
mass spectrometry (GC-MS) and measured PUFA and oxylipin profiles in plasma by liquid 





Female APOE*3-Leiden.CETP mice were bred at the Leiden University Medical Center. 
At age 15 ± 1 week, mice were fed a western type diet (Diet T with 0.1 g% cholesterol, 
which consisted of 16 kcal% protein, 43 kcal% carbohydrate and 41 kcal% fat. AB Diets, 
Woerden, the Netherlands) with or without niacin (0.3 g%, Sigma Aldrich, St Louis, MO, 
USA). Supplementary table S2 shows the fatty acid composition of the diet. Body weight 
was registered weekly. Animals were housed in a controlled environment (21°C, 40-50% 
humidity) with a daily 12h photoperiod (07h00-19h00). Food and tap water were available 
ad libitum during the whole experiment. Food intake was determined weekly by weighing 
the food in the cages at t=0 and at t= 1 days. The difference between these time points was 
equal to 24h food intake of the mice. The mice in this study are the same as in our previously 
published study (16). All experiments were performed after a 15 week dietary intervention 
period. All animals (n=14 per group) were anaesthetized and sacrificed in the fed state 
between 08h00 and 9h30 by cardiac puncture. Organs and plasma were collected and stored 
at -80°C. Fresh gonadal white adipose tissue (gWAT) was harvested and kept in PBS with 
or without niacin. One niacin treated animal did not have sufficient gWAT for the analyses. 
All animal experiments were performed in accordance with the regulations of Dutch law 
on animal welfare. The institutional scientific committee and ethics committee for animal 
procedures from the Leiden University Medical Center, Leiden, The Netherlands approved 
the protocols.
gWAT gene expression analysis
RNA was isolated from gWAT using the Nucleospin RNA/Protein kit (MACHEREY-NAGEL 
GmbH & Co. KG, Düren, Germany) after which RNA quality was assessed by NanoDrop 
(NanoDrop) and 2100 BioAnalyzer (Agilent). All samples had an RNA Integrity Number of 
>7.5. cRNA was synthesized using the TotalPrep RNA Amplification Kit (Ambion, Illumina). 
cRNA levels were normalized to 150ng/µL and loaded onto MouseWG-6 v2.0 Expression 
BeadChips by Service XS (Leiden, The Netherlands). Each BeadChip contains eight arrays. 
Hybridization and washing were performed according to the Illumina manual. Image analysis 
and extraction of raw expression data was performed with Illumina GenomeStudio v2011.1 
gene expression software with default settings.
Lumi [21] module in the R-based Bioconductor package was used to read in the combined 
(average) signal intensities per probe. A variance-stabilizing transformation (lumiT) available 
in the R package was used to stabilize the expression variance based on the bead level 
expression variance and mean relations. Expression data were normalized using the function 
lumiN available within the lumi package. We used limma [22] an R-based Bioconductor 
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package to calculate the level of differential gene expression. In addition to determining 
significant differentially expressed genes, gene set analysis based on KEGG pathway and Gene 
Ontology was performed using the Bioconductor package “GlobalTest” [23]. 
Quantitative PCR
RNA was isolated from gWAT and liver using the Nucleospin RNA/Protein kit (MACHEREY-
NAGEL GmbH & Co. KG, Düren, Germany). Subsequently, 1μg of RNA was used for cDNA 
synthesis by iScript (BioRad, Hercules, CA, USA), which was purified by the Nucleospin Gel 
and PCR clean-up kit (Machery Nagel). Real-Time PCR was carried out on the IQ5 PCR 
machine (BioRad) using the Sensimix SYBR Green RT-PCR mix (Quantace, London, UK) 
and QuantiTect SYBR Green RT-PCR mix (Qiagen, Venlo, the Netherlands). Target mRNA 
levels were normalized to Rplp0 & Ppia mRNA levels. Primer sequences and PCR conditions 
can be found in Supplementary table S1.
gWAT, liver and diet fatty acid composition
FA composition analysis of gWAT, liver and diet was carried out as described recently by Kloos 
et al. [24]. Briefly: triplicate samples were weighed of approximately 10 mg diet or organ from 
niacin treated and control mice. 1 mL of water, 3 mL MeOH and 1 mL 10M NaOH were added, 
the samples flushed with argon and hydrolyzed for 1 h at 90 °C. After acidification with 2 mL 
of 6M HCl, 10 µL of an internal standard solution ([2H31]palmitic acid and ergosterole 10 µg/
mL each) was added. The samples were extracted twice with 3 mL n-hexane and the combined 
organic extracts were dried under a gentle stream of nitrogen. Dried samples were derivatized 
using 25 µL of N-tert.-butyldimethylsilyl-N-methyltrifluoroacetamide (Sigma Aldrich, 
Schnelldorf, Germany) for 10 min at 21 °C, subsequently 25 µL of N,O-bis(trimethylsilyl)
trifluoroacetamide containing 1% trimethylchlorosilane (Thermo Scientific, Waltham, MA, 
USA) and 2.5 µL of pyridine were added and the sample was heated for 15 min to 50 °C. 
Next, 947.5 µL of n-hexane, containing 10 µg/mL octadecane (C18) as system monitoring 
component, was added. Samples were analyzed in SIM mode on a Scion TQ GC-MS (Bruker, 
Bremen, Germany) equipped with a 15 m × 0.25 mm × 0.25 mm BR5MS column (Bruker). 
The injection volume was 1 µL, the injector was operated in splitless mode at 280 °C and the 
oven program was as follows: 90 °C kept constant for 0.5 min, then ramped to 180 °C with 
30 °C/min then to 250 °C with 10 °C/min then to 266 °C with 2 °C/min and finally to 300 °C 
with 120 °C/min, kept constant for 2 min. Helium (99.9990%, Air Products, The Netherlands) 




Gonadal adipocyte PUFA release assay
Fresh gonadal adipose tissue was minced and digested in 0.5 g/L collagenase type I in HEPES 
buffer (pH 7.4) with 20 g/L of dialyzed bovine serum albumin (BSA, fraction V, Sigma Aldrich) 
for 1 h at 37°C. The disaggregated WAT was filtered through a nylon mesh with a pore size 
of 236 μm. For the isolation of mature adipocytes, cells were obtained from the surface of the 
filtrate and washed several times. Adipocytes (~10,000 cells/mL) were incubated in triplicate 
in a 96 well plate at 37°C in 200µL per well of DMEM/F12 medium with 2%w/w BSA with or 
without niacin (10-6 M) for 2 hours. The adipocyte conditioned medium (100 μL) was frozen 
at -20°C until further analysis. 
Plasma PUFA and oxylipins measurement
Protein precipitation was performed on adipocyte conditioned medium (80 μL) or plasma 
(20 μL) by the addition of methanol (233.6 μL for medium and 53.6 μl for plasma) and 6.4 




DHA, each 50 ng/mL in methanol), which was left to equilibrate for 20 minutes at -20°C. The 
samples were spun down for 10 min, 16200g at 4°C. Supernatant (240 μL for medium and 
30 μL for plasma) was pipetted into a deactivated glass insert (Agilent, CA, USA). Plasma 
supernatant was diluted in 30 μL of H2O, while medium supernatant was dried by Speedvac 
at room temperature. The dried medium sample was dissolved in 60 μL 1:2 methanol/H2O. 
For both sample types, 20 μL was injected for LC-MS/MS analysis as described previously 
[25, 26]. 
LC-MS/MS analysis is carried out on a QTrap 6500 mass spectrometer (AB Sciex, Nieuwerkerk 
aan den Ijssel, The Netherlands), coupled to a Dionex Ultimate 3000 LC-system including 
auto-sampler and column oven (Dionex part of Thermo, Oberschleiβheim, Germany). The 
employed column was a Kinetex C18 50 × 2.1 mm, 1.7 µm, protected with a C8 pre-column 
(Phenomenex, Utrecht, The Netherlands). H2O (A) and methanol (B) both with 0.01% acetic 
acid were used. The gradient program started at 40% eluent B and was kept constant for 1 
min, then linearly increased to 45% B at 1.1 min, then to 53.5% B at 4 min, to 55% B at 6.5 
min, then to 90% B at 12 min and finally to 100% B at 12.1 min, kept constant for 3 min. The 
flow rate was set to 250.0 μL/min. The MS was operated under the following conditions: the 
collision gas flow was set to medium, the drying temperature was 400 ºC, the needle voltage 
-4500 V, the curtain gas was 30 psi, ion source gas 1 was 40 psi and the ion source gas 2 was 
30 psi (air was used as drying gas and nitrogen as curtain gas). For quantitation, the multiple 
reaction monitoring (MRM) transitions and collision energies (CE) given in supplementary 
table S5 were used combined with calibration lines. All substances used as standards were 
from Cayman Chemicals (Ann Arbor, MI, USA) if not stated otherwise, except RvE1, RvE2 
18S-RvE3 and 18R-RvE3 (gifts from Dr. Makoto Arita, Tokyo, Japan). Metabolite identification 
in plasma was verified by MS/MS spectral comparison with standards, of which leukotriene 
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E4, thromboxane B2 and 19,20-diHDPA are included in the supplements (Supplementary 
figure S4 until S6).
Statistics
Mean values and standard deviations are reported in all figures. The gene expression data were 
statistically analyzed by using the multiple test correction method of Benjamin-Hochberg for 
control of false discovery rate (FDR) for both differentially expressed individual genes and for 
KEGG pathways. An adjusted p-value < 0.05 was considered significant. Calculations for the 
lipid measurements were performed in Prism version 6 (GraphPad Software, La Jolla, USA). 
Multiple T-tests were performed and a 5% FDR value was applied. An F-test was applied to 
test whether linear regression lines were significantly non-zero. The levels of significance were 




gWAT gene expression analysis
Female APOE3.Leiden.CETP mice (n=14 per group) were fed a Western type diet (containing 
0.1% cholesterol) with and without niacin for 15 weeks. As previously published [16], niacin 
treatment did not lead to differences in body weight nor gonadal white adipose tissue weight 
in these mice. However, plasma lipids, i.e. total cholesterol, triglycerides and phospholipids 
were all decreased [16]. Gene expression analysis generated 24 differentially expressed genes 
due to niacin treatment after multiple test correction (adjusted p<0.05, see Table 1). The global 
test was applied to identify KEGG pathways affected by niacin treatment. Table 2 depicts 
the top 5 pathways identified by global test, however only “biosynthesis of unsaturated fatty 
acids” remained significant after correction for false discovery rate (q<0.05). The differentially 
expressed genes from Table 1 were clustered and highlighted according to KEGG pathways. 
The top-hits from the “biosynthesis of unsaturated fatty acids” (Elovl6, Tecr and Elovl5) were 
all specifically involved in FA elongation, not FA desaturation, and were all up-regulated. 
Quantitative PCR measurements of Elovl6 and Elovl5 in gWAT confirmed up-regulation of 
mRNA levels of these enzymes after niacin treatment (Fig. 1). The rate-limiting desaturase 
enzyme of PUFA synthesis encoded by Fads2 (Fatty acid desaturase 2) showed a trend towards 
increased expression after niacin. 
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Table 1: Differentially expressed gene hits from microarray analysis of gWAT after niacin treatment. P-value after 
multiple testing correction. The fold change was calculated as log2((Niacin/Control). The gene symbols highlighted 
in black are part of the KEGG pathway “Biosynthesis of unsaturated fatty acids”.
Gene symbol Gene ID Gene name Adj. p-value
Log(fold 
change)
Pdzk1ip1 67182 PDZK1 interacting protein 1 0.002 1.190
Orm2 18406 Orosomucoid 2 0.002 0.857
Orm1 18405 Orosomucoid 1 0.003 0.550
Elovl6 170439 Elongation of long chain fatty acids 6 0.004 1.371
Lctl 235435 Lactase-like 0.004 1.107
Rdh11 17252 Retinol dehydrogenase 11 0.007 0.887
Nudt7 67528 Nudix (nucleoside diphosphate linked moiety X)-type motif 7 0.012 0.537
Acat2 110460 Acetyl-Coenzyme A acetyltransferase 2 0.013 0.695
Mup3 17842 Major urinary protein 3 0.013 1.047
1500017E21Rik 668215 RIKEN cDNA 1500017E21 gene 0.013 0.612
Clstn3 232370 Calsyntenin 3 0.013 0.607
Apoc1 11812 Apolipoprotein C-I 0.013 0.523
Comt 12846 Catechol-O-methyltransferase 0.014 0.536
Zfp385b 241494 Zinc finger protein 385B 0.014 -0.436
Tecr 106529 Trans-2,3-enoyl-CoA reductase 0.029 0.498
G6pdx 14381 Glucose-6-phosphate dehydrogenase X-linked 0.029 0.454
Elovl5 68801 Elongation of long chain fatty acids 5 0.033 0.405
Pkm2 18746 Pyruvate kinase, muscle 0.034 0.521
D430019H16Rik 268595 RIKEN cDNA D430019H16 gene 0.034 -0.505
Aacs 78894 Acetoacetyl-CoA synthetase 0.035 0.524
Lpcat3 14792 Lysophosphatidylcholine acyltransferase 3 0.035 0.504
Kcnj15 16516 Potassium inwardly-rectifying channel, subfamily J, member 15 0.035 0.450
Cyp51 13121 Cytochrome P450, family 51 0.039 0.747
Aard 239435 Alanine and arginine rich domain containing protein 0.039 -0.547
Fasn 14104 Fatty acid synthase 0.126 0.487
Acly 104112 ATP citrate lyase 0.139 0.691
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Table 2: Pathways regulated on gene expression level by niacin in the gWAT according to global test. FDR: false 
discovery rate. 
KEGG ID KEGG pathway name p-value FDR q-value
map01040 Biosynthesis of unsaturated fatty acids 1.81E-05 0.00381
map00310 Lysine degradation 7.97E-04 0.16654
map00900 Terpenoid backbone biosynthesis 1.02E-03 0.21273
map00620 Pyruvate metabolism 1.09E-03 0.22603
map00100 Steroid biosynthesis 1.32E-03 0.27205
Figure 1: Gene expression by qPCR of gWAT and liver tissue isolated from unfasted control and niacin treated 
mice. A) Elovl5, B) Elovl6 and C) Fads2 mRNA levels expressed as fold change from control. *p<0.05, **p<0.01, 
***p<0.001 compared to control.
gWAT fatty acid composition and adipocyte PUFA secretion
To investigate whether the increased mRNA levels of genes in the “biosynthesis of unsaturated 
fatty acids” translated to adipose tissue FA metabolism changes, we examined the FA 
composition of the gWAT by GC-MS. In the adipose tissue the fractions of the substrates 
for PUFA synthesis, the essential fatty acids α-linolenic acid (ALA, n-3) and linoleic acid 
(LA, n-6), were decreased after niacin treatment while their down-stream products were not 
fractionally different (Supplementary figure S1 and table S2). As the only source of essential FAs 
was the diet, of which the consumption was equal (data not shown), an increased enzymatic 
processing of essential FAs towards down-stream elongated and desaturated PUFAs would 
be plausible. To examine enzymatic processing, we investigated the substrate/product ratios 
for the enzymes in the PUFA synthesis pathway. We exclusively found differential elongase 
ratios and no desaturase ratios between control and niacin treatment (data not shown). 
Furthermore, the differential ratios that were decreased were the C18 to C20 elongation ratios, 
while the C20 to C22 ratios were increased indicating a possible increase in the metabolism 
and processing of essential FAs towards down-stream PUFAs in gWAT from niacin treated 
mice (Table 3). Given that niacin did no elevate the fractional content of the down-stream 
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PUFAs of the essential FAs, we studied whether niacin treatment increased PUFA secretion 
from freshly isolated adipocytes. 
Although the fraction of medium chain fatty acids (MCFA, C10:0 / C12:0 / C14:0) was 
also increased in gWAT after niacin, adipocyte release of these MCFA was not different 
(Supplemental figure S 7). Of the PUFAs, both ALA and LA were secreted in equal amounts 
for control and niacin treated adipocytes (Figure 2A). Interestingly, down-stream metabolic 
products of the essential n-3 fatty acid ALA, namely EPA (non-significant after FRD 
correction) and DHA, were secreted to a greater extent after niacin treatment. 
Table 3: Gene expression level of significant genes in the “Biosynthesis of unsaturated fatty acids” pathway and 
the associated enzymatic substrate/product ratio of FAs. The fold changes were calculated as log2(niacin / control).




Ratio p-value Fold 
change
Trans-2,3-enoyl-CoA 
reductase Tecr 0.029 0.498(↑) General fatty acid elongation
Elongation of long 
chain fatty acids 6
Elovl6 0.004 1.371(↑) C16:0 / C18:0 0.416 -0.152(↓)
C16:1n-9 / C18:1n-9 0.019 -0.370(↓)
Elongation of long 
chain fatty acids 5
Elovl5 0.033 0.405(↑) C18:3n-3 / C20:3n-3 0.007 -0.619(↓)
C18:4n-3 / C20:4n-3 Sub & prod not measured
C18:2n-6 / C20:2n-6 0.028 -0.540(↓)
C18:3n-6 / C20:3n-6 0.049 -0.390(↓)
Elongation of long 
chain fatty acids 
5/2
Elovl5/
Elovl2 C20:5n-3 / C22:5n-3 0.155 0.529(↑)
C20:4n-6 / C22:4n-6 0.032 0.387(↑)
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Figure 2: A) PUFA release from ex vivo isolated adipocytes from control and niacin treated mice incubated for 
two hours in DMEM/F12 medium. B) PUFA concentration in unfasted plasma of control and niacin treated mice. 
Mean±SD, n=14 for Control/n=13 for Niacin. *p<0.05 compared to control gWAT after FDR correction. P-values 
listed were before FDR correction.
Liver PUFA biosynthesis gene expression and fatty acid composition
As adipose tissue and the liver are the main sites of NEFA processing, we also examined 
the effects of prolonged niacin on the liver. We found by using qPCR that Elovl5 and Fads2 
expression were unaffected by niacin treatment, while Elovl6 expression was down-regulated 
(Figure 1). Liver fatty acid composition did not differ between control and niacin treated mice 
(supplementary figure S2 and table S3), neither did the substrate/product ratios relevant for 
PUFA biosynthesis (Data not shown). Although the PUFA fractions of the livers from niacin 
treated mice went in the inverse direction as seen in gWAT, this effect was non-significant.
Plasma PUFAs and oxylipins
In addition to measuring PUFA levels in adipocyte medium ex vivo we also examined PUFA 
levels in plasma by LC-MS/MS. Niacin reduced circulating levels of ALA and tended to 
increase the levels of its down-stream product DHA (Figure 2B and supplementary table S4, 
DHA was NS after FDR correction). EPA levels were not affected by niacin. We next examined 
the ratio of DHA over AA as a surrogate marker for PUFA associated cardiovascular risk 
[27-29] and found that the ratio was shifted towards DHA, both in adipocyte medium and 
in plasma (Figure 3A). PUFA derived oxylipin signaling molecules were also measured in the 
plasma (Figure 3B and supplementary table S4). Arachidonic acid metabolite prostaglandin 
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D2 was not affected by niacin treatment, whereas thromboxane B2 levels increased (NS after 
FDR correction). AA metabolite leukotriene E4 decreased after niacin treatment (NS after 
FDR correction), whereas 12-hydroxy eicosatetraenoic acid (12-HETE) levels remained 
unchanged. The n-3 PUFA derived diol metabolite 19,20-dihydroxy docosapentaenoic acid 
(19,20-diHDPA) produced by cytochrome P450 was significantly increased. Due to the 
increase in DHA levels we investigated the presence of DHA derived resolvins [30], which 
could however not be detected by our approach. 
Figure 3: A) Docosahexaenoic acid over arachidonic acid ratio in adipocyte secreted medium and in plasma. B) 
Oxylipin concentration in plasma of control and niacin treated mice. Mean±SD, n=14 per group. *p<0.05 compared 
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Figure 4: Schematic overview of the synthesis of poly unsaturated fatty acids and the subsequent conversion to a 
selection of oxylipins. Genes are in italic, metabolites in bold and essential FAs are encircled. Metabolites in grey 
were not measured. Based on the review by Guillou et al.[31]
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Discussion
The current study demonstrates for the first time that prolonged niacin treatment results 
in an up-regulation of the n-3 PUFA synthesis pathway in adipose tissue. Gene expression 
analysis of gWAT showed that our hyperlipidemic mouse model responded to niacin by up-
regulating genes involved in the unsaturated FA biosynthesis. Fatty acid composition analysis 
corroborated the increased PUFA synthesis. A higher degree of n-3 PUFA secretion from 
prolonged niacin treated adipocytes was seen, which was also reflected in increased n-3 
PUFA plasma levels. Markedly, the plasma levels of n-3 PUFA derived oxylipins produced 
by cytochrome P450 and hydrolyzed by soluble epoxy hydrolases were increased. Oxylipins 
produced by cytochrome P450 from n-3 PUFAs and the n-3 PUFAs themselves suggest a 
beneficial vascular health profile, which might contribute to the prolonged niacin-induced 
atheroprotective effect.
Gene expression analysis of the gonadal white adipose tissue of hyperlipidemic mice treated 
with niacin for 15 weeks demonstrated an up-regulation of the “biosynthesis of unsaturated 
fatty acid” pathway, mostly by up-regulation of Elovl6, Tecr and Elovl5. All three genes are 
involved in FA elongation, not desaturation (as shown in figure 4 and table 3). This discovery 
was confirmed by qPCR, but also by gWAT FA composition and FA ratio analysis, which all 
pointed towards PUFA elongation. This increase in PUFA elongation was seen in adipose 
tissue, but not in liver tissue, where a more inverse trend towards PUFA accumulation could 
be seen in the fatty acid composition. When examining the PUFA secretion of adipocytes 
isolated from these mice, we found that specifically end-products of n-3 PUFA biosynthesis 
were secreted to a higher degree, as seen by DHA (C22:6) and also by EPA (C20:5) secretion. 
As the genes involved in PUFA biosynthesis are the same for n-3 PUFAs as for n-6 PUFAs, 
the specificity for increased n-3 PUFA secretion was puzzling. It is conceivable that the 
PUFA biosynthesis enzymes have a higher affinity for n-3 PUFAs, as was already shown for 
zebrafish desaturase enzymes [32]. The rat elongase 5 enzyme possesses a higher affinity 
for n-3 substrates than for n-6 substrates [33], and the mouse equivalent was found to be 
up-regulated in our study. Selective DHA biosynthesis, unlike AA or EPA, requires partial 
peroxisomal beta oxidation (Figure 4). Although the microarray did not point towards 
this pathway,  increased peroxisomal beta oxidation after niacin could lead to preferential 
DHA synthesis.  Asides from preferential n-3 PUFA biosynthesis, preferential mobilization 
from adipose tissue would also explain an increased n-3 PUFA release. A well-documented 
phenomenon is selective PUFA release from adipocytes [34], exemplified by fasting-induced 
preferential n-3 PUFA depletion of adipose tissue triglycerides [35]. Our preliminary results 
also indicate preferential n-3 PUFA release from adipocytes when (fasting-induced) lipolysis 
is stimulated by 8Br-cAMP (Supplemental figure S8c). Other potential mechanisms for 
preferential n-3 PUFA release might be phospholipid hydrolysis, as it has been previously 
shown that cytosolic PLA2 releases AA and EPA from phospholipids whereas the release of 
DHA from phospholipids requires calcium-independent PLA2 [36]. Although 99% of the 
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fatty acids are located in the triglyceride fraction, the contribution of the 1% fatty acids 
contained in the phospholipid fraction to n-3 PUFA release cannot be excluded. Additional 
research is required to investigate the underlying mechanisms for the preferential n-3 PUFA 
release after prolonged niacin treatment.
Adipocyte lipolysis contributes to the free fatty acid pool in the circulation. In the plasma 
of the niacin treated animals, we found a tendency for increased levels of the n-3 PUFA DHA 
in the NEFA pool. Although we do not have direct proof, our data suggest that DHA secretion 
by  adipocytes is the main source of DHA in the plasma. Interestingly we did not find up-
regulation of gene expression levels of Elovl5,Elovl6 nor Fads2, or any change in fatty acid 
composition in the livers of the niacin treated mice, indicating that the niacin induced PUFA 
synthesis is selective for adipose tissue.
The n-3 PUFAs have been reported to confer CVD protective abilities via their 
conversion to anti-inflammatory oxylipins. For example, DHA can be converted to the 
oxylipin 19(20)-epoxy docosapentaenoic acid (19(20)-EpDPA) by cytochrome P450 (CYP) 
as can be seen in figure 4. Likewise, the n-3 PUFA EPA can be converted to 14(15)-epoxy 
eicosatetraenoic acid (14(15)-EpETE) by CYP. These epoxide metabolites have powerful 
biological effects on cardiovascular health. This was shown by previous studies where the 
epoxide metabolism pathway was genetically manipulated [37] or its compounds were 
pharmacologically elevated [38]. These studies showed the importance of epoxy metabolites 
in resolving inflammation, preserving vascular tone and general vascular homeostasis. 
The biologically active 19(20)-EpDPA and 14(15)-EpETE can be hydrolyzed by soluble 
epoxy hydrolases (encoded by the Ephx2 gene in mice) to their respective diol metabolites 
19,20-diHDPA and 14,15-dihydroxy eicosatetraenoic acid (14,15-diHETE). The levels of both 
these diol products were increased in plasma of niacin treated animals. The hydrolyzed diol 
metabolites have a far lower biological effect than their epoxide metabolites, but are more 
stable and can be detected in plasma by LC-MS/MS. Although we did not directly measure 
whether the levels of the bioactive epoxy metabolites 19(20)-EpDPA or 14(15)-EpETE were 
increased after niacin treatment, we found a positive correlation in plasma between the 
precursor and diol metabolite of 19(20)-EpDPA (DHA and 19,20-diHDPA) in niacin treated 
mice (Supplementary figure S3). This correlation suggests that the levels of 19(20)-EpDPA 
must also have increased after niacin treatment. 
In general, the anti-inflammatory oxylipins such as epoxy metabolites produced by CYP 
(high affinity for n-3 PUFAs), are balanced by the pro-inflammatory oxylipins such as those 
produced by cyclooxygenases (COX) and arachidonate lipoxygenases (ALOX) (both with high 
affinity for n-6 PUFAs, such as AA) [39]. Prolonged niacin treatment did not dramatically 
affect AA derived oxylipin levels, although there was a tendency towards decreased levels 
of leukotriene E4, a lipoxygenase pathway product stimulating inflammation, and towards 
increased levels of thromboxane B2, a cyclooxygenase product stimulating coagulation. 
Acute treatment of mouse adipocytes with niacin did not lead to an increased release of 
DHA or AA, nor a change in the ratio of DHA/AA in the adipocyte conditioned medium 
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(Supplemental figure S 9). Acute niacin treatment however, is a well-known trigger for AA-
derived oxylipin synthesis in the skin. Irritative subcutaneous skin flushing is a common 
acute side-effect of niacin, induced by cyclooxygenase product prostaglandin D2 [40] in 
Langerhans cells and keratinocytes. As mentioned above, we did not see an increase in pro-
inflammatory prostaglandins after prolonged niacin treatment. These results are in line with 
results by Stern et al. [17] and suggest tolerance for flushing after prolonged niacin treatment. 
It is possible that the tolerance for flushing after prolonged niacin is mediated via n-3 PUFAs 
as suggested by vanHorn et al. [41]. Whether there is a role for anti-inflammatory n-3 
PUFA derived oxylipins after acute niacin remains unclear. Inceoglu et al. [42] have acutely 
administered niacin to mice being treated with a soluble epoxide hydrolase inhibitor, which 
resulted in a blunted flushing response compared to wild type mice, while acute prostaglandin 
D2 treatment did not blunt flushing. These results support a role for cytochrome P450 epoxide 
metabolites not only after prolonged niacin treatment, but also acutely in inhibiting the 
flushing response by niacin. Flushing severity also suggests an important balance between 
pro- and anti-inflammatory oxylipins, which can be modulated by niacin treatment. Most 
likely, the n-6 derived oxylipins prevail during acute niacin treatment, while after prolonged 
niacin treatment the n-3 derived oxylipins prevail. 
Plasma DHA/AA ratio has been shown to be a diagnostic marker for PUFA associated 
cardiovascular health [27-29]. In addition to being metabolized to anti-inflammatory 
oxylipins, n-3 PUFA confer their CVD protective abilities by direct competition with n-6 
PUFAs. Vanhorn et al. [41] have described that DHA supplementation increases the DHA/
AA ratio in membrane phospholipids of Langerhans cells, thereby diminishing the relative 
availability of AA for pro-inflammatory prostaglandin synthesis. As a low n-3/n-6 ratio is 
associated with a risk for cardiovascular disease, increasing the ratio by supplementary n-3 
PUFAs has been posed as a treatment target [43]. In our study, we see that the DHA/AA ratio 
has increased towards the anti-inflammatory DHA side without supplementary n-3 PUFAs. 
We have seen this increased DHA/AA ratio in both the ex vivo adipocyte PUFA secretion 
profile and in the in vivo plasma NEFA profile of niacin treated mice. These effects of niacin 
on adipose tissue and plasma PUFAs and oxylipins pose a potential contributing mechanism 
by which niacin treatment reduces cholesterol levels and CVD risk. Although we used mice in 
this study which are human like with respect to lipoprotein profile it remains to be investigated 
whether there are changes in the plasma DHA/AA ratio in humans treated with niacin.
In conclusion, prolonged niacin treatment of our hyperlipidemic mouse model with niacin 
resulted in up-regulation the entire pathway of PUFA biosynthesis in gWAT, increased n-3 
PUFA secretion from the adipocytes and an increased plasma level of n-3 PUFAs and their 
anti-inflammatory oxylipins, which together point towards an atheroprotective plasma profile 
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Supplemental data
Table S1: 
Gene Forward primer Reverse primer Temperature
Rplp0 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG 60
Ppia ACTGAATGGCTGGATGGCAA TGTCCACAGTCGGAAATGGT 61
Elovl5 CAGCTTGCTTCTGTTCCCG TCCATTTTAAAACCTCTCTGCCT 61
Elovl6 GCACTAAGACCGCAAGGCAT CTACGTGTTCTCTGCGCCTC 61
Fads2 CTGGTGGAACCACCGACATT TCTTGCCATACTCAAGGGGC 61
Figure S1: Adipose tissue fatty acid composition of gWAT from APOE*3-Leiden.CETP mice fed a western type diet 
with 0.1% cholesterol with and without niacin. Mean±SD, N=14 for Control/N=13 for Niacin, *p<0.05 compared to 
control gWAT after false discovery rate correction. 
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Table S 2: Adipose tissue fatty acid composition of gWAT from APOE*3-Leiden.CETP mice fed a western type diet 
with 0.1% cholesterol with and without niacin and fatty acid composition of the western type diet. Fraction of total 
area corrected sum. Mean±SD, N=14 for Control/N=13 for Niacin/N=3 for diet. (*)Significant finding after false 
discovery rate correction. 
 Control gWAT Niacin gWAT Diet Control vs Niacin
Average  SD Average  SD Average  SD P-value
SFA
C10:0 0,0008 0,0003 0,0012 0,0004 0,0013 0,0009 (*)0,0078
C12:0 0,0022 0,0005 0,0036 0,0011 0,0019 0,0013 (*)0,0005
C14:0 0,0173 0,0054 0,0271 0,0061 0,0059 0,0038 (*)0,0003
C16:0 0,2153 0,0285 0,2339 0,0360 0,4351 0,0571 0,1679
C17:0 0,0005 0,0002 0,0004 0,0001 0,0014 0,0006 0,2804
C18:0 0,0239 0,0081 0,0250 0,0069 0,2162 0,0331 0,7049
C20:0 0,0005 0,0003 0,0004 0,0002 0,0030 0,0009 0,4066
C22:0 2,88E-05 1,99E-05 2,51E-05 1,55E-05 3,00E-04 7,01E-05 0,6070
MUFA       
C14:1 0,0012 0,0004 0,0018 0,0004 0,0003 0,0002 (*)0,0006
C16:1 0,0652 0,0131 0,0745 0,0202 0,0055 0,0035 0,1773
C17:1 0,0007 0,0002 0,0007 0,0002 0,0002 0,0001 0,1951
C18:1 0,6400 0,0459 0,6007 0,0532 0,3036 0,0445 0,0593
C20:1 0,0022 0,0018 0,0019 0,0010 0,0004 0,0002 0,5577
C22:1 2,94E-05 2,05E-05 2,65E-05 1,47E-05 1,62E-05 1,13E-05 0,6729
PUFA n-3       
ALA C18:3 3,32E-04 3,89E-05 2,72E-04 3,37E-05 4,58E-04 9,25E-05 (*)0,0003
ETA C20:3 2,63E-05 2,06E-05 2,51E-05 1,31E-05 2,82E-06 1,61E-06 0,8598
EPA C20:5 6,01E-07 5,83E-07 4,93E-07 4,93E-07 9,89E-07 9,91E-07 0,7985
DPA C22:5 6,95E-07 5,62E-07 7,28E-07 5,00E-07 4,11E-07 3,58E-07 0,8961
DHA C22:6 5,02E-07 4,58E-07 6,00E-07 4,28E-07 2,06E-06 4,75E-07 0,5940
PUFA n-6       
LA C18:2 2,19E-02 4,13E-03 1,78E-02 2,82E-03 2,32E-02 9,00E-03 (*)0,0080
C20:2 4,91E-05 4,09E-05 4,43E-05 2,49E-05 1,15E-05 4,28E-06 0,7206
C22:2 1,62E-06 1,47E-06 1,67E-06 1,45E-06 7,95E-06 1,70E-06 0,9370
C18:3 8,86E-06 2,45E-06 7,84E-06 1,59E-06 7,16E-07 4,56E-07 0,2231
C20:3 1,31E-06 8,78E-07 1,02E-06 3,31E-07 3,55E-07 1,66E-07 0,2789
AA C20:4 2,60E-05 1,47E-05 2,25E-05 1,18E-05 1,47E-06 9,51E-07 0,5065
AdA C22:4 1,90E-06 1,07E-06 1,42E-06 9,62E-07 2,86E-07 - 0,2540
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Figure S2: Liver fatty acid composition from APOE*3-Leiden.CETP mice fed a western type diet with 0.1% cholesterol 
with and without niacin. Fraction of total area corrected sum. Mean±SD, N=14 for Control/N=13 for Niacin. *p<0.05 
comparing control gWAT to niacin gWAT after false discovery rate correction.
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Table S3: Liver fatty acid composition from APOE*3-Leiden.CETP mice fed a western type diet with 0.1% cholesterol 
with and without niacin. Fraction of total area corrected sum. Mean±SD, N=14 for Control/N=13 for Niacin. (*)
Significant finding after false discovery rate correction. 
 Control Liver Niacin Liver Control vs Niacin
Average SD Average SD  P-value
SFA
C10:0 8,23E-05 4,42E-05 9,74E-05 7,38E-05 0,5248
C12:0 0,000143 5,17E-05 0,000152 5,92E-05 0,6948
C14:0 0,003877 0,000907 0,003968 0,001167 0,8245
C16:0 0,20753 0,013181 0,196168 0,020302 0,0989
C17:0 0,000625 9,85E-05 0,000565 5,39E-05 0,0739
C18:0 0,057714 0,014338 0,059939 0,013182 0,6860
C20:0 0,000262 0,000122 0,000229 6,67E-05 0,4218
C22:0 0,000147 0,000125 0,000107 3,45E-05 0,2909
MUFA      
C14:1 9,46E-05 3,57E-05 9,7E-05 2,96E-05 0,8528
C16:1 0,019737 0,00563 0,020314 0,004366 0,7759
C17:1 0,00056 0,000161 0,000524 0,000112 0,5268
C18:1 0,621529 0,018559 0,628717 0,023243 0,3893
C20:1 0,010283 0,002869 0,009425 0,001852 0,3834
C22:1 0,000124 8,64E-05 9,79E-05 2,31E-05 0,3213
PUFA n-3      
ALA C18:3 9,17E-05 4,6E-05 0,00011 3,92E-05 0,2796
ETA C20:3 0,000388 0,000133 0,000438 0,000173 0,4111
EPA C20:5 0,00721 0,00204 0,00886 0,002503 0,0763
DPA C22:5  -   -   -   -  
DHA C22:6 0,000669 0,000237 0,000828 0,000228 0,0945
PUFA n-6      
LA C18:2 0,019119 0,003479 0,020887 0,003278 0,1973
C20:2 0,000276 9,29E-05 0,000271 0,000102 0,9115
C22:2 1,49E-05 2,02E-05 9,08E-06 4,02E-06 0,3334
C18:3 2,17E-05 1,29E-05 2,69E-05 1,31E-05 0,3204
C20:3 1,39E-05 7,87E-06 1,19E-05 4,41E-06 0,4437
AA C20:4 0,008023 0,002318 0,009784 0,002791 0,0916
AdA C22:4 1,47E-05 3,65E-06 1,69E-05 6,41E-06 0,3014
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Table S 4: Unfasted plasma PUFA and oxylipin concentrations of APOE*3-Leiden.CETP mice fed a western type diet 
with 0.1% cholesterol with and without niacin. Mean±SD, N=14 for Control/N=13 for Niacin. (*)Significant finding 
after false discovery rate correction. 
 Control Niacin Control vs Niacin
Average (ng/mL) SD (ng/mL) Average (ng/mL) SD (ng/mL) P-value
PUFA
ALA 1139,98 69,76 784,61 61,24 (*)0,0007
EPA 91,51 7,10 82,03 6,51 0,3342
DPA 1373,47 118,48 1133,20 81,11 0,0996
DHA 1012,96 52,65 1194,23 52,00 0,0226
LA 9033,60 427,04 8875,20 273,66 0,7614
AA 5833,59 417,18 5342,29 192,80 0,2949
AdA 139,25 11,33 119,86 7,21 0,1608
Oxylipins      
12-HETE 140,60 100,95 138,77 121,74 0,9666
Leukotriene E
4
0,125 0,020 0,112 0,005 0,0324
Prostaglandin D
2
0,545 0,073 0,528 0,097 0,6066
Thromboxane B
2
3,25 0,95 4,67 2,00 0,0252
14,15-diHETE 0,247 0,075 0,291 0,127 0,2891
19,20-diHDPA 0,696 0,131 1,011 0,345 (*)0,0065
Figure S3: Correlation between the plasma concentrations of 19,20-dihydroxydocosapentaenoic acid and 
docosahexaenoic acid. N=14 mice per group, *p<0.05 compared to a slope of zero.
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Table S5: Multiple Reaction Monitoring setup for ion transitions of the target compounds. Symbols in bold refer to 
internal standards. RT retention time, Q1 quadrupole 1 ion selection, Q3 quadrupole 3 ion selection, EP entrance 
potential, CE, collision energy, CCEP collision cell exit potential. HODEs, HOTrEs, HETEs, HEPEs, diHETEs and diHDPAs 
are given without chiral descriptors. Internal standards are indicated in grey.














RvE1 LMFA03070019 4.0 349.1 195.0 -95 -10 -22 -13
20-hydroxy LTB
4
LMFA03020018 4.4 351.1 195.0 -60 -10 -24 -17
8-iso-PGF
2
α LMFA03110001 5.1 353.1 193.0 -135 -10 -34 -11
15-keto-PGE
2
LMFA03010030 5.1 349.0 234.9 -65 -10 -20 -13
TxB
2
LMFA03030002 5.2 369.1 169.0 -55 -10 -24 -15
8-iso-PGE
2









LMFA03010008 5.6 355.1 193.0 -50 -10 -26 -17
PGE
2
LMFA03010003 5.7 351.2 271.1 -50 -10 -22 -21
PGD
2
LMFA03010004 5.8 351.1 233.0 -30 -10 -16 -13
LXB
4
LMFA03040002 6.0 351.1 220.9 -60 -10 -22 -13
PGF
2α
LMFA03010002 6.1 353.1 193.0 -80 -10 -34 -11
RvD2 LMFA04000007 6.2 375.1 277.1 -60 -10 -18 -15
LXA
4





LMFA03010027 6.6 353.1 195.0 -110 -10 -32 -11
AT-RvD1 LMFA04000074 6.7 375.0 215.0 -50 -10 -26 -11
RvD1 LMFA04000006 6.7 375.1 215.0 -50 -10 -26 -11
epi-LXA
4
LMFA03040003 6.8 351.1 114.9 -20 -10 -22 -11
RvE2 LMFA03070036 7.8 333.1 114.9 -35 -10 -18 -15
18S-RvE3 LMFA03070048 8.8 333.1 245.2 -25 -10 -16 -17
6-trans-LTB
4
LMFA03020013 8.9 335.1 194.9 -105 -10 -22 -11
8S,15S-diHETE LMFA03060050 8.9 335.1 207.9 -55 -10 -22 -17
LTD
4
LMFA03020006 9.0 495.1 177.0 -70 -10 -28 -19
6-trans-12-epi-LTB
4
LMFA03020014 9.1 335.1 194.9 -80 -10 -22 -25
10S,17S-diHDHA (PDX) LMFA04000047 9.2 359.1 153.0 -70 -10 -22 -9
18R-RvE
3
LMFA03070049 9.2 333.1 245.0 -55 -10 -18 -23
7S-MaR1 n.a. 9.3 359.1 249.9 -20 -10 -20 -19





LMFA03020030 9.4 339.1 196.9 -70 -10 -22 -19
LTB
4
LMFA03020001 9.4 335.1 195.0 -65 -10 -22 -21
14,15-diHETE LMFA03060077 9.5 335.1 207.0 -65 -10 -24 -21
7,17-diHDPA n.a. 9.5 361.1 198.9 -45 -10 -26 -23
LTE
4
LMFA03020002 9.6 438.1 333.1 -55 -10 -26 -15
19,20-diHDPA LMFA04000043 10.2 361.1 273.0 -55 -10 -22 -15
5
111
PROLONGED NIACIN INCREASED PUFA & OXYLIPIN LEVELS IN ADIPOSE TISSUE














9-HOTrE LMFA02000024 10.2 293.0 170.9 -75 -10 -20 -15
13-HOTrE LMFA02000051 10.3 293.0 195.0 -45 -10 -24 -19
18-HEPE LMFA03070038 10.4 317.1 259.0 -5 -10 -16 -7
15-HEPE LMFA03070009 10.5 317.1 219.0 -65 -10 -18 -19
13-HODE LMFA02000228 10.8 295.0 194.9 -110 -10 -24 -21
9-HODE LMFA02000188 10.8 295.0 171.0 -130 -10 -22 -7
15-HETE-d
8
LMFA03060080 10.9 327.2 226.0 -85 -10 -18 -11
15-HETE LMFA03060001 11.0 319.1 219.1 -55 -10 -18 -9
11-HETE LMFA03060003 11.1 319.1 167.0 -70 -10 -22 -15
17-HDHA LMFA04000072 11.1 343.1 245.0 -65 -10 -16 -15
12-HETE LMFA03060007 11.2 319.1 179.0 -65 -10 -20 -23
8-HETE LMFA03060006 11.2 319.1 154.9 -70 -10 -20 -19
5-HETE LMFA03060002 11.3 319.1 115.0 -65 -10 -18 -11
ALA LMFA01030152 12.4 277.0 233.0 -90 -10 -22 -29
EPA LMFA01030759 12.4 301.0 202.9 -125 -10 -18 -21
DHA-d
5
LMFA01030762 12.4 332.0 288.1 -75 -10 -16 -13
DHA LMFA01030185 12.7 327.1 229.2 -115 -10 -18 -11
AA LMFA01030001 12.7 303.0 205.1 -155 -10 -20 -11
LA LMFA01030120 12.8 279.0 261.0 -115 -10 -28 -13
DPA n-3 LMFA04000044 13.0 329.1 231.1 -50 -10 -20 -17
AdA LMFA01030178 13.1 331.1 233.0 -130 -10 -22 -11
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Figure S4a: MS/MS of 0.1 ng/mL standard sample at Relative RT 1.016 (Leukotriene E4).

























Figure S4b: MS/MS spectra of representative sample at Relative RT 1.015 (Leukotriene E4).
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Figure S5a: MS/MS spectra of 0.1 ng/mL standard sample at Relative RT 0.925 (Thromboxane B2).
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Figure S5b: MS/MS spectra of representative sample at Relative RT 0.927 (Thromboxane B2).
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Figure S6a: MS/MS spectra of 0.1 ng/mL standard sample at Relative RT 1.087 (19,20-diHDPA).






















Figure S6b: MS/MS spectra of representative sample at Relative RT 1.087 (19,20-diHDPA).
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Figure S7: Release of medium chain saturated fatty acids from adipocytes isolated from APOE*3-Leiden.CETP mice 
fed a western type diet with 0.1% cholesterol with and without niacin. Fatty acid release in arbitrary units during a 
2 hour ex vivo basal incubation. Mean±SD, N=14 for Control/N=13 for Niacin. 
Figure S8: Release of DHA and AA from adipocytes isolated from APOE*3-Leiden.CETP mice fed a western type diet 
with 0.1% cholesterol without niacin. Fatty acid release in arbitrary units during a 2 hour ex vivo incubation in basal 




Figure S9: Ratio of DHA/AA released fatty acids from adipocytes isolated from APOE*3-Leiden.CETP mice fed a 
western type diet with 0.1% cholesterol without niacin. Fatty acid release in arbitrary units during a 2 hour ex vivo 
incubation under basal and acute niacin conditions. Mean±SD, N=14 for Control/N=10 for Acute niacin. 
5
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Increased PUFA content and 5-lipoxygenase 
pathway activity are associated with sub-
cutaneous adipose tissue inflammation in 
obese women
Mattijs M. Heemskerk, Martin A. Giera, Fatiha el Bouazzaoui, Mirjam A. Lips, Hanno Pijl, Ko 
Willems van Dijk, Vanessa van Harmelen




Background/Objectives: White adipose tissue inflammation plays an important role in 
the development of insulin resistance and type 2 diabetes mellitus (T2DM). We have 
previously shown that obese women with T2DM have more inflammation in their 
subcutaneous adipose tissue than age and BMI similar obese women with normal glucose 
tolerance (NGT). The aim of the current study was to investigate whether adipose tissue 
fatty acids and/or oxylipins are associated with the enhanced inflammatory state in 
adipose tissue of the T2DM women.
Subjects/Methods: Fatty acid profiles were measured by GC-MS in both subcutaneous 
(sWAT) and visceral adipose tissue (vWAT) of 19 obese (BMI>40kg/m2) women with NGT 
and 16 BMI-and age-comparable women with T2DM. Oxylipin levels (in total 49 lipid 
mediators) were measured in sWAT of all women. 
Results: Arachidonic acid (AA) and docosahexaenoic acid (DHA) percentages were 
higher in sWAT but not vWAT of the T2DM women and correlated positively (trend for 
DHA) to CD68 gene expression levels. For the oxylipins there were tendencies for higher 
concentrations of the leukotrienes, LTD4, 6-trans LTB4 and 6-trans-12-epi LTB4, in sWAT 
of T2DM women. Gene expression of ALOX5, ALOX5AP and DPEP2 (involved in the 
5-LOX leukotriene biosynthesis pathway) was significantly higher in sWAT of T2DM 
women.
Conclusions: In conclusion, AA and DHA content were higher in sWAT of T2DM 
women and correlated to the inflammatory state in the tissue. The increased AA content 
was accompanied by an up-regulation of the 5-LOX pathway and this seems to have led 
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Introduction
Obesity is closely associated with insulin resistance, type-2 diabetes mellitus (T2DM), 
dyslipidemia, hypertension and cardiovascular disease. Expanding adipose tissue plays 
an important role in the patho-physiology of obesity-associated disorders as it responds 
to the energy overload with stress signals which in turn can elicit local immune responses 
and inflammation [1]. Although the majority of obese individuals (~80%) will eventually 
develop metabolic disorders associated with a reduced life expectancy, there seems to be a 
subset of obese individuals that remains relatively insulin sensitive and metabolically healthy 
throughout life [2, 3]. The reason why these individuals are unaffected is still not completely 
understood. We have previously shown that subcutaneous white adipose tissue (sWAT) from 
obese women with T2DM contained a larger number of crown-like-structures (CLS) than 
sWAT of similarly obese women with normal glucose tolerance (NGT) [4]. In a parallel 
study, we analyzed the transcriptome in adipose tissue samples by RNA deep sequencing in 
the same cohort of women and observed an up-regulation of genes in inflammatory pathways 
and a down-regulation of genes in metabolic pathways in WAT of the women with T2DM 
[5]. Our data thus indicate that metabolically healthy and unhealthy obese women can be 
differentiated by the inflammatory status of their adipose tissue. 
Adipose tissue inflammation involves the accumulation of macrophages in CLS around 
adipocytes that are stressed or dying due to cellular lipid overload [6]. The enlarged stressed 
adipocytes exhibit an increased release of pro-inflammatory adipocytokines and chemokines 
which attract immune cells into the adipose tissue [7]. Hypertrophic adipocytes also store 
and release increased levels of fatty acids which are known to mediate inflammatory processes 
as well [8]. Not only the amount of fatty acids released, but also the type of fatty acid stored 
in adipose tissue has been associated to systemic inflammation [9] and T2DM [10, 11]. 
For example, an increased percentage of saturated fatty acids or their metabolites has been 
suggested to induce inflammation by activating Toll-like receptor 4, which in turn leads to 
an up-regulation of the ceramide biosynthesis pathway [12]. Ceramides activate the NLPR3 
inflammasome which is an important contributor to obesity induced inflammation and insulin 
resistance [13]. Other fatty acids that are involved in inflammation are the polyunsaturated 
fatty acids (PUFAs). n-3 and n-6 PUFAs can induce pro- and anti-inflammatory pathways 
respectively [14] via a variety of different mechanisms including signaling via GPR120. 
PUFAs can be converted to inflammatory lipid mediators called oxylipins. Oxylipin synthesis 
usually occurs via the cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 (CYP) 
pathways [15]. All three pathways can metabolize both n-3 and n-6 PUFAs, but the affinity for 
these substrates differs as does the pro- or anti-inflammatory potency of the different resulting 
products. For example the 2-series prostaglandins, synthesized from arachidonic acid (AA; 
C20:4n-6) via the COX pathway, induce mainly pro-inflammatory effects; while the 3-series 
prostaglandins, synthesized from eisosapentaenoic acid (EPA; 20:5n-3) via COX, induces less 
potent inflammatory effects [16] and the epoxy metabolites derived from n-3 PUFAs via the 
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CYP pathway induce anti-inflammatory effects [17]. PUFA-derived oxylipin synthesis can be 
rapidly induced when triggered by inflammasome signaling [18]. A wide range of oxylipins 
has been identified in both human [19] and mouse WAT [20]. Oxylipins have been shown 
to play a role in WAT inflammation, mostly in rodent studies [8]. In the current study we 
hypothesized that the adipose fatty acid composition is linked to the enhanced inflammatory 
state in adipose tissue of obese women with T2DM. To test this hypothesis, we determined 
fatty acid profiles by GC-MS and oxylipin profiles by LC-MS/MS in white adipose tissue of 
both obese women with T2DM and obese women with NGT.
6
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Subjects and methods
Subjects
The study group consisted of 19 obese women with normal fasting glucose (i.e. normal 
glucose tolerant (NGT)) and 16 women with T2DM. The women were part of a clinical trial 
of which the research methods and design have been described elsewhere [21]. The groups 
were comparable for age and BMI (see Table 1). All women had been morbidly obese (mean 
BMI=43.4 ± 3.8 kg/m2) for at least five years. Women who reported the use of weight loss 
medications within 90 days prior to enrolment in the study were excluded. Body weight of 
all women had been stable for at least 3 months prior to inclusion. All women were non-
smokers, had no signs of any infections nor had any history of auto-immune diseases. The 
women underwent bariatric surgery (gastric bypass or banding). Within 1h after opening 
the abdominal wall adipose tissue specimens were taken from the epigastric region of the 
abdominal wall (subcutaneous sWAT) and from the major omentum (visceral vWAT). These 
samples were used for determination of fatty acid composition and oxylipin profiles. The 
study (ClinicalTrials.gov: NTC01167959) was approved by the p5. All subjects gave informed 
consent to participate in the study.
Medication
For obvious reasons we could not restrict obese individuals to not using any type of 
medication. All T2DM women were treated with oral medication only (metformin or 
sulfonylurea derivatives). Participants were allowed to use cholesterol lowering statins and 
antihypertensive medication. The use of drugs such as statins and antihypertensive drugs 
was slightly higher in the T2DM women. The patients were not using any anti-inflammatory 
agents (i.e. NSAIDS, thiazolidinediones or steroids (prednisone)).
Analysis of number of crown like structures and adipocyte size
In a previous study the number of crown like structures in the adipose tissue of our participants 
was determined by immunohistochemistry and the adipocyte size by direct microscopy [4].
Fatty acid composition of WAT by GC-MS
FA composition analysis of sWAT and vWAT was carried out as described recently by Kloos 
et al. [22]. Briefly: approximately 10 mg WAT was weighed from the obese women. 1 ml 
of water, 3 ml of methanol and 1 ml of 10M NaOH were added, the samples flushed with 
argon and hydrolyzed for 1 h at 90 °C. After acidification with 2 ml of 6M HCl, 10 µl of an 
internal standard solution ([2H31]palmitic acid and ergosterol 10 µg/ml each) was added. The 
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samples were extracted twice with 3 ml n-hexane and the combined organic extracts were 
dried under a gentle stream of nitrogen. Dried samples were derivatized using 25 µl of N-tert.-
butyldimethylsilyl-N-methyltrifluoroacetamide (Sigma Aldrich, Schnelldorf, Germany) for 
10 min at 21 °C, subsequently 25 µl of N,O-bis(trimethylsilyl)trifluoroacetamide containing 
1% trimethylchlorosilane (Thermo Scientific, Waltham, MA, USA) and 2.5 µl of pyridine were 
added and the sample was heated for 15 min to 50 °C. Next, 947.5 µl of n-hexane, containing 
10 µg/ml octadecane (C18) as system monitoring component, was added.
Samples were analyzed in SIM mode on a Scion TQ GC-MS (Bruker, Bremen, Germany) 
equipped with a 15 m × 0.25 mm × 0.25 mm BR5MS column (Bruker). The injection volume 
was 1 µl, the injector was operated in splitless mode at 280 °C and the oven program was as 
follows: 90 °C kept constant for 0.5 min, then ramped to 180 °C with 30 °C/min then to 250 
°C with 10 °C/min then to 266 °C with 2 °C/min and finally to 300 °C with 120 °C/min, kept 
constant for 2 min. Helium (99.9990%, Air Products, The Netherlands) was used as carrier 
gas. For data analysis a total area correction was applied.
Oxylipin measurements in WAT by LC-MS/MS
Oxylipin analysis was carried out as described elsewhere ([23],[24]) with some modifications. 
Approximately 100 mg of tissue were cut using a razor blade on a glass plate, transferred into 
a 2 ml Eppendorf tube and accurately weighed. Three µl of an internal standard solution 
containing 50 ng/ml each of PGE2-d4, LTB4-d4, 15-HETE-d8 and DHA-d5 was added. 
Subsequently 3-5 stainless steel beads, 500 µl of methanol and 2 µl of a 20 mg/ml butylated 
hydroxyl toluene solution were added. Next, the samples were homogenized in a bead beater 
for 4 min centrifuged at 16100 g for 3 min. 400 µl of the supernatant were transferred into 
a 12 ml glass tube. The samples were re-extracted using 500 µl of methanol by shaking for 5 
min. The combined organic extracts were diluted with approximately 9 ml of water, acidified 
with 6M HCl and further cleaned up using solid phase extraction (employing 100 mg SPE 
columns) as described elsewhere [25] and finally reconstituted in 150 µl 40% methanol 
before LC-MS/MS analysis.
Statistics
Data are expressed as mean ± SD or as median and range of the values. Differences between 
NGT and T2DM were analyzed using unpaired non-parametric t-test’s. Linear regression was 
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Results
Characteristics of participants 
Characteristics of the participants are shown in Table 1. Fasting plasma glucose and LDL-
cholesterol levels were significantly higher in T2DM than in NGT women. HOMA-IR index 
and triglyceride levels tended to be higher in the T2DM women. The gene expression of CD68 (a 
macrophage marker) and the number of CLS per area adipose tissue on immunohistochemistry 
slides was used as an index for the extent of adipose tissue inflammation. The sWAT but 
not the vWAT of the T2DM women had a significantly higher gene expression of CD68 and 
contained more CLS. Adipocyte sizes did not differ between NGT and T2DM women both 
for sWAT and vWAT.
Table 1: Characteristics of the NGT and T2DM women. Crown like structures (CLS) were determined by 
immunohistochemistry of CD68 and expressed as number (#) of CLS per area of adipose tissue (AT) section on the 
slide. Adipocyte size was expressed as mean adipocyte diameter in µm. CLS counts and adipocyte sizes have been 
published previously [4]. Gene expression was determined by RNA deep sequencing in a previous study [5] and 
expressed as log transformed normalized gene expression levels (relative units [RU]: log2-scale). Data are expressed 
as mean ± SD.
NGT T2DM P-value t-test
N 19 16
BMI (kg/m2) 43.4 ±3.3 43.4±4.5 NS
Age (y) 47±7 52±6 NS
Weight (kg) 121±8 127±12 NS
HOMA-IR 2.7±2.2 4.0±3.0 0.08
Fasting glucose (mmol/l) 5.0±0.6 9.0±2.6 <0.01
Fasting insulin (mU/l) 10.9±7.7 13.3±7.3 NS
Total cholesterol (mmol/l) 4.7±1.1 4.2±0.8 NS
HDL cholesterol (mmol/l) 1.1±0.3 1.1±0.3 NS
LDL cholesterol (mmol/l) 3.0±1.0 2.2±0.6 0.03
Triglycerides (mmol/l) 1.5±0.7 2.0±0.7 0.08
CRP (mg/l) 7.8±7.5 8.2±6.3 NS
CD68 gene expression in sWAT 8.2±0.4 8.9±0.7 0.003
CD68 gene expression in vWAT 8.2±0.4 8.4±0.5 NS
# of CLS in sWAT (no/AT section) 2.3±1.4 12.3±7.1 0.05
# of CLS in vWAT (no/AT section) 1.9±1.2 2.7±1.0 NS
Adipocyte size in sWAT (µm) 122±16 126±15 NS
Adipocyte size in vWAT (µm) 112±16 118±8 NS
126
CHAPTER 6
Differences in adipose tissue content of saturated fatty acids and PUFAs 
between NGT and T2DM obese women
The fatty acid composition of sWAT and vWAT samples from the NGT and T2DM obese 
women was determined by GC-MS. For both sWAT and vWAT for the T2DM women, we 
found lower percentages of C10:0 (Decanoic acid) and C12:0 (Lauric acid) (Fig. 1A). The 
MUFAs did not show large differences between the NGT and T2DM women (Fig. 1B). For 
the PUFAs in vWAT of the T2DM women, a lower percentage of C18:3n-6 (gamma-linolenic 
acid) was seen. In the sWAT of the T2DM women, differences in both n-6 and n-3 PUFAs 
were found. For the n-6 PUFAs higher percentages of C20:4n-6 (Arachidonic acid (AA)) 
and C22:4n-6 (Adrenic acid (AdA)) were found (Fig. 1C), whereas for the n-3 PUFAs higher 
percentages of C20:3n-3 (Eicosatetraenoic acid (ETA)), C20:5n-3 (Eicosapentaenoic acid 
(EPA)), C22:5n-3 (Docosapentaenoic acid (DPA)) and C22:6n-3 (Docosahexaenoic acid 
(DHA)) were found (Fig. 1D).
Figure 1: Fatty acid composition of sWAT and vWAT for NGT versus T2DM individuals.  A) Saturated fatty acids. B) 
Mono-unsaturated fatty acids. C) n-6 and D) n-3 poly-unsaturated fatty acids. Data are expressed as mean ± SD. 
*p<0.05 for NGT vs T2DM. 
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Arachidonic acid and docosahexaenoic acid correlated to CD68 
expression in sWAT 
The percentage AA of the total fatty acid pool correlated to the gene expression level of CD68 
in sWAT and a trend was visible for DHA. For the correlation of AA with CD68 expression 
the goodness-of-fit was r=0.42, p=0.029 (Fig. 2A). For the correlation of DHA with CD68 
expression the goodness-of-fit was r=0.34, p=0.087 (Fig. 2B). There were no significant 
correlations between any other fatty acid percentage and CD68 expression in sWAT. 
Figure 2: CD68 expression versus PUFA percentage in sWAT. Linear regression of sWAT gene expression of 
the macrophage marker CD68 with the sWAT percentage of C20:4n-6 (AA) and C22:6n-3 (DHA). Data are log 
transformed normalized gene expression levels (relative units [RU]: log2-scale). Data are expressed as mean ± SD.
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Oxylipin levels in sWAT of women with NGT and T2DM
Table 2 shows the list of the oxylipins that were measured and the levels that were detected 
per mg of sWAT of the women with NGT and with T2DM. Many of the oxylipins measured, 
in particular the resolvins, were below the detection limit (see Table 2). There was a large 
variation in oxylipin concentrations between the women. Of the detectable oxylipins there 
was a tendency for higher content of some leukotrienes; i.e. LTD4, 6-trans LTB4 and 6-trans-
12-epi LTB4 in sWAT of women with T2DM (See Fig. 3A). 
Figure 3: 5-LOX oxylipins in sWAT. A) Non-esterified oxylipins derived from arachidonic acid via the 5-LOX pathway in 
sWAT of NGT vs T2DM obese individuals. LTE4 was below the detection limit (ND=not detectable). LTA4, LTC4 and LTF4 
were not included in the LC-MS/MS method. B) Gene expression of genes involved in the leukotriene biosynthesis 
pathway in sWAT of NGT versus T2DM individuals (ALOX5, ALOX5AP, LTA4H, LTC4S, GGT1, GGT5 and DPEP2). Data 
are log transformed normalized gene expression levels (relative units [RU]: log2-scale). Data are expressed as mean 
± SD. *p<0.05 and ****p<0.0001 for NGT vs T2DM.
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Table 2: Oxylipins in sWAT of NGT versus T2DM obese women. NGT vs T2DM values were compared using non-
parametric t-test. ND= non-detectable. NS= non-significant. *= Compound not in calibration line. P-value calculated 
from area ratios compared to internal standard. #= Detected, but only in fewer than five individuals in total. Data 
are expressed as median and range of the concentrations.
 NGT T2DM NGT vs T2DM
Oxylipin 
(ng/mg sWAT)
Range Median Range Median P-value 
5-HETE 7.91E-04 - 3.19E-02 3.70E-03 1.47E-03 - 5.07E-02 5.01E-03 NS
8-HETE 4.53E-04 - 1.83E-02 2.28E-03 5.56E-04 - 2.24E-02 2.86E-03 NS
11-HETE 3.58E-04 - 1.46E-02 1.55E-03 3.90E-04 - 1.84E-02 1.89E-03 NS
12-HETE 1.63E-03 - 8.36E-02 1.06E-02 2.77E-03 - 7.90E-02 1.17E-02 NS
15-HETE 7.36E-04 - 3.20E-02 3.49E-03 8.13E-04 - 4.62E-02 4.04E-03 NS
15-HEPE 9.23E-05 - 3.13E-03 4.36E-04 1.54E-04 - 2.62E-03 5.72E-04 NS
18-HEPE 1.25E-04 - 4.94E-03 5.55E-04 2.40E-04 - 3.91E-03 5.04E-04 NS
7-HDHA *  *  NS
10-HDHA *  *  NS
17-HDHA 0 - 3.17E-03 5.34E-04 0 - 3.23E-03 1.14E-03 NS
LTB4 6.42E-05 - 2.69E-03 4.10E-04 4.66E-05 - 4.17E-03 4.24E-04 NS
6-trans-12-epi LTB4 2.97E-05 - 3.22E-04 1.29E-04 5.98E-05 - 1.71E-03 1.90E-04 0.08
6-trans LTB4 3.91E-05 - 4.36E-04 1.14E-04 6.39E-05 - 1.86E-03 1.57E-04 0.10
20-OH LTB4 ND  ND   
LTD4 0 - 2.08E-04 3.80E-05 0 - 7.75E-04 7.74E-05 0.06
LTE4 ND  ND   
PGD2 5.79E-05 - 1.14E-03 2.26E-04 3.93E-05 - 2.65E-03 2.68E-04 NS
PGE2 7.06E-05 - 2.12E-03 5.95E-04 7.68E-05 - 3.58E-03 4.76E-04 NS
PGF2α 0 - 2.12E-03 6.94E-04 1.02E-04 - 2.53E-03 5.11E-04 NS
TxB2 0 - 1.24E-02 1.54E-03 4.49E-05 - 2.05E-02 1.59E-03 NS
LXA4 0 - 2.49E-04 0 0 - 1.53E-03 1.52E-05 NS
LXB4 ND  ND   
AT LXA4 ND  ND   
8-iso PGE2 ND  ND   
8-iso PGF2α 0 - 1.83E-04 4.50E-05 0 - 7.64E-04 4.39E-05 NS
15-keto PGE2 1.69E-05 - 3.62E-04 8.60E-05 6.63E-06 - 1.21E-03 6.35E-05 NS
13,14-dihy-
dro-15-keto PGF2α
0 - 5.05E-03 0 0 - 4.60E-03 0 NS
RvD1 ND  ND   
RvD2 ND  ND   
AT RvD1 ND  ND   
RvE1 ND  ND   
RvE2 #  #   
18S-RvE3 ND  ND   
18R-RvE3 ND  ND   
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 NGT T2DM NGT vs T2DM
Oxylipin 
(ng/mg sWAT)
Range Median Range Median P-value 
7,17-DiHDPA 0 - 1.68E-03 7.39E-05 0 - 8.76E-04 0.00E+00 NS
19,20-DiHDPA 0 - 3.53E-04 9.56E-05 5.99E-05 - 4.30E-04 1.11E-04 NS
10S,17S-diHDHA 
(PDX) 0 - 1.97E-04 4.00E-05 0 - 2.44E-04 3.93E-05 NS
MaR1 #  #   
7S-MaR1 ND  ND   
5,15-diHETE 0 - 2.08E-02 2.20E-03 0 - 8.71E-02 3.43E-03 NS
14,15-diHETE 0 - 6.32E-04 2.21E-04 0 - 2.15E-03 1.85E-04 NS
8S,15S-diHETE 4.00E-05 - 1.32E-03 1.47E-04 0 - 1.63E-03 1.85E-04 NS
9-HoDE 7.46E-02 - 9.24E-01 3.17E-01 1.27E-01 - 8.32E-01 2.59E-01 NS
13-HoDE 4.74E-02 - 5.27E-01 1.61E-01 6.52E-02 - 4.71E-01 1.42E-01 NS
9-HoTrE 3.41E-03 - 4.90E-02 2.08E-02 3.89E-03 - 3.74E-02 1.49E-02 NS
13-HoTrE 4.45E-02 - 5.02E-01 2.85E-01 5.68E-02 - 3.96E-01 1.95E-01 NS
8(9)EET *  *  NS
11(12)EET *  *  NS
14(15)EET *  *  NS
Differential expression of ALOX5, ALOX5AP and DPEP2 in sWAT between 
NGT and T2DM women
In a previous study, the adipose tissues of 15 of the NGT and 15 of the T2DM women included 
in the current study were used for transcriptome analysis by RNA deep sequencing [5]. From 
the gene expression profiles obtained in that study we could extract gene expression levels of 
the genes involved in the leukotriene biosynthesis pathway (i.e. ALOX5, ALOX5AP, LTA4H, 
LTC4S, GGT1, GGT5 and DPEP2). See Fig. 4 for a scheme of the leukotriene biosynthesis 
pathway and the genes involved therein. Of these genes ALOX5, ALOX5AP and DPEP2 were 
significantly higher expressed and GGT5 tended (p=0.06) to be higher expressed in sWAT of 
T2DM women (see Fig. 3B).
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We have previously shown that the macrophage content in the sWAT but not the vWAT 
of obese women with T2DM was higher. In the current study we investigated whether this 
increased inflammatory state was linked to a higher percentage of fatty acids that mediate 
inflammatory processes such as the saturated fatty acids or the PUFAs. We found that the 
higher inflammatory state in the sWAT of T2DM women was not associated with a higher 
percentage of saturated fatty acids. The saturated fatty acid percentages of C10:0 and C12:0 
were even lower in T2DM women, both in sWAT and vWAT. Interestingly, the sWAT of T2DM 
women showed increased percentages of both n-3 and n-6 long-chain PUFAs (including AA 
and DHA) which was not seen in vWAT. AA percentage in sWAT correlated positively with 
gene expression of the macrophage marker CD68 (trend for DHA) indicating that PUFAs 
were associated with the macrophage infiltration in the adipose tissue. 
The content of PUFAs in adipose tissue is dependent on several processes including uptake 
of PUFAs into the cell via fatty acid transporters or passive transport, the biosynthesis of 
PUFAs within a cell, the degradation of PUFAs and the release of PUFAs from a cell. Previously, 
we analyzed the transcriptome of adipose tissue by RNA sequencing in the same individuals 
as included in this study [5]. By using a network-based approach to analyze gene expression 
in NGT versus T2DM women, we identified the down-regulation of the complete acetyl-
CoA metabolic network in the adipose tissue of the T2DM women. This network included a 
down-regulation of fatty acid biosynthesis, fatty acid degradation as well as fatty acid release. 
Thus, although there seem to be clear differences in gene expression of PUFA metabolism, we 
cannot determine the net flux of PUFAs in the adipose tissue based on this gene expression 
analysis. Further research is required to determine the PUFA mass balance in vivo in the 
adipose tissue to be able to explain the increased PUFA content in the T2DM individuals.
Although most of the fatty acids in adipose tissue are stored in triglycerides within the 
adipocytes (99%) there is a small fraction of the fatty acids present in phospholipids. We could 
not determine which of the fatty acid based lipid species in the adipose tissue contributed 
to the difference in PUFAs in T2DM women. In addition, the (immune) cells of the stromal 
vascular fraction in adipose tissue contribute to the fatty acid pool and can produce fatty 
acid-derived mediators. Immune cells are the main producers of oxylipins [27]. It is possible 
that the observed difference in FA and oxylipin content are due to differences in the cellular 
composition of the adipose tissues. Additional research is necessary to determine whether 
the cellular composition of adipose tissue contributed to the observed differences in FA and 
oxylipin content.
Both AA and DHA can be metabolized into oxylipins with pro or anti-inflammatory 
properties. We detected several oxylipins in human sWAT, derived either from AA, DHA or 
EPA. The levels of most of these oxylipins did not differ between NGT and T2DM women, but 
there were tendencies for higher concentrations of some of the AA derived leukotrienes (LTD4, 
6-trans LTB4 and 6-trans-12-epi LTB4). For the leukotriene biosynthesis pathway (see Fig. 4), 
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AA is metabolized by 5-lipoxygenase (5-LOX) in the presence of an integral nuclear membrane 
protein, 5-LOX activating protein (also called FLAP). In this reaction, AA is metabolized 
into the sequential intermediates 5-hydroperoxyeicosatetraenoic acid (5-HpETE) and LTA4. 
LTA4 is conjugated with reduced glutathione by LTC4 synthase (LTC4S) and released from 
the cell for extracellular conversion to LTD4 and LTE4. Alternatively, cytosolic LTA4 hydrolase 
(LTA4H) converts LTA4 to LTB4. LTA4 is also hydrolyzed non-enzymatically into 6-trans LTB4 
and 6-trans-12-epi LTB4. To further study the leukotriene biosynthesis pathway we analyzed 
gene expression of genes involved in this pathway. We found a significant higher expression 
of ALOX5 (5-LOX), ALOX5AP (FLAP) and DPEP2 (Dipeptidase 2), indicating an overall 
up-regulation of the 5-LOX pathway in sWAT of T2DM women. The fact that both LTD4 and 
the non-enzymatically hydrolyzed LTB4’s tended to be higher (and not only one particular 
leukotriene) is in line with this notion. Subcutaneous adipose tissue expression of ALOX5AP 
has previously been shown to be positively associated to body weight and insulin resistance 
as determined by HOMA-IR index [28]. The 5-LOX pathway has also been shown to be 
increased in obese adipose tissue [29]. Mouse and human adipocytes produce leukotrienes 
in vitro and this production is increased in hypertrophic adipocytes in obesity in mice [30]. 
Taken together, previous studies and our study suggest that the 5-LOX pathway may provide 
a link between adipose tissue, inflammation and insulin resistance. 
The results obtained in this study differ from those of a previous study by Lieb et al. [31] 
who measured fatty acids and some downstream oxylipins in obese non-diabetic and T2DM 
individuals. They did not observe any differences in AA or DHA content between the subjects 
groups neither in sWAT nor vWAT. Instead, they observed an up-regulation of ALOX12 
expression and its metabolite 12(S)-hydroxyeicosatetraenoic acid in vWAT but not sWAT 
of the T2DM individuals and suggested that the ALOX12 pathway may have a critical role 
in adipose tissue inflammation. Differences in the subject groups (their study also included 
males) may explain the discrepancies between their and our study.
Most of the studies on lipid signaling and oxylipins in adipose tissue have been performed 
in rats or mice. We have performed a study in humans and have made a thorough analysis 
of several types of oxylipins and concentrations thereof in adipose tissue. We did not detect 
resolvins in adipose tissue apart from 10S,17S-diHDHA (PDX) and in fewer than five 
women we could detect some Resolvin E2 and Maresin 1. This is in contrast with several 
mouse studies that detected more resolvins in adipose tissue and suggested a role for these 
mediators in counteracting adipose tissue inflammation [32],[33],[34]. Apart from the 
fact that there may be species specific differences between the studies it is also possible that 
discrepancies can be explained by the stage of adipose tissue inflammation studied. Most of 
the mouse studies examine adipose tissue inflammation during a high fat diet feeding, thus 
during progressive adipose tissue expansion and inflammation. Our obese women had been 
obese for a relatively long period of time and their adipose tissue inflammation was likely 
fairly established. Further research is required to determine whether species-specificity or 
the stage and duration of obesity is responsible for the observed differences. Additionally, 
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the analysis of oxylipins in adipose tissue is a challenging task due to the large amounts of 
triglycerides and other hydrophobic matrix constituents. In the presented study we adapted 
a published protocol for the analysis of adipose tissue, however it has to be mentioned that 
the recoveries particularly for the internal standards 15-HETE-d8 and DHA-d5 were rather 
low (< 40%), suggesting that an improvement of the described method for further studies 
might be of importance.  In conclusion, AA and DHA content were higher in sWAT of T2DM 
women and associated with the inflammatory state in the tissue. The increased AA content 
was accompanied by an up-regulation of the genes in the leukotriene pathway and this seems 
to have led to a modest increase in the conversion of AA into pro-inflammatory leukotrienes 
in the subcutaneous adipose tissue of individuals with T2DM. 
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Figure S1: SRM transition m/z 319 -> 115 showing 5-HETE at RT=11.2 min and its two isomers. Upper left corner 
characteristic MS/MS spectrum and fragmentation of 5-HETE.
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Figure S2: SRM transition m/z 335 -> 195 showing LTB4 at RT=9.3 min and its two isomers. Upper left corner 
characteristic MS/MS spectrum and fragmentation of LTB4.
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Figure S3: SRM transition m/z 495 -> 177 showing LTD4 at RT=8.9 min. Upper right corner characteristic MS/MS 
spectrum and fragmentation of LTD4.
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Table S1: Multiple Reaction Monitoring setup for ion transitions of the target compounds. Symbols in bold refer to 
internal standards. RT=retention time, Q1=quadrupole 1 ion selection, Q3=quadrupole 3 ion selection, EP=entrance 
potential, CE=collision energy, CCEP=collision cell exit potential. HODEs, HOTrEs, HETEs, HEPEs, diHETEs and 
diHDPAs are given without chiral descriptors. Internal standards are indicated in grey.














RvE1 LMFA03070019 4.0 349.1 195.0 -95 -10 -22 -13
20-hydroxy LTB
4
LMFA03020018 4.4 351.1 195.0 -60 -10 -24 -17
8-iso-PGF
2
α LMFA03110001 5.1 353.1 193.0 -135 -10 -34 -11
15-keto-PGE
2
LMFA03010030 5.1 349.0 234.9 -65 -10 -20 -13
TxB
2
LMFA03030002 5.2 369.1 169.0 -55 -10 -24 -15
8-iso-PGE
2





LMFA03010008 5.6 355.1 193.0 -50 -10 -26 -17
PGE
2
LMFA03010003 5.7 351.2 271.1 -50 -10 -22 -21
PGD
2
LMFA03010004 5.8 351.1 233.0 -30 -10 -16 -13
LXB
4
LMFA03040002 6.0 351.1 220.9 -60 -10 -22 -13
PGF
2α
LMFA03010002 6.1 353.1 193.0 -80 -10 -34 -11
RvD2 LMFA04000007 6.2 375.1 277.1 -60 -10 -18 -15
LXA
4





LMFA03010027 6.6 353.1 195.0 -110 -10 -32 -11
AT-RvD1 LMFA04000074 6.7 375.0 215.0 -50 -10 -26 -11
RvD1 LMFA04000006 6.7 375.1 215.0 -50 -10 -26 -11
AT-LXA
4
LMFA03040003 6.8 351.1 114.9 -20 -10 -22 -11
RvE2 LMFA03070036 7.8 333.1 114.9 -35 -10 -18 -15
18S-RvE3 LMFA03070048 8.8 333.1 245.2 -25 -10 -16 -17
6-trans-LTB
4
LMFA03020013 8.9 335.1 194.9 -105 -10 -22 -11
8S,15S-diHETE LMFA03060050 8.9 335.1 207.9 -55 -10 -22 -17
5,15-diHETE LMFA03060010 9.2 `335.0 173.1 -55 -10 -20 -11
8(9)-EET LMFA03080003 11.4 319.0 155.0 -60 -10 -10 -13
11(12)-EET LMFA03080004 11.4 319.0 167.0 -90 -10 -18 -19
14(15)-EET LMFA03080005 11.2 319.0 219 -5 -10 -16 -55
LTD
4
LMFA03020006 9.0 495.1 177.0 -70 -10 -28 -19
6-trans-12-epi-LTB
4
LMFA03020014 9.1 335.1 194.9 -80 -10 -22 -25
10S,17S-diHDHA (PDX) LMFA04000047 9.2 359.1 153.0 -70 -10 -22 -9
18R-RvE
3
LMFA03070049 9.2 333.1 245.0 -55 -10 -18 -23
7S-MaR1 n.a. 9.3 359.1 249.9 -20 -10 -20 -19





LMFA03020030 9.4 339.1 196.9 -70 -10 -22 -19
LTB
4
LMFA03020001 9.4 335.1 195.0 -65 -10 -22 -21
14,15-diHETE LMFA03060077 9.5 335.1 207.0 -65 -10 -24 -21
7,17-diHDPA n.a. 9.5 361.1 198.9 -45 -10 -26 -23
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LMFA03020002 9.6 438.1 333.1 -55 -10 -26 -15
19,20-diHDPA LMFA04000043 10.2 361.1 273.0 -55 -10 -22 -15
9-HOTrE LMFA02000024 10.2 293.0 170.9 -75 -10 -20 -15
13-HOTrE LMFA02000051 10.3 293.0 195.0 -45 -10 -24 -19
18-HEPE LMFA03070038 10.4 317.1 259.0 -5 -10 -16 -7
15-HEPE LMFA03070009 10.5 317.1 219.0 -65 -10 -18 -19
13-HODE LMFA02000228 10.8 295.0 194.9 -110 -10 -24 -21
9-HODE LMFA02000188 10.8 295.0 171.0 -130 -10 -22 -7
15-HETE-d
8
LMFA03060080 10.9 327.2 226.0 -85 -10 -18 -11
15-HETE LMFA03060001 11.0 319.1 219.1 -55 -10 -18 -9
11-HETE LMFA03060003 11.1 319.1 167.0 -70 -10 -22 -15
7-HDHA n.a. 11.3 343.1 141.1 -85 -10 -18 -23
10-HDHA n.a. 11.2 343.1 153.0 -25 -10 -20 -15
17-HDHA LMFA04000072 11.1 343.1 245.0 -65 -10 -16 -15
12-HETE LMFA03060007 11.2 319.1 179.0 -65 -10 -20 -23
8-HETE LMFA03060006 11.2 319.1 154.9 -70 -10 -20 -19
5-HETE LMFA03060002 11.3 319.1 115.0 -65 -10 -18 -11
ALA LMFA01030152 12.4 277.0 233.0 -90 -10 -22 -29
EPA LMFA01030759 12.4 301.0 202.9 -125 -10 -18 -21
DHA-d
5
LMFA01030762 12.4 332.0 288.1 -75 -10 -16 -13
DHA LMFA01030185 12.7 327.1 229.2 -115 -10 -18 -11
AA LMFA01030001 12.7 303.0 205.1 -155 -10 -20 -11
LA LMFA01030120 12.8 279.0 261.0 -115 -10 -28 -13
DPA n-3 LMFA04000044 13.0 329.1 231.1 -50 -10 -20 -17






New functional roles of genes in disturbed energy metabolism
Some 10-50% of the variation in blood (energy) metabolites can be explained by hereditary 
factors, the remaining variation most likely by environmental factors or by a combination 
of genetic and environmental factors. The technology for measuring genetic and epigenetic 
parameters is one of the fastest growing fields at the moment. Linking these parameters to 
diseases, disease markers and biological variation in general has resulted in the association 
of many new genes with metabolic diseases. This thesis has investigated the association 
of certain genes with metabolites to gain more mechanistic insight into the gene-disease 
relationship. Here, I will discuss some of the questions which followed from the research into 
the functional roles of the genes in general and in particular the genes involved in BCAA 
metabolism (Chapter 2), the APOA5 gene (Chapter 3) and genes showing an interaction with 
PUFAs (Chapter 5 & 6). 
How to improve research towards the functional effects of SNPs?
Currently, 150 genetic loci have been associated with obesity or T2DM [1]. Unfortunately 
the translation of these genotype-disease associations into a molecular disease mechanism 
is lagging. The technology for measuring DNA variation has advanced rapidly. On the other 
hand, the effects of changes to DNA sequence on DNA functionality can be very diverse, 
require many different measurement technologies and are less compatible for computer 
analysis. Therefore an increased effort in discovering the functional roles of genes involved in 
disturbed energy metabolism is required to gain mechanistic insight. 
In Chapter 2, we have designed and utilized a new bioinformatics tool to assist researchers 
in discovering functional associations between SNPs, genes and metabolites. Typically, a 
SNP is assumed to affect the nearest gene, and knowledge of this gene is used to explain 
the associated disease(marker). Our tool accumulates information from various databases in 
order to assist the user in rationally exploring more distal genes as possible candidates. Using 
this tool, we provided evidence in Chapter 2 for an alternative SNP-to-gene mapping with a 
more distal gene, which was functionally more plausible. 
Smemo et al. recently also showed that the nearest gene to the SNP is not always the gene 
being affected [2]. SNPs in introns of the FTO gene have consistently and repeatedly been 
associated to obesity and SNPs in this region are able to explain several kilograms of variation 
in body weight between individuals. For years, genetic studies have explained the body weight 
consequences of the SNPs by their influence on the FTO gene itself. But Smemo et al. argue 
that the SNPs in fact do not influence the FTO gene, but the IRX3 gene further away. They 
functionally pursued the IRX3 gene, to discover its role in hypothalamic energy metabolism 
control. Research by Smemo and by our group shows that high-throughput genetic 
screening techniques need to be combined with bio-informatic data analyses, knowledge-




laboratory work. Cooperation between bioinformatics and biological disciplines is needed 
to unravel the story from genetic architecture up to the cellular functions triggered by the 
relevant circumstances.
How is branched-chain amino acid metabolism functionally involved in 
T2D?
As an example of new functional roles for genes, Chapter 2 of this thesis describes the 
functional association of branched-chain keto and hydroxy acids to a SNP that most likely 
affects the gene expression of Lactate dehydrogenase A (LDHA). The functional association 
of the SNP with LDHA was more rational than with the nearest gene, HPS5. This was based 
on the theoretical capability of lactate dehydrogenase to convert branched-chain α keto acids 
into branched-chain α hydroxy acids and this was confirmed experimentally. This association 
is interesting from an energy metabolism standpoint, as we and others have previously found 
that increased levels of branched-chain amino acids (BCAA) and branched-chain α keto acids 
(BCKA) are associated with obesity and T2DM, but functionally little is known about this 
association [3]. 
There is discussion on whether increased BCAAs are a cause or a consequence of obesity 
and T2DM. If BCAAs are causally involved in developing obesity and T2DM, then DNA 
variants that influence BCAAs must also be associated to the diseases. Indeed, several SNPs 
affecting genes involved in BCKA degradation have been shown to increase the risk of obesity 
and T2DM (BCKDHA, IVD, PPM1K and KLF15) [4]. In contrast, subjects with SNPs affecting 
BCAT1 or mice deficient for Bcat2 have a reduced risk of obesity and T2DM [4, 5]. As these 
genes are involved in BCKA formation, these results would point towards a pathogenic role of 
BCKA and its down-stream metabolites, but not of the upstream BCAAs. The SNP affecting 
LDHA described in this thesis is involved in BCKA degradation; therefore it seems likely that 
the SNP would increase the risk of obesity and T2DM. 
A variety of possible mechanisms by which increased BCAA degradation metabolites 
increase the risk of obesity and T2DM have been proposed, summarized by Lynch et al. 
[4]. One mechanism involves the persistent activation of the indirect amino acid sensor 
mTORC1. The intracellular signaling of activated mTORC1 can interfere with intracellular 
insulin signaling, thereby inducing insulin resistance. On the other hand, other observations 
do not support a role of mTORC1. For instance, BCAA supplementation leads to persistent 
mTORC1 activation and would therefore be expected to induce insulin resistance. However, 
BCAA supplementation leads to metabolic improvements [4]. 
Another mechanism involves defective metabolism of BCAA. Valine, leucine and 
isoleucine are transaminated to BCKAs by BCAT enzymes, which are then further reduced 
to branched-chain α hydroxy acids by the BCKDC enzymes. A toxic accumulation of BCKA 
metabolic products has been shown to result in lipid peroxidation and oxidative stress [4], 
leading to mitochondrial bioenergetic dysfunction and the activation of stress kinases. All 
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these effects are associated with the development of insulin resistance. 
We and others have shown that genetic defects in the BCKA degradation pathway lead to 
defective BCKA metabolism and therefore accumulation of BCKA metabolites [3-6]. High 
levels of these metabolites can induce insulin resistance via several mechanisms. Whether 
mutations affecting LDHA expression could also induce these effects will require further 
research. 
How is APOA5 functionally capable of inducing neuronal satiety 
signaling? 
A second gene of which SNPs have been shown to be associated with energy metabolism 
disorders and for which the functional mechanism is currently incomplete, is APOA5. In 
Chapter 3 we describe a newly discovered role for APOA5 in inducing neuronal satiety 
signaling. However the exact mechanism of inducing this neuronal signaling remains unclear. 
First, the source and trigger for APOA5 expression is unknown. An appealing mechanism 
was introduced by Guardiola et al. who proposed that the intestinal expression of APOA5 
is triggered by PPARα, a (dietary) fatty acid sensor [7]. Our data confirm that a high fat 
dietary trigger is necessary to induce food intake differences between WT and Apoa5-/- 
mice. Unpublished follow-up experiments corroborate the fact that small intestinal Apoa5 
expression is detectable at low levels and that intestinal expression is up-regulated on a high 
fat diet. However, the expression levels were very low. It seems more likely that the majority 
of APOA5 originates from the liver, where different nuclear receptors, PPARα, FXR, ROR, 
HNF4, Nur77 and CREBPH could trigger APOA5 expression [8, 9]. 
After induction of APOA5 gene expression in either the intestine or the liver, most of 
the APOA5 is secreted into the bloodstream [10, 11]. Due to its hydrophobic nature most 
APOA5 is bound to the lipoprotein particles chylomicrons, VLDL and HDL. In order to 
induce satiety signaling, APOA5 must bind to a neuronal receptor. Several potential binding 
partners of APOA5 have been suggested, including members of the LDL receptor family and 
VPS10P domain containing receptors (such as Sortilin-1 and Sortilin-related receptor [12]), 
but also heparin and glycosylphosphatidylinositol HDL-binding protein 1 (GPIHBP1) [9]. 
SNPs in the VPS10P domain containing receptors themselves were found to associate with 
plasma TG, LDL-cholesterol and CVD in a GWAS [13] and potentially play important roles 
in neuronal signaling [14]. A role for GPIHBP1 in binding APOA5 was suggested when an iv 
injection of APOA5 bound to recombinant HDL lowered plasma TG in Apoa5-/- mice, while 
Gpihbp1-/- mice did not show TG lowering after APOA5-rHDL injection [15]. 
In order for APOA5 to bind to neuronal receptors in the brain, it must first cross the blood 
brain barrier (BBB). Certain apolipoproteins, namely APOA1, APOE and APOB100 are 
capable of crossing the BBB by endocytosis [16]. Whether APOA5 is capable of crossing 
the BBB is unknown, although proteomics studies have identified APOA4 in cerebrospinal 




inducing satiety, but at a 500 fold higher dose than is required for APOA5 to induce satiety. 
APOA4, the closest protein homologue of APOA5, was shown to interact with the satiety 
inducting melanocortin system in the paraventricular nucleus of the hypothalamus, but did 
not activate proopiomelanocortin positive neurons in the arcuate nucleus [19]. Therefore it 
is possible that APOA5 also passes the BBB and binds to certain neurons of the melanocortin 
system to induce satiety signaling. 
For future research, it is necessary to verify the role of the intestinal APOA5 expression in 
response to dietary fat and to investigate whether APOA5 crosses over the BBB and binds to a 
receptor in certain brain cells of the melanocortin system in order to induce neuronal satiety 
signaling. 
Is APOA5 a target to reduce CVD risk?
With the newly discovered satiety-inducing properties of APOA5 described in Chapter 3, it is 
tempting to speculate about any therapeutic possibilities. If hyperphagia could be prevented, 
obesity and its co-morbidities might also be reduced. Obesity has been widely associated to 
hyperphagia-inducing SNPs in several GWA studies [20, 21]. Therapy aimed at reducing 
food intake has been attempted using several strategies before. One of the first drugs  that 
have proven very effective as appetite suppressants were amphetamine-like drugs. However 
these drugs can only be used short-time due to side effects and become less effective over time 
[22]. Therapy with endogenous hormones, such as leptin, has gained attention, as  leptin-
deficiency resulted in constant hunger and overeating [23]. Unfortunately, it quickly became 
clear that the intended obese target individuals demonstrated hyperleptinemia as a result of 
leptin resistance [24]. Therefore therapies aimed at reducing food intake using leptin in the 
obese (leptin-resistant) individuals have proven challenging [24]. Currently glucagon-like 
peptide 1 (GLP-1) analogues and inhibitors of GLP-1 degradation are being tested for their 
anti-hyperphagia properties [25, 26]. Unfortunately, desensitization to GLP-1 analogue-
induced satiety signaling has been shown upon long-term treatment in hyperphagic rodent 
models [27, 28]. 
An important question that needs to be addressed is therefore whether APOA5 resistance 
also occurs in obese individuals. Similar to leptin resistant obese subjects with hyperleptinemia, 
obese subjects might also be APOA5 resistant indicated by increased APOA5 concentrations. 
Interestingly, there is controversy about the direction of the association of obesity and plasma 
APOA5. Unpublished data from our group indicates that a higher BMI is associated with 
higher plasma APOA5 levels, while Hahne et al. has found equal APOA5 levels in a large BMI 
range [29] and Huang et al. have even found lower plasma APOA5 levels in individuals with 
a high BMI [30]. Overexpression of Apoa5 as a prolonged appetite suppressant therapy was 
tested in mice fed a high fat diet for 18 weeks, but did not result in reduced body weight or 
reduced plasma cholesterol levels [31]. 
Modulating appetite control has proven to be resilient to pharmacological interventions 
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due to neuronal adaptations that appear to defend a certain body weight and fat mass set 
point [32]. On the other hand, bariatric surgery, such as implemented in the individuals of 
Chapter 6, has proven very effective not only against obesity, but also against hyperphagia. 
Intestinal hormone secretion (e.g. GLP-1) as a consequence of bariatric surgery was increased, 
perhaps partly explaining its appetite-reducing effect [33]. Interestingly, unpublished work 
from our group indicated a consistent increase in the APOA5 plasma levels after bariatric 
surgery, possibly indicating an appetite-reducing effect via APOA5. Further research into 
resistance to satiety hormones such as APOA5 and the effect of bariatric surgery on intestinal 
satiety hormones, will be required before APOA5 could be pursued as a treatment to reduce 
overeating.
How do interactions between genes and PUFAs modulate CVD risk?
The new roles of recently discovered genes in disturbed energy metabolism have also 
implicated the importance of triggers to which these genes respond. For example, a high fat 
trigger is required to bring about the satiety signaling function of APOA5. Recently PUFAs 
have gained attention both as triggers and as markers in relation to a disturbed energy 
metabolism. Multiple GWA studies have detected significant interactions between the risk-
markers for CVD or CVD itself and the amount of dietary PUFAs consumed or the amount 
of endogenous PUFAs in the blood [34, 35]. 
Intriguingly, SNP rs662799 affecting APOA5 interacts with the amount of n-6 PUFAs in 
the diet, modulating the risk of developing hypertriglyceridemia [36, 37]. If more than 6 
energy-percent of the diet is derived from n-6 PUFAs, subjects with SNP rs662799 are more 
prone to develop hypertriglyceridemia. The interaction between APOA5 and n-6 PUFAs 
could involve the intestinal APOA5 expression, triggered by consumption of dietary fat (more 
specifically n-6 PUFAs). If this feedback signal is compromised by a SNP in APOA5, it would 
result in less satiety signaling and therefore more fat consumption and possibly higher plasma 
TG levels. This hypothetical mechanism would require further experimentation.
In Chapters 5 & 6 we found associations between PUFAs in adipose tissue and adipose 
tissue inflammation. Recently, nutrigenomic interactions between PUFA content in the diet 
and the genes involved in the production of PUFA-derived inflammatory mediators have been 
found, which modulate risk-markers of CVD [34, 35]. The SNPs interacting with PUFAs on 
risk markers for CVD showed only a small overlap with the SNPs found to associate directly 
with risk markers of CVD, indicating the complementary importance of gene-environment 
interactions in explaining the variation in CVD risk markers [34]. The interaction between 
genes and PUFAs on CVD indicate sensor proteins triggered by PUFAs, which can directly or 
indirectly affect gene expression of genes involved in CVD. These interactions point towards 
metabolic regulatory mechanisms that can be influenced by the environment. Whether or not 
these regulatory mechanisms can be influences by adjusting PUFA metabolism or the dietary 




Adipose tissue characteristics during a disturbed energy 
metabolism
Dysfunctional adipose tissue is an important feature associated with metabolic diseases. 
Therefore, in the second part of this thesis, we performed studies investigating the 
characteristics of dysfunctional adipose tissue.  In Chapters 4 & 5, we pharmacologically 
influenced adipose tissue function using niacin to learn more about the adipose tissue changes 
that could occur during disease development. We found that niacin critically modifies cAMP 
signaling in the adipocyte, while also increasing long-chain n-3 PUFA biosynthesis, secretion 
and conversion. Changes in PUFA metabolism of adipose tissue were also detected in obese 
women that developed T2DM compared to obese women resistant to T2DM development 
(Chapter 6). 
What is the impact of niacin treatment on cAMP metabolism in 
adipocytes?
Niacin, nicotinic acid or vitamin B3 (Chapter 4 & 5) has been known for almost 60 years to 
be an effective treatment of dyslipidemia when given in gram-dosages daily. However the 
mechanism by which it conveys these beneficial properties has not been completely unraveled. 
For example, niacin displays effects that are initiated acutely, but most of the beneficial effects 
leading to CVD risk reduction only occur after days of continuous niacin treatment. Niacin 
acutely binds to the HCA2 receptor expressed by certain immune cells and adipocytes. 
Binding this G-protein coupled receptor in skin Langerhans cells and keratinocytes leads 
to the activation of phospholipase A2, releasing arachidonic acid, which is converted to 
prostaglandins. These prostaglandins acutely induce vasodilation and thereby skin flushing. 
Also, binding of HCA2 acutely inhibits cAMP formation in adipocytes, leading to reduced 
lipolysis and fatty acid release from adipose tissue.
These acute effects are followed by later-stage effects of prolonged niacin administration. 
These effects bring about marked improvements of dyslipidemia, inflammation and free-
radical formation, which help reduce CVD-risk. Although these prolonged effects are 
preceded by the acute effects induced by HCA2 receptor signaling, the necessity of the HCA2 
receptor in inducing the beneficial prolonged effect is questioned. Prolonged niacin treatment 
of Hcar2-deficient mice still resulted in improvements to dyslipidemia, mostly by cholesterol 
lowering [38]. Therefore, cholesterol-lowering by niacin is likely not dependent on the HCA2 
receptor and independent of lipolysis inhibition or skin prostaglandin release. 
The adipocyte signaling effects after prolonged niacin treatment described in Chapter 4 on 
the other hand are most likely dependent on the HCA2 receptor. As niacin binding inhibits 
the production of an important signaling metabolite, cAMP, signaling events are distorted. 
In order to restore signaling functionality, adaptions are made in the adipocyte. First, on the 
protein phosphorylation level [39] and later on gene expression level as described in Chapter 
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4. Most importantly, the expression of the cAMP degrading enzyme phosphodiesterase 3B 
was diminished. The adaptation made to the cAMP signaling, likely induced to counteract the 
effect of niacin binding to the HCA2 receptor, also modified cAMP-dependent insulin and 
adrenergic signaling. A side effect of prolonged niacin treatment is therefore decreased insulin 
sensitivity and increased adrenergic sensitivity of adipocytes. Despite niacin’s beneficial anti-
dyslipidemic properties combined with its disadvantageous insulin resistant and adrenergic 
hypersensitivity properties, it is a potent treatment for dyslipidemia to reduce atherosclerosis 
[40]. The fact that niacin treatment is equally effective as statin treatment in mice, despite 
these side-effects suggests that improvements could be possible [41]. However further 
research would be required to dissociate the HCA2 receptor-mediated disadvantageous 
effects from the beneficial non-HCA2 receptor mediated effects on dyslipidemia. Whether 
the effects on PUFA metabolism after prolonged niacin described in Chapter 5 are dependent 
on the HCA2 receptor is unknown.
What are the consequences of modulating adipose PUFA metabolism 
on CVD? 
The therapeutic role of PUFAs in CVD prevention is disputed. There are several PUFA-
based therapeutic strategies currently being investigated. The first is dietary supplementation 
of additional n-3 PUFAs. The second is induction of endogenous n-3 PUFA biosynthesis. 
The third is modulation of the PUFA-derived oxylipin profile. Combination approaches are 
also being investigated. The effect of dietary n-3 PUFA supplementation showed significant 
improvements of risk factors of CVD, such as reduced hypertriglyceridemia and hypertension 
[42] and hepatosteatosis [43]. However in a systematic review of the randomized clinical 
trials of n-3 PUFA supplementation in a primary and/or secondary CVD prevention setting 
[44], a meta-analysis showed no effect of supplementing the diet with n-3 PUFAs on CVD 
outcomes itself. Therefore, PUFA supplementation might not have the desired effects on CVD 
endpoints. 
Another therapeutic strategy is the endogenous induction of PUFA biosynthesis. Increasing 
n-3 PUFA and decreasing n-6 PUFA synthesis in transgenic mouse models led to resistance 
to obesity, dyslipidemia and diabetes [45]. In Chapter 5 we have detected an endogenous 
increase in PUFA biosynthesis after niacin treatment, which was associated with an anti-
inflammatory PUFA metabolite plasma profile. The niacin treated mice with increased PUFA 
biosynthesis also showed improvements of dyslipidemia. Reversely, in Chapter 6 we detected 
a decreased PUFA biosynthesis in adipose tissue from obese women with T2DM compared to 
obese without T2DM. This result is in concordance with a beneficial effect of increased PUFA 
biosynthesis on metabolic diseases. Outside the context of metabolic disease, increased PUFA 
biosynthesis might be harmful due to their potential oxidation to lipoperoxide inflammatory 
triggers. Reducing PUFA biosynthesis by knockdown of PUFA elongation genes in non-




biosynthesis as a therapeutic strategy must have a proper disease indication.
Therapies aimed at modulating PUFA conversion to specific (sets of) oxylipins is an 
active research field for possible vascular disease therapies. For example inhibition of soluble 
epoxide hydrolase, which increases the levels of cytochrome P450 metabolites, may assist in 
maintaining vascular homeostasis in patients at risk of CVD [47, 48]. On the other hand, 
modulating the inflammatory pathway by this way could be a double-edged sword, as these 
metabolites also play an important role in cancer progression [49].  
The PUFA dependent therapeutic strategies described above have shown clear improvements 
on metabolic disease-markers, such as improved plasma triglycerides, inflammation and 
vascular homeostasis. Whether these advantages will propagate to reduced CVD risk is less 
clear. PUFA consumption seems to be ineffective. Although PUFA biosynthesis and PUFA 
conversion modulation both seem promising, using these treatments might harm the patient 
when they are prescribed without a proper indication of dysfunctional PUFA metabolism. 
Conclusions and outlook
In a world where the genetic basis for the risk of developing diseases is gaining more and more 
attention, it is important to pursue the functional mechanism behind the genetic associations 
as well. In this thesis we have looked further into the mechanisms of some of the risk alleles 
for cardiovascular diseases. In doing so, we have found new roles for two genes. We show that 
if the regulation of these genes is altered by a genetic mutation, the role of these genes provide 
a mechanism by which they could be involved in the development of metabolic disease. 
APOA5 can suppress appetite, while mutations affecting APOA5 induce overeating leading 
to obesity. LDHA can metabolize branched chain amino acid metabolites, while mutations 
affecting LDHA induce BCAA dysmetabolism and accumulation of toxic BCAA metabolites 
which is associated with insulin resistance. These studies provide scientific insight into the 
pathology of metabolic disease, which could point to possible new therapeutic targets to 
prevent and treat cardiovascular disease and T2DM. 
Aside from possible genetic contributors to metabolic diseases, this thesis has also 
investigated some of the consequences of metabolic diseases, especially on adipose tissue. 
As energy continues to accumulate in the body due to a positive energy balance, the stressful 
consequences on adipose tissue become visible. Adipose tissue is also an important location 
where the accumulated lipids and fatty acids can modify inflammatory processes. In our 
studies we have seen important modifications to PUFA metabolism, both in human and mice. 
As PUFA metabolism is closely linked to the production of inflammatory mediators, PUFAs 
can connect the accumulating lipids to the development of inflammation during obesity. 
Endogenous up-regulation of PUFA synthesis could modify the inflammatory processes 
involved in obesity related diseases. The studies from this thesis have proven once again that 
PUFA metabolism is a powerful marker of CVD health and it provides new insights in the 
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[3H]-TO  Glycerol tri(9,10(n)[3H]oleate
[14C]-CO  [1α,2α(n)-14C]cholesteryl oleate
aCSF    Artificial cerebrospinal fluid
APOA5   Apolipoprotein A5
CHox    Carbohydrate oxidation 
EE    Energy expenditure 
FAox    Fat oxidation 
FI    Food intake
GIR    Glucose infusion rate
HFD    High fat diet
HSL    Hormone sensitive lipase
MCR    Metabolic clearance rate
NPY    Neuropeptide Y 
PLIN1    Perilipin-1
RER    Respiratory exchange ratio
VCO2    Carbon dioxide production 
VO2    Oxygen consumption
WT    Wild type
Chapter 4: 
AC    Adenyl cyclase, 
ADRB1,2,3   β-Adrenoceptor 1,2,3, 
ARRB1   β-Arrestin 1, 
CETP    Cholesteryl ester transfer protein, 
HSL    Hormone sensitive lipase, 
ip   Intraperitoneal, 
INSR    Insulin receptor, 
IRS1   Insulin receptor substrate 1, 
PDE3B   Phosphodiesterase 3B, 
PKA/B   Protein kinase A/B, 




12-HETE  12-hydroxy eicosatetraenoic acid
14(15)-EpETE  14(15)-epoxy eicosatetraenoic acid
14,15-diHETE  14,15-dihydroxy eicosatetraenoic acid
19(20)-EpDPA  19(20)-epoxy docosapentaenoic acid
19,20-diHDPA  19,20-dihydroxy docosapentaenoic acid
AA   Arachidonic acid
AdA   Adrenic acid
ALA   α-Linolenic acid
ALOX   Arachidonate lipoxygenases
APOE*3-Leiden  Apolipoprotein E3 Leiden
CETP   Cholesteryl ester transfer protein 
COX   Cyclooxygenase
CVD   Cardiovascular disease
CYP   Cytochrome P450
DHA   Docosahexaenoic acid
DPA   Docosapentaenoic acid
EPA   Eicosapentaenoic acid
FDR   False discovery rate
GC-MS  Gas chromatography mass spectrometry
gWAT   Gonadal white adipose tissue
LA   Linoleic acid
LC-MS/MS  Liquid chromatography tandem mass spectrometry
NEFA   Non-esterified fatty acid





Overweight and obesity have been on the rise since the late 1970’s. With it, the risks of 
developing metabolic disorders such as the metabolic syndrome, type 2 diabetes and 
cardiovascular disease have also risen. This sudden increase in the prevalence of obesity 
and related metabolic disorders is most likely due to a sudden change in our environment. 
Most of us are ill-adapted to deal with the recent ‘obesogenic environment’. In Chapter 1, 
an overview of our energy metabolism and regulation of the energy balance is introduced, 
showing that animals and humans are well-adapted for energy conservation and storage, but 
ill-adapted for energy overload. The subsequent work presented in this thesis focused on the 
development of obesity and insulin resistance by investigating the underlying energy,- and 
fatty acid metabolism.  
Differences in our energy metabolism can have a genetic origin. Genome Wide Association 
Studies (GWAS) have revealed numerous single nucleotide polymorphisms (SNPs) associated 
with differences in energy metabolism. However, translating this genetic information to a 
mechanism by which the disease could arise has proven difficult. In order to assist scientists 
in reviewing possible mechanisms by which a SNP could be associated with a disease or 
disease-marker, we describe the application of a newly developed knowledge-based workflow 
in Chapter 2. This workflow assists users in mapping SNPs to genes. Suhre et al. have 
described metabolic variation in plasma metabolite levels and their association to SNPs in 
the general population. By applying our workflow to the 37 quantitative trait loci associated 
with metabolite levels described by Suhre et al. we generated metabolite-gene-SNP reports 
for these associations. We found that the report generated for SNP rs2403254 indicated that 
an alternative candidate gene (LDHA) might be affected by this SNP, which could account for 
the observed association with branched chain amino acid (BCAA) degradation products. To 
further strengthen the new-found association, we demonstrated using chromatin interaction 
databases that the SNP rs2403254 could indeed interact with LDHA and using in vitro 
experiments we demonstrated that the enzyme transcribed from the LDHA gene could indeed 
generate the BCAA degradation products that it associates with. Therefore it is plausible that 
SNP rs2403254 affects the transcription of LDHA, which could lead to changes in the levels of 
BCAA degradation products.
Other GWAS have shown that the APOA5 gene is associated with triglyceride metabolism 
and obesity. In Chapter 3 we investigated the mechanism underlying this association by using 
a mouse model deficient for Apoa5.  We observed that Apoa5-/- mice consume more food and 
gain more body weight, but only on a high fat diet. As APOA5 plasma levels are very low 
and increase after consumption, we hypothesized that APOA5 might be involved in satiety 
signaling after fat consumption. We tested this hypothesis by injecting APOA5 into the blood 
and by injecting APOA5 into the brain of fasted Apoa5-/- mice. In both cases APOA5 injection 
resulted in decreased high fat diet consumption. Also, hepatic overexpression of APOA5 
prevented the increased high fat diet consumption observed in Apoa5-/- mice. Together, these 
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experiments demonstrate a role for APOA5 as a fat-inducible satiety hormone. 
Aside from genetic influences, the development of metabolic diseases can also be affected 
by drugs. For example, the drug niacin inhibits atherosclerosis, but as a side-effect niacin 
treatment induces the development of insulin resistance. Niacin is known to influence 
energy metabolism by acutely inhibiting fatty acid release from adipocytes. However, the 
mechanisms by which niacin induces its long-term effects are not entirely understood. In 
Chapter 4 we further investigated the niacin-induced insulin resistance of adipocytes. After 
prolonged niacin treatment we confirmed that mice developed whole-body insulin resistance 
and that their isolated adipocytes were less sensitive to lipolysis-inhibition by insulin. We 
also showed that the adipocytes from niacin-treated mice were more sensitive to lipolysis-
stimulation by cAMP (via both 8Br-cAMP and adrenergic stimulation). Subsequently, we 
examined gene expression of the proteins in the insulin signaling pathway and the adrenergic 
signaling pathway controlling lipolysis and found that both pathways were down-regulated. 
This included the gene Pde3b encoding for a cAMP degradation protein, which is involved in 
both pathways. Using a PDE3B inhibitor on isolated adipocytes, we showed that decreasing 
PDE3B activity can stimulate lipolysis. Therefore, the niacin-induced decreased PDE3B 
activity could lead to both the observed insulin resistance and the increased sensitivity 
towards cAMP stimulation.
In Chapter 5, we further investigated the effect of niacin on adipose tissue gene expression 
and composition. Microarray analysis demonstrated up-regulation of gene expression of 
the pathway of biosynthesis of (poly) unsaturated fatty acid. By examining the fatty acid 
composition of the adipose tissue, we found that increased substrate-product ratios in the 
PUFA biosynthesis pathway matched the increased gene expression for the catalyzing enzyme. 
By measuring the adipocyte secreted fatty acid levels and the plasma NEFA levels, which are 
mostly determined by adipose lipolysis, an increased level of the end-products of the PUFA 
biosynthesis pathway was found. Specifically, increased levels of n-3 PUFAs were found, 
which can be converted to anti-inflammatory oxylipins. Indeed, increased plasma levels of 
the hydrolysis products of these n-3 PUFA derived oxylipins were found, which suggests an 
anti-inflammatory plasma profile that could contribute to the anti-inflammatory vascular 
effects of niacin. 
In Chapter 6, the role of fatty acids in the development of obesity and diabetes was 
examined in an obese human population. We previously found that adipose tissue of obese 
women with type 2 diabetes mellitus (T2DM) was more inflamed than adipose tissue from 
obese women without T2DM (NGT). As this inflammatory difference might be partially 
mirrored by differences in adipose PUFA composition and PUFA-derived oxylipin formation, 
the fatty acid composition was determined. Long chain PUFAs of both n-3 and n-6 were more 
abundant in the adipose tissue of T2DM women compared to NGT women. Measuring the 
oxylipin concentrations in the adipose tissue suggested an increased conversion of the n-6 
PUFA arachidonic acid towards leukotrienes. Moreover, as gene expression of the leukotriene 




in the subcutaneous adipose tissue of the T2DM women. The increased arachidonic acid 
conversion to chemo-attractant leukotrienes might explain the positive correlation between 
the adipose arachidonic acid content and the gene expression of the macrophage marker 
CD68, suggesting a role for PUFAs and leukotrienes in the development of adipose tissue 
inflammation.
Taken together, these studies provide novel insight into the role of dysfunctional energy 
and fatty acid metabolism in the development of obesity and insulin resistance. As discussed 
in Chapter 7, our results illustrate the importance of functional research into the discovered 
genetic associations to gain more mechanistic insight. A better insight may lead to new 
therapeutic strategies to combat metabolic diseases. We have also seen the extensive changes 
in adipose tissue in obesity and insulin resistance, especially with regard to PUFA metabolism. 
Adipose tissue PUFA storage and PUFA conversion to inflammatory mediators provide a 
clear link between obesity and inflammation, which can be targeted to improve inflammation 







Overgewicht is een groeiend probleem wereldwijd. Meer mensen sterven aan de gevolgen van 
overgewicht dan aan de gevolgen van ondergewicht. Overgewicht op zichzelf is schadelijk voor 
bijvoorbeeld knie- en heupgewrichten, maar is vooral een risico door de nadelige gevolgen 
van de verstoorde energiestofwisseling. Deze stofwisseling veranderingen kunnen leiden tot 
ziektes, zoals het metabool syndroom, diabetes mellitus type 2 (DM2) en aderverkalking. Al 
deze ziektes dragen bij aan een vergrote kans op hart en vaatziekten (HVZ). Overgewicht 
en obesitas worden veroorzaakt door een hogere energie inname dan een energie verbruik, 
ofwel door meer te eten dan te verbranden. Er zijn sterke aanwijzingen dat de huidige 
obesitas epidemie vooral veroorzaakt wordt door een hogere energie inname, met name 
van koolhydraten, ook al is men zeker ook minder gaan bewegen. Het onderzoek wat hier 
beschreven is gaat niet zozeer over de vraag waarom de bevolking als geheel dikker wordt, 
maar waarom sommige mensen wèl en sommige mensen géén nadelige gevolgen van de 
energiestofwisseling ontwikkelen. De aandacht gaat in het bijzonder uit naar welke onderlinge 
verschillen in bijvoorbeeld het DNA en het dieet een rol spelen. Daarnaast onderzoeken we 
het mechanisme van een ooit veelbelovend geneesmiddel.
In Hoofdstuk 1 wordt beschreven hoe de energiestofwisseling van voornamelijk vet en 
suiker in elkaar zit. De stofwisseling is zorgvuldig afgestemd op het conserveren van energie 
voor tijden van schaarste. Echter, in onze overvloedige maatschappij waar schaarste zeldzaam 
is raakt de regulatie uit balans. De gevolgen van een toenemende energieopslag in de vorm van 
vet, in de levercellen (hepatocyten) en de vetcellen (adipocyten), kunnen stress veroorzaken 
in deze cellen wat kan leiden tot een verminderde gevoeligheid voor bijvoorbeeld het voedsel-
hormoon insuline. Insuline wordt vrijgegeven aan het bloed wanneer voedingsstoffen van 
een maaltijd het bloed bereiken. Vervolgens geeft insuline het signaal aan voorraadcellen om 
hun voorraad op te bouwen en te stoppen met de afgifte van hun voorraad aan het bloed. 
Tevens geeft insuline het signaal aan niet-voorraad cellen zoals spiercellen en zenuwcellen 
om de voedingsstoffen op te nemen en te gebruiken. Bij een verminderde gevoeligheid 
(resistentie) voor insuline worden voedingsstoffen niet efficiënt opgenomen uit het bloed en 
blijft de concentratie voedingsstoffen in het bloed hoog. Dit heet insuline resistentie en kan 
uiteindelijk leiden tot DM2. Dit proefschrift is gewijd aan de rol die de energiestofwisseling 
en vetzuurstofwisseling spelen bij de ontwikkeling van obesitas en insuline resistentie, met 
name in het vetweefsel.
In het eerste deel van mijn proefschrift hebben we geprobeerd om genetische aanwijzingen 
die in verband staan met een verstoorde stofwisseling, te vertalen naar een verfijnder 
werkingsmechanisme voor die aanwijzing. Obesitas is gedeeltelijk genetisch bepaald. Vele 
studies hebben variatie in DNA-volgorde (bijvoorbeeld een SNP) in verband gebracht met 
variatie in lichaamsgewicht, metabole ziektes en energie metabolisme. Maar ondanks alle 
kennis over DNA is nog steeds grotendeels onbekend wat voor uitwerking een SNP kan 
hebben op eiwitproductie. Vandaar dat genetische studies die een verband laten zien tussen 
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SNPs en metabolisme soms niet verder komen dan precies dat: een (indirect) verband waarbij 
mechanistisch inzicht in het metabolisme ontbreekt. Door gebruik te maken van een door 
ons ontwikkelde koppeling van computerprogramma’s (workflow) kunnen de verschillende 
mechanismen waarop een SNP in verband staat met een ziekte of een ziekte-marker worden 
vergeleken. In Hoofdstuk 2 laten we zien dat onze workflow helpt om te beredeneren of een 
verschil in de productie van een bepaald eiwit, veroorzaakt door een SNP, logischerwijze 
zou kunnen passen bij de verschillen in het gemeten metabolisme. Een eerder onderzoek in 
de algemene populatie heeft 37 nieuwe verbanden gevonden, namelijk dat bepaalde SNPs 
in verband staan met hogere of lagere concentraties van metabolieten in het bloed. Door 
onze workflow toe te passen op de 37 verbanden uit dat onderzoek hebben we resultaten 
gegenereerd voor ieder van deze 37 verbanden van een SNP via een eiwit naar een metaboliet. 
Zo vonden we in ons onderzoek dat SNP rs2403254 mogelijk de eiwitproductie van een ander 
eiwit kan beïnvloeden dan de eiwitproductie gesuggereerd door eerdere onderzoekers. De 
productie van dit andere eiwit, Lactaat dehydrogenase A (LDHA), zou een directe invloed 
hebben op de bloed metaboliet concentraties van de afbraak producten van de vertakte-keten 
aminozuren, waar de SNP rs2403254 mee in verband staat. Om onze hypothese ten aanzien 
van dit kandidaat-eiwit verder te onderbouwen hebben wij in databases gevonden dat de 
DNA positie van SNP rs2403254 en van het LDHA gen een interactie hebben. Ook hebben 
we met onze experimenten aangetoond dat Lactaat dehydrogenase A de afbraak producten 
van de vertakte-keten aminozuren waar de SNP mee geassocieerd is direct kan omzetten. 
Het is daarom waarschijnlijk dat SNP rs2403254 de eiwitproductie van LDHA verlaagd 
waardoor minder afbraak producten van de vertakte-keten aminozuren omgezet kunnen 
worden. Via dit mechanisme zou de SNP rs2403254 veranderingen in de concentratie van 
deze metabolieten in het bloed kunnen bewerkstelligen.
Andere genetische studies hebben aangetoond dat SNPs die de eiwitproductie voor 
Apolipoproteïne A5 (APOA5) beïnvloeden ook in verband staan met obesitas en nadelige 
veranderingen in het vet metabolisme. In Hoofdstuk 3 onderzoeken we het onderliggende 
mechanisme voor dit verband in een muismodel wat het Apoa5 eiwit niet aanmaakt. Deze 
Apoa5/- muizen worden sneller zwaarlijvig en eten ook meer dan muizen die het Apoa5 
gen wèl hebben, echter deze bevindingen werden alleen geobserveerd bij een vetrijk dieet. 
Normaliter is de concentratie van het APOA5 eiwit in het bloed zeer laag, maar deze stijgt na 
inname van (vetrijk)voedsel. Hieruit vormden wij de hypothese dat het APOA5 eiwit wellicht 
betrokken is bij het doorgeven van het verzadigingsgevoel na het eten van een vetrijke 
maaltijd. Deze hypothese hebben we getoetst door het APOA5 eiwit niet alleen in het bloed, 
maar ook direct in de hersenen van gevaste Apoa5/- muizen te injecteren. In beide gevallen 
resulteerde APOA5 eiwit injectie in een verlaagde inname van vetrijk voedsel. Daarnaast 
hebben wij ook gevonden dat als het APOA5 gen weer terug geïntroduceerd werd in Apoa5/- 
muizen, dan voorkomt dat het overeten aan vetrijke voedsel wat de Apoa5/- muis kenmerkt. 
Deze experimenten laten samen zien dat APOA5 een rol speelt als verzadigingshormoon wat 




Het tweede deel van mijn proefschrift gaat vooral over de rol van het vetzuurmetabolisme 
in vetweefsel van obese mensen en muizen. Niacine is een voorbeeld van een medicijn wat 
hart- en vaatziekte voorkomt door in te grijpen op onder andere de vetafbraak in vetweefsel. 
Niacine werkt door een centrale regelaar van allerlei cel processen (zo ook vetafbraak), cAMP, 
te  beïnvloeden. Als bijwerking veroorzaakt niacine insuline resistentie. Het mechanisme 
waarmee niacine behandeling pas na dagen leidt tot insuline resistentie niet volledig bekend. 
In Hoofdstuk 4 wordt dit verder onderzocht. Na langdurige niacine behandeling van muizen 
laten we inderdaad zien dat insuline resistentie is opgetreden op lichaamsniveau, maar ook 
geïsoleerde vetcellen waren resistent voor insuline-gemedieerde remming van de vetafbraak. 
Daarnaast werd duidelijk dat vetcellen geïsoleerd uit niacine behandelde muizen gevoeliger 
waren voor vetafbraak-stimulatie door cAMP, zowel via het synthetische 8Bromo-cAMP als 
via adrenerge (stress) stimulatie. Vervolgens hebben we naar de genexpressie gekeken van 
de insuline signaal transductie eiwitten en de adrenerge signaal transductie eiwitten die 
vetafbraak reguleren, maar de genen in beide signaal transductieketens kwamen verminderd 
tot expressie. Eén van deze genen, Pde3b, codeert voor een cAMP afbrekend eiwit, wat 
betrokken is in beide transductieketens via cAMP. Met behulp van een PDE3B-remmer 
lieten we in geïsoleerde vetcellen zien dat een verminderde PDE3B activiteit de vetafbraak 
kan stimuleren. We concluderen uit deze resultaten dat de verlaging van PDE3B activiteit 
veroorzaakt door niacine kan leiden tot zowel de geobserveerde insuline resistentie als de 
verhoogde gevoeligheid voor cAMP stimulatie. 
In Hoofdstuk 5 vervolgen we ons onderzoek van de effecten van niacine op vetweefsel. 
Een genexpressie microarray liet zien dat vetweefsels van niacine behandelde muizen een 
verhoogde genexpressie hadden van de eiwitten betrokken bij de(poly) onverzadigde vetzuur 
(PUFA) productie. Het vetweefsel van langdurig met niacine behandelde muizen bleek 
na analyse van de vetzuursamenstelling verhoogde substraat-product ratio’s in de PUFA 
biosyntheseketen te hebben. Deze verhoogde ratio’s overlapten met de verhoogde genexpressie 
van het corresponderende eiwitten die het substraat tot product omzetten. Door te meten 
welke vetzuren worden uitgescheiden vanuit de vetcellen en welke vetzuren in het bloed zitten 
werd een verhoging van de eindproducten van de PUFA biosyntheseketen gevonden. Specifiek 
werden er verhoogde concentraties van n-3 PUFAs gevonden, welke omgezet kunnen worden 
naar ontstekingsremmende oxylipines. Daarnaast werden ook verhoogde concentraties van 
het hydrolyse product van een oxylipine gevonden wat geproduceerd word van deze n-3 
PUFAs. Dit wijst op een ontstekingsremmend bloedplasma profiel wat zou kunnen bijdragen 
aan de verminderde ontsteking van bloedvaten die typisch zijn bij niacine behandeling van 
hart- en vaatziekte patiënten.
De rol van vetzuren in de ontwikkeling van overgewicht en suikerziekte wordt verder 
onderzocht in Hoofdstuk 6 bij een populatie van vrouwen met obesitas. Vetweefsel van 
obese vrouwen met DM2 was meer ontstoken dat vetweefsel van obese vrouwen zonder 
DM2 (NGT). Dit verschil in vetweefsel ontsteking zou gedeeltelijk verklaard kunnen worden 
door verschillen in de PUFA vetzuursamenstelling van het vetweefsel en de oxylipines die 
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geproduceerd worden van PUFAs. Er waren meer langketenige PUFAs van zowel n-3 als n-6 
in het vetweefsel van vrouwen met DM2 vergeleken met NGT vrouwen. Metingen aan het 
oxylipine metabolisme in het vetweefsel leken te wijzen op een verhoogde omzetting van 
de n-6 PUFA arachidonzuur naar leukotriënen, omdat de genexpressie van de leukotrieen 
biosyntheseketen hoger was en er een trend was tot verhoogde  leukotrieen metabolieten 
in het onderhuidse vetweefsel van vrouwen met DM2. De mogelijk verhoogde leukotrieen 
metaboliet concentraties zouden kunnen verklaren waarom de arachidonzuur hoeveelheid in 
onderhuids vetweefsel gecorreleerd is aan de vetweefsel genexpressie van de macrofaag marker 
CD68. Dit zou kunnen wijzen op een rol voor PUFAs en leukotriënen in de ontwikkeling van 
vetweefsel inflammatie. 
Samengenomen laten deze studies zien dat een slechtwerkende energie en vetzuur 
stofwisseling sterke voorbodes zijn voor de ontwikkeling van obesitas en diabetes. 
Zoals beschreven in Hoofdstuk 7, benadrukken deze studies het belang van functioneel 
laboratoriumonderzoek naar de ontdekte genetische verbanden tussen SNPs en ziektemarkers 
om meer inzicht te krijgen in het werkingsmechanisme. Een beter inzicht kan leiden tot 
nieuwe behandelstrategieën in de strijd tegen metabole ziektes. We hebben ook de grote 
veranderingen van vetweefsel tijdens de ontwikkeling van obesitas en insuline resistentie 
beter in kaart gebracht, specifiek van het PUFA metabolisme. Vetweefsel PUFA opslag en 
PUFA omzetting naar ontstekingsmediatoren zijn een duidelijke verbinding tussen obesitas 
en ontsteking, wat het mogelijk maakt om gerichtere behandelingen te kunnen ontwikkelen 
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